Phenotypic Analysis of the Plp-Deficient Mouse by Yool, Donald Andrew
Phenotypic analysis of the P/p-deficient mouse
A thesis presented to the Faculty of Veterinary Medicine,
University of Glasgow
for the degree of 
Doctor of Philosophy
April 2000
©
Donald Andrew Yool
ProQuest Number: 13818710
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13818710
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
S B B &
Abstract
The myelinproteolipidprotein {Pip) gene encodes the major protein components of 
compact central nervous system myelin. Mutations of this gene lead to severe 
dysmyelinating disease and oligodendrocyte death suggesting roles for Pip gene 
products as vital structural components of compact myelin and as oligodendrocyte 
maturation or survival factors. The Pip gene knockout mouse was generated 
(Klugmann et al., 1997) to study the effects of loss of Pip gene function on 
oligodendrocyte development and myelination in the central nervous system. 
Surprisingly the Pip gene knockout mouse showed no gross evidence of 
dysmyelination but did develop a late onset phenotype associated with progressive 
axonal changes. This study characterised the phenotype of these mice and assessed 
the ability of Pip gene isoforms to modify the phenotype of Pip gene knockout mice 
by transgenic complementation.
The Pip gene knockout mouse formed large volumes of myelin and maintained 
oligodendrocyte numbers into adulthood. However, in the central nervous system, 
myelin was ultrastructurally abnormal and a proportion of small diameter axons 
failed to acquire myelin sheaths. Axonal changes consisted of swollen and 
degenerate axons and were confined to myelinated regions of the central nervous 
system where small diameter fibres appeared to be preferentially affected. 
Transgenic complementation with constructs expressing all of the components of 
the Pip gene ameliorated the phenotype of the Pip gene knockout mouse 
demonstrating that these changes were the direct result of loss of Pip gene function.
These results indicate that, although the Pip gene products play roles in initiating 
myelination and in stabilising myelin lamellae, they are not vital components for 
oligodendrocyte development or myelin formation. The development of axonal 
changes appears to depend on the presence of myelin and demonstrates a potential 
role for the Pip gene in axoglial interaction. In addition, the changes in the Pip gene 
knockout mouse highlight the increasingly recognised role of gene dosage in the 
pathogenesis of Pip gene-related disease.
Klugmann,M., Schwab,M.H., Puhlhofer,A., Schneider,A., Zimmermann,F.,
Griffiths,I.R. and Nave,K.-A. (1997) Assembly of CNS myelin in the absence of 
proteolipid protein. Neuron. 18, 59-70.
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1. Introduction
1.1 Background
Myelin disorders account for a large group o f  debilitating human diseases and 
similar disorders in experimental animals have proved useful in studying the 
mechanisms o f these diseases and o f myelin formation. Particular interest has 
centred on the functions and roles of the proteolip id  protein {Pip) gene, the major 
myelin gene o f the central nervous system (CNS). Although the Pip  gene products 
constitute a large proportion of the CNS m yelin proteins and disorders o f  this gene 
lead to severe disruptions o f myelin formation, the functions o f the gene remain 
elusive. In order to clarify some of the roles o f  the Pip  gene and the pathogenic 
mechanisms o f Pip gene-related disease, a Pip  gene knockout mouse was generated 
(Klugmann et al., 1997) that was expected to  mirror the severe dysmyelinated 
phenotypes characteristic o f other Pip gene-related disorders. However, the Pip 
gene knockout mouse appeared to develop normally and survived into old age 
before a clinical phenotype became obvious. This study describes the pathological 
changes that developed in the Pip  gene knockout mouse and the ability o f transgenic 
complementation to modify these changes. Early in the course o f the investigation, 
it became apparent that Pip  gene knockout mice develop a progressive axonopathy, 
a finding that is hard to correlate with the available data on Pip  gene function. The 
introduction to this thesis summarises the current knowledge o f Pip gene function as 
it relates to myelin formation and disease pathogenesis and summarises the role of 
axoglial interaction in the mature CNS. This will enable the results from this study 
to be discussed within the context of myelin formation and the pathogenesis o f 
myelin disease.
1.2 CNS structure
The cellular architecture o f the CNS is extremely specialised with complex 
interactions between neuronal processes and the macroglial supporting cells, the 
oligodendrocytes and astrocytes. In addition, microglia, a CNS-subpopulation o f 
mononuclear phagocytic cells, and vascular endothelial cells contribute to the CNS 
structure. This section describes how these cells relate to one another particularly in 
the context o f myelination. It does not expand on the complex organisation o f 
neurones and their processes into functional groups or on the differences between 
CNS and peripheral nervous system (PNS) structure.
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Membranous sheaths of myelin surround many of the axons of the central and 
peripheral nervous systems and are a feature of most vertebrates. The majority of 
CNS axons are myelinated by oligodendrocyte processes that form regular sheaths 
around consecutive sections of axon. Each internode (a single myelin/ axon 
subunit) is separated from neighbouring intemodes by a small gap (0.8 to 0.11pm), 
the node of Ranvier. This gap represents a specialised section of the axon (the nodal 
axon) that is capable of depolarisation to generate an action potential and then 
repolarisation to return it to a resting state. Myelin appears to have two important 
roles in nerve conduction (Hildebrand et al., 1993). Firstly, it increases the speed of 
nerve conduction by enabling saltatory conduction. The lipid-rich structure 
insulates the axolemma maintaining its electrophysiological stability and enables 
action potentials to pass between nodes of Ranvier rather than along consecutively 
depolarising sections of axon. Secondly, as only nodal regions of the axolemma 
need to depolarise and repolarise to generate action potentials, myelination 
improves the energy efficiency of conduction.
1.2.1 The axon
Axons are elongated neuronal cell processes that conduct action potentials away 
from the neuronal soma. Action potentials originate in the axon initial segment and 
pass down the axon either by depolarisation of consecutive regions of the axolemma 
or by saltatory conduction along myelinated axons. Most CNS axons greater than 
0.2pm in diameter are myelinated.
The axoplasm is divided into three compartments. The subaxolemmal domain 
constitutes the axoplasmic cortex, a peripheral layer of microfilaments located just 
beneath the axolemma that supports the axolemma and anchors the cytoskeleton to 
it. The neurofilament domain contains the neurofilamentous cytoskeleton and 
determines the shape and size o f the axon. Micro tubular domains intersperse 
through the neurofilament domain and contain fast axonal transport mechanisms 
that move membrane-bound organelles along the axon. These mechanisms are 
necessary because the axon lacks transcriptional machinery and cellular products 
must be produced in the soma and transported along the axon. The fast axonal 
transport mechanisms have high energy requirements utilising translocators such as 
kinesin (anterograde) and dynein (retrograde) to transport membrane bound 
organelles along the microtubular network (reviewed by Hirokawa, 1993). Golgi- 
derived vesicles are transported anterogradely away from the soma; lysosomal- 
derived vesicles are transported rcetrogradely towards the soma; organelles such as 
mitochondria move bidirectionally' along the axon.
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1.2.2 The oligodendrocyte
1.2.2.1 Oligodendrocyte development
The mature oligodendrocyte is a highly specialised CNS-specific cell that is 
responsible for the elaboration and maintenance of myelin from its numerous cell 
processes (see below). It plays a vital role in maintaining the normal CNS 
architecture and perturbations of the oligodendrocyte can severely affect 
neurological function. Evidence of other roles for the oligodendrocyte is emerging. 
Perineuronal oligodendrocytes may control the microenvironment surrounding the 
neuronal cell body and roles in influencing axonal development and maintenance 
have also been proposed (see 1.2.5 Axoglial interaction, page 8).
The origin and migration of immature oligodendrocytes remains a contentious issue. 
Most recent evidence points towards oligodendrocyte precursors originating from 
neuroectodermal cells in the ventral subventricular region of the neural tube (Warf 
et al., 1991; Noll and Miller, 1993; Timsit et al., 1995; Ono et al., 1995; Dickinson 
et al., 1996; Hall et al., 1996; Spassky et al., 1998; Chandross et al., 1999). Two 
separate lineages of oligodendrocyte progenitor can be identified from embryonic 
day 9.5 in the mouse (Spassky et al., 1998) and appear to migrate to populate all 
white matter areas (Noll and Miller, 1993; Spassky et al., 1998). However, 
alternative views are that oligodendrocyte progenitors are capable of developing 
ubiquitously throughout the white matter (Hardy and Friedrich, Jr., 1996) or 
originate in both the dorsal and ventral areas of the developing neural tube 
(Cameron-Curry and Le Douarin, 1995). Whether the progenitors migrate or 
develop ubiquitously throughout the embryonic CNS, they must proliferate in the 
future white matter tracts before maturing into myelin-competent oligodendrocytes. 
A combination of intrinsic and extrinsic factors appears to control these processes 
(reviewed by McMorris and McKinnon, 1996). One feature of this system is that 
immature oligodendrocyte numbers far exceed the final requirements for these cells 
and many of these progenitors, as much as fifty percent, undergo apoptotic cell 
death (Barres et al., 1992).
1.2.2.1.1 M yelinogenesis
As oligodendrocytes reach maturity, they elaborate numerous cell processes. These 
contact and start to enwrap neighbouring axons forming multilamellar myelin 
sheaths (reviewed by Raine, 1984). The oligodendrocyte process closely associates 
with the axolemmal membrane maintaining a 12 to 14nm gap, the periaxonal space. 
Successive layers of the oligodendrocyte process become closely apposed at their 
extracellular surfaces forming paired thin electron-dense structures, the intraperiod 
lines. Initially the cytoplasmic membrane surfaces remain separated but, as spiral
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enwrapment progresses, cytoplasm becomes extruded from the oligodendrocyte 
process and the cytoplasmic surfaces fuse to form an electron dense layer, the major 
dense line. In cross section, myelin lamellae repeat through the myelin sheath with 
a regular interval referred to as the periodicity of myelin (approximately llnm  in 
the CNS from electron-microscopy images). Cytoplasm is retained at the outer 
edges of each successive myelin lamellae, which collectively form the lateral 
cytoplasmic loops, and in the inner and outer tongues of oligodendrocyte process. 
Each consecutive lateral cytoplasmic loop overlaps the loop below it to attach to the 
paranodal axolemma by tight junction-like complexes collectively forming the 
paranodal loops. Each oligodendrocyte is capable of producing up to fifty myelin 
sheaths however consecutive intemodes along a single axon are unlikely to originate 
from the same cell.
Myelination has a spatio-temporal pattern of development; myelination in the PNS 
preceding that in the CNS and myelination of different parts of the CNS initiating at 
different time points. In general, the first CNS area to myelinate is the cervical 
spinal cord. From here, a wave of myelination spreads caudally along the spinal 
cord and rostrally through the brain. The optic nerve myelinates later than the 
spinal cord and hindbrain. Large diameter fibre tracts myelinate in advance of small 
diameter fibre tracts so that the ventral columns of the spinal cord myelinate before 
the dorsal tracts, the corticospinal tracts being last (Schwab and Schnell, 1989).
Oligodendrocytes can be divided into subpopulations on the basis of the number and 
diameter of the axons that they myelinate (reviewed by Hildebrand et al., 1993). 
Some oligodendrocytes myelinate large numbers of small diameter axons whereas 
others myelinate smaller numbers of larger diameter axons. At one extreme, some 
oligodendrocytes in the ventral white matter tracts of the spinal cord form a 1:1 
relationship with large axons so that each cell only elaborates one myelin sheath 
(Remahl and Hildebrand, 1990). Although it is difficult to demonstrate directly, the 
molecular structure of myelin does appear to vary with axon diameter (reviewed by 
Norton and Cammer, 1984). For example, myelin from large diameter axons has 
more myelin basic protein (MBP) and less PLP immunostaining than myelin from 
small diameter axons (Hartman et al., 1982). This could support the view that 
oligodendrocytes myelinating small diameter axons are intrinsically different from 
those myelinating large diameter axons. Alternatively, the stoichiometric 
relationship between myelin proteins may change depending on the thickness (and 
total myelin volume) of each internode. Some cell markers such as carbonic 
anhydrase II (Butt et al., 1995) and transferrin (Espinosa de los Monteros and 
Vellis, 1990) also vary between oligodendrocytes but a clear molecular basis for 
dividing oligodendrocytes into functional subpopulations has not been found. In
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fact, work from transplantation experiments suggests that all oligodendrocytes are 
capable of myelinating a full range of axon sizes (Fanarraga et al., 1998). This 
indicates that an extrinsic factor, possibly axonally derived, may be responsible for 
oligodendrocyte diversity.
1.2.2.1.2 M yelin biology
The myelin sheath is composed of lipids contributing to the phospholipid bilayer, 
which are interspersed with the myelin proteins. Although mature oligodendrocytes 
are post-mitotic, they remain extremely active continually turning over the lipid and 
protein components of myelin.
1.2.2.1.2.1 Lipid composition
Lipids constitute approximately seventy percent of the dry weight of myelin (Norton 
and Cammer, 1984). Although none of the lipids is unique to myelin, the high 
proportions of the galactosphingolipids (galactocerebroside and the sulphatides), 
cholesterol and plasmalogen are characteristic of myelin (Hildebrand et a l, 1993). 
Galactocerebroside, in particular, is restricted almost exclusively to the 
oligodendrocyte making it a useful myelin marker (Raff et al., 1978). As well as 
having structural roles, the sphingolipids have been implicated in signal 
transduction (Dyer, 1993).
1.2.2.1.2.2 Protein composition 
Proteolipid protein
PLP is the major myelin protein and, with its minor isoform, DM20, accounts for 
fifty percent of the myelin proteins. These proteins may have important structural 
roles in maintaining myelin compaction. In particular, they may act as adhesive 
struts supporting the intraperiod line and retaining the close apposition of the 
extracellular surfaces of adjacent myelin lamellae (see 1.3 The proteolipid protein 
gene: structure and function, page 9).
M yelin basic protein
MBP proteins are a group of at least five isoforms of the Mbp gene ranging in size 
from 14 to 21.5kDa (Ferra et al., 1985; Newman et al., 1987; Aruga et al., 1991) 
that are among the first myelin proteins to be upregulated during active myelination 
in the CNS (Kanfer et al., 1989). These proteins are present in myelin forming cells 
and contribute forty percent of central myelin proteins (Lemke, 1988). These small
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extrinsic membrane proteins are extremely basic, hydrophilic, charged molecules 
that localise to the cytoplasmic surface of compacted myelin (McLaurin et al., 
1993). In the CNS, the MBP proteins are responsible for maintaining fusion of the 
cytoplasmic surfaces of myelin lamellae to produce the major dense line (Privat et 
al., 1979; Readhead et al., 1987).
The Mbp gene transcriptional unit is itself contained within a larger gene complex, 
the gene-of-oligodendrocyte-lineage (Golli-mbp gene) (Pribyl et al., 1993). The 
Golli-mbp gene utilises additional exons and the Mbp gene to express a range of 
isoforms predominantly in neural tissue. However, the regulation of the Mbp gene 
appears to be separate from that of the Golli-mbp gene (Pribyl et al., 1993).
M yelin-associated oligodendrocyte basic protein (M OBP)
The MOBP group of proteins are small, highly charged, basic proteins produced by 
alternative splicing of the Mobp gene (Yamamoto et al., 1994). These proteins 
localise in compact myelin at the major dense line and with the microtubular 
cytoskeletal elements (Montague et al., 1998). They may have roles in the initiation 
of myelin compaction and in the late formation or stabilisation of the major dense 
line (Yamamoto et al., 1994; Montague et al., 1997). These proteins may also 
contribute to the formation of the radial component of myelin (Yamamoto et al., 
1999).
2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP)
The Cnp gene products catalyse the hydrolysis of several 2', 3'-cyclic nucleoside 
monophosphates in vitro and, in the CNS, are expressed exclusively by 
oligodendrocytes. Two isoforms of CNP (46 and 48kDa) constitute five percent of 
the total myelin proteins (Lemke, 1988) and localise to non-compacted regions of 
the myelin membrane (Trapp et al., 1988). These proteins are expressed in 
oligodendrocyte progenitors and mature cells localising to the cytoplasmic surface 
of the plasma membrane where they bind microtubules possibly anchoring 
cytoskeletal elements to the membrane (Laezza et al., 1997).
Myelin associated glycoprotein (MAG)
MAG proteins are highly glycosylated transmembrane proteins that constitute two 
differentially regulated isoforms (67 and 72kDa). These are not major components 
of myelin and account for only one percent of central and peripheral myelin proteins 
(Quarles et al., 1992). The MAG protein isoforms are not structural components of 
compact myelin but localises to the non-compacted regions of the central myelin
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sheath including the adaxonal cytoplasmic sheath and the paranodal loops (Trapp 
and Quarles, 1984). Specifically, they localise at points where oligodendrocyte and 
axonal membranes come into close apposition and are expressed before myelin 
compaction in ensheathing oligodendrocytes. They have marked similarities to 
N-CAM, an adhesive membrane protein expressed by neurones, and may have roles 
in axoglial interaction or in forming and maintaining the periaxonal space 
(Yoshihara et a l ,  1991). However, M ag  gene knockout mice myelinate well and 
have normal periaxonal spaces (Fruttiger et al., 1995; Fujita et al., 1998).
Minor myelin proteins
Small amounts o f other myelin specific proteins have been identified but the 
functions o f many o f these remain obscure. These include myelin/ oligodendrocyte 
protein (MOG) (Linington et a l ,  1984), oligodendrocyte-myelin glycoprotein 
(OMpg) (Mikol et a l ,  1993) and myelin oligodendrocyte specific protein (MOSP) 
(Dyer et a l ,  1991). Although these are not major components o f myelin, they may 
have important roles in myelin production and maintenance.
1.2.3 The astrocyte
Astrocytes make up a heterogeneous population o f cells that are thought to have 
roles in neural development and in supporting the architecture o f the mature CNS 
(reviewed by Montgomery, 1994). During development, radial glia, which develop 
into astrocytes, provide a radial support for neuroblasts to migrate along and may 
guide axonal migration. In the mature CNS, in addition to supporting neural 
architecture and forming the glia limitans, astrocytes may support the nodal 
architecture and may help to maintain the ionic homeostasis o f the CNS. During 
CNS injury, astrocytic hypertrophy supports damaged regions o f the CNS and roles 
in modifying immune and inflammatory responses have also been proposed.
1.2.4 The microglia
The microglia are a resting population o f mononuclear phagocytic cells that remove 
cellular debris produced from normal cell turnover within the CNS (reviewed by 
Stoll and Jander, 1999). Microglia also respond to CNS injury where they have 
phagocytic and antigen presenting roles. In the murine CNS microglia rarely 
become fully activated and marked microglial-induced inflammatory changes are 
uncommon. Active inflammatory lesions are produced when circulating 
macrophages migrate into damaged regions o f the murine CNS.
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1.2.5 Axoglial interactions
As well as supporting CNS architecture, axoglial interactions play important roles in 
neural development (reviewed by Barres, 1997). Neurones, for example, secrete 
mitogenic and survival factors that regulate glial maturation. Early in 
oligodendrocyte development, these factors promote progenitor proliferation and 
survival but prevent their differentiation and maturation (Barres et a l, 1993; Canoll 
et a l, 1996; Canoll et a l, 1999). As numbers of immature oligodendrocytes 
increase above demand, apoptotic pathways are triggered possibly through 
increasing competition for these survival factors (Barres et a l, 1992). These 
mechanisms control oligodendrocyte numbers ensuring that sufficient precursors 
populate the CNS to myelinate the white matter tracts. Myelination itself may 
simply be regulated through permissive signalling that allows oligodendrocytes to 
survive until they become myelin competent. However, there is mounting evidence 
that other, non-survival orientated pathways regulate myelination. For example, 
axons in the corticospinal and other tracts do not acquire myelin sheaths until after 
they have stopped migrating (Schwab and Schnell, 1989). One explanation is that, 
until reaching its target, the axon may release inhibitory factors that prevent 
oligodendrocyte differentiation (Barres, 1997). Other in vitro work suggests that 
soluble factors secreted by astrocytes mediate oligodendrocyte maturation and 
myelination (Bhat and Pfeiffer, 1986; Rosen et a l, 1989).
Increasingly, roles for glial cells in determining neuronal development are being 
identified. There is some evidence to suggest that glial cells guide migration of 
neuronal processes and promote the differentiation and survival of neuronal 
precursors (Barres, 1997). In the differentiated neurone, glial interactions are 
involved in regulating axonal structure (Colello et a l, 1994). Oligodendrocyte 
ensheathment induces local radial axonal growth. This is independent of myelin 
formation and may be mediated through a local membrane-bound kinase system that 
causes neurofilament phosphorylation (Sanchez et a l, 1996). Oligodendrocytes 
also release a soluble factor that induces sodium channel clustering, a vital step in 
defining the nodal axon. However, the location and spacing of the nodes is an 
intrinsic axonal feature and is not influenced by oligodendrocyte interaction (Kaplan 
et a l, 1997).
Collectively, these studies show that neurones and glia interact extensively during 
development through the release of soluble factors and through direct cellular 
contact. Altered gene regulation in oligodendrocytes following axotomy indicates 
that regulatory axoglial interactions continue throughout life (McPhilemy et a l, 
1990). The identification of axonal pathology in increasing numbers of myelin 
diseases such as quaking, rumpshaker and jimpy mice (see 1.4.2.3 Axonal changes,
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page 28) and in some chronic, progressive multiple sclerosis lesions may indicate a 
reciprocal role for oligodendrocytes in maintaining normal axon function (De 
Stefano et al., 1998). Axoglial interactions are clearly important in neural 
development and maintenance and increasing evidence suggests that they may also 
have roles in disease pathogenesis.
1.3 The proteolipid protein gene: structure and 
function
1.3.1 The Pip gene locus
The PLP gene maps to a single locus on the X-chromosome (at Xq21.33-22 in man) 
(Willard and Riordan, 1985; Milner et al., 1985; Mattei et al., 1986) and encodes 
the major integral membrane proteins of compacted CNS myelin. Although the 
gene is predominantly expressed in oligodendrocytes, the recent identification of an 
eighth exon located within intron 1 has led to the discovery of splice variants of the 
Pip gene that are expressed in neuronal subpopulations (Bongarzone et al., 1999). 
The gene is also expressed in premyelinating CNS tissue, Schwann cells, 
thymocytes, cardiac myocytes and spleen (Campagnoni et al., 1992; Griffiths et al., 
1995; Dickinson et al., 1996; Pribyl et a l, 1996). The organisation of the Pip gene 
and its transcription products are shown in Figure 1 (page 10).
The Pip structural gene covers approximately 17kb and contains eight exons and 
seven introns (Diehl et al., 1986; Macklin et al., 1987; Bongarzone et al., 1999). 
The Pip gene contains two translation initiation codons (Bongarzone et al., 1999). 
Exon 1 contains the 5'-UTR and major translation initiation codon with the first 
nucleotide of codon 2 (glycine) that will become the amino-terminal of the major 
mature Pip gene products (Macklin et al., 1987). Exon 1.1 is located 122 base pairs 
downstream from exon 1 (Bongarzone et al., 1999). It divides intron 1 in two and 
contains the second translation initiation codon and eleven additional codons that 
are spliced in-frame into exon 2 (Bongarzone et al., 1999). The intronic sequence 
between exons 1.1 and 2 is the largest intron of the Pip gene and may have 
important regulatory functions (Wight and Dobretsova, 1997) (see 1.3.3.1 
Transcriptional control, page 12). The remaining exons are more closely spaced 
with exon 7 encoding the carboxy-terminus and the entire 3'-UTR (2.3kb) (Macklin 
et a l, 1987). Through alternate splicing of the primary transcript, the Pip gene 
produces two major protein isoforms, PLP (30kDa) and DM20 (26.5kDa) and two 
minor protein isoforms, srPLP and srDM20 (molecular weights not available) (see
1.3.3.2 Post-transcriptional regulation o f  Pip , page 13). The presence of a ninth
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exon in the 3' flanking region has been proposed by Kamholz et al. (1992) and 
several lower molecular weight proteolipids may represent rarer splice variants of 
the Pip gene (see 1.3.7 Lower molecular weight proteolipid proteins in the CNS, 
page 19).
Pip gene transcript heterogeneity exists through alternative use of three cap sites in 
the 5'-UTR (Milner et a l, 1985; Macklin et a l, 1987) and three polyadenylation 
signals in the 3'-UTR (Milner et al., 1985; Gardinier et al., 1986; Macklin et al., 
1987) (see Figure 1, page 10). Three populations of transcripts, each containing all 
message isoforms, are produced by alternate use of these polyadenylation signals 
(Macklin et al., 1987; Bongarzone et al., 1999). Although 5' transcript 
heterogeneity has been associated with regulation of tissue-specific expression of 
other genes, no clear functional consequences have been identified for the Pip gene. 
Similarly, differential polyadenylation of the Pip gene transcripts appears to have no 
biological effect.
1.3.2 The DM  gene family and phylogenetic evolution of the P/p 
gene
1.3.2.1 Conservation o f the Pip  gene
The Pip gene shows a remarkable level of sequence conservation between species at 
both the amino acid and nucleotide levels. When compared to man, amino acid 
sequence identity reaches 100% in rodents, >99% in the dog and >97% in the cow 
(Milner et al., 1985; Macklin et al., 1987). Nucleotide changes that occur between 
species tend to be silent and the exon boundaries are invariant. Even more 
unusually, high levels of sequence identity extend into the non-coding and non­
transcribed regions. Between rat and human there is 93% overall identity of the 
5'-UTR and up to 86% identity (overall 76%) of the 3'-UTR (Roth et al., 1986). 
The proximal region of the 5'-UTR at the cap sites is one of the most highly 
conserved areas of the gene (100% between rodents and man) (Macklin et al., 
1987). Conservation of sequence also extends a considerable distance into the 5' 
flanking (95% over l.lkb  between rat and mouse; 75% over 0.7kb between rat and 
man) (Montague and Griffiths, 1997).
This level of conservation is almost unique to the Pip gene. Proteins that have 
specialised functions, particularly if these depend on close interaction with other 
proteins, can show high levels of conservation of their primary structure (75 to 
90%). For example, the actin monomers structurally interact with six other 
molecules to function and show a comparable level of conservation of their primary 
structures (reviewed by Hudson and Nadon, 1992). The high level of conservation
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within the non-coding and non-transcribed regions of the Pip  gene is highly unusual 
and may be of more interest than the conservation of the peptide sequence. This 
level of conservation may indicate that the Pip gene is under tight regulatory control 
that could be vital for the function of the gene (see 1.3.3.1 Transcriptional control, 
page 12). The extreme conservation of the transcription initiation sites and the 
immediate 5' flanking sequence of the Pip gene strongly supports this hypothesis 
(Macklin e ta l ., 1987).
1.3.2.2 Phylogenetic evolution of the Pip gene and the DM  gene family
The evolution of the Pip gene has been reviewed by Schliess & Stoffel (1993), 
Yoshida & Colman (1996) and Kurihara et al. (1997). The primordial gene 
encoding the DM20 protein first appeared in cartilaginous fish where myelin protein 
zero (P0) contributes to myelin compaction in both the peripheral and central 
nervous systems. The unique region of the PLP protein isoform was acquired after 
terrestrial vertebrates diverged from bony fish. The subsequent formation of the 
internal splice site within exon 3 as higher vertebrates diverged from amphibians 
enabled the expression of both isoforms. The evolution of the Pip gene appears to 
have been permissive with the drop out of P0 from the CNS indicating that Pip gene 
products may also have adhesive properties necessary for maintaining myelin 
compaction.
The Pip  gene appears to be part of a large family of related genes with high levels of 
sequence identity, the D M  gene family. These locate predominantly to the CNS and 
include the glycoprotein-encoding genes D m -a, D m -p  and D m -/  in bony fish 
(Kitagawa et al., 1993) and M6a and M6b in mammals (Yan et al., 1993). Some 
members of the D M  gene family are found on epithelial surfaces involved in active 
ion transport and show significant degrees of sequence identity with the channel- 
forming regions of the ligand-gated acetylcholine and glutamate receptors 
(Kitagawa et a l ,  1993). This adds weight to possible non-structural roles for the 
Pip gene (see 1.3.6.2 Non-structural roles, page 18) and may indicate that the D M  
gene family evolved from a duplicated ancestral gene that preceded the 
development of myelin (Kitagawa et al., 1993).
1.3.3 Regulation o f Pip gene expression in the CNS
1.3.3.1 Transcriptional control of Pip gene expression
Pip gene expression is controlled predominantly at the level of gene transcription. 
This is a common feature of genes that are expressed in a tissue-specific pattern and 
have transcripts that account for a large proportion of total cellular mRNA. Nuclear
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run-on assays show that Pip gene transcripts are moderately stable and protein 
production closely mirrors transcript levels (Cook et al., 1992). There is no 
evidence to support transcript instability or regulation of protein translation and 
degradation as being major points of control of Pip gene regulation (Cambi and 
Kamholz, 1994). The developmental profiles of the Mbp and Pip gene transcripts 
closely parallel each other and MBP protein levels mirror transcript production. 
This suggests that the Mbp gene is also transcriptionally controlled and that a single 
pathway may control the expression of both genes (Cook et al., 1992). Comparison 
of the 5' flanking regions of the Pip, Mag, Mog and Mbp genes has revealed 
putative cA-regulatory elements, including a Sp-l-like binding site, that may co­
ordinate expression of myelin genes through common trans-acting factors (Nave 
and Lemke, 1991; Janz and Stoffel, 1993).
In vitro and in vivo studies have been used to identify promoter and enhancer 
elements in the 5' flanking region and in intron 1 of the Pip gene. Wight and 
Dobretsova (1997) have identified potential cA-regulatory elements in intron 1 
although the significance of these is unknown. They suggest that the Pip gene 
promoter is promiscuous and that intron 1 controls tissue specific expression by 
repressing promoter activity in non-glial cells. However, mounting evidence from 
other studies suggests that relatively short sequences of the Pip gene promoter itself 
control tissue specific expression (Nadon et al., 1989; Nave and Lemke, 1991; Gout 
et al., 1991; Cook et al., 1992; Janz and Stoffel, 1993; Cambi and Kamholz, 1994; 
Johnson et al., 1995).
1.3.3.2 Post-transcriptional regulation o iP lp  gene expression
The two major protein isoforms of the Pip gene, PLP and DM20, are translated from 
mRNAs produced by alternate splicing of the same pre-mRNA to give open reading 
frames of 831 and 726 base pairs respectively (Nave et al., 1987a). The Dm20- 
mRNA differs from the Plp-mRNA only by the omission of 115 nucleotide residues 
that constitute exon 3b (see Figure 1, page 10). This results from alternate use of an 
internal 5' splice site (5 '-c a a c g G T a a c a g -3 ') within exon 3 instead of the 5' splice 
site at the exon 3/ intron 3 boundary. This splice site delineates exon 3a from exon 
3b and its utilisation causes the in-frame deletion of exon 3b. Although the 
production of multiple isoforms by alternate splicing to exclude entire exons is well 
described (for example Mbp and Mag genes), the utilisation of splice sites within 
exons is rare in mammalian genes (for example CD44: Screaton et al., 1992; 
EAAT2: Meyer et al., 1998; 11-15: Prinzet al., 1998). The two minor protein 
isoforms, srPLP and srDM20, show similar alternate use of the internal splice site 
within exon 3. In addition, the srPlp and srDm20 transcripts retain exon 1.1 that is
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spliced in-frame with exon 2 and produces transcripts with open reading frames of 
864 and 759 base pairs respectively (Bongarzone et al., 1999).
Pip and Dm20 message isoforms show different spatio-temporal expression patterns 
that are determined by splice site selection. There is no difference in the affinity for 
either 5' splice site in exon 3 so differential splicing patterns are not dependent on 
the position of the splice sites (Nave et al., 1987a). One possibility is that splice site 
selection is under tight regulatory control and is regulated in a spatio-temporal 
manner. However, as the expression of the PLP protein isoform predominates 
during maximum Pip gene expression, splice site selection may be a feature of total 
transcript level. This would explain the marked change in proportion of the two 
isoforms that coincides with upregulation of the Pip gene. It may also offer an 
explanation as to why the DM20 protein predominates in the PNS and extra-neural 
tissues that express the Pip gene at low levels (see 1.3.4 Expression o f  the Pip gene 
in the PNS, page 15).
1.3.3.3 Developm ental expression o f the Pip  gene in the CNS
The major cell type expressing the Pip gene in the CNS is the mature 
oligodendrocyte (Hartman et al., 1982). Pip isoform transcripts can be detected 
from 0 to 2 days post-natally in the murine CNS, coinciding with the onset of 
myelination, and are rapidly followed by the incorporation of protein into myelin. 
Pip gene upregulation follows the developmental pattern of myelination starting in 
the medulla oblongata and proceeding rostrally in the brain and caudally in the 
spinal cord (Verity and Campagnoni, 1988). Pip isoform expression peaks when 
myelination is most active (post-natal day 22 in the mouse) (Verity and 
Campagnoni, 1988) but drops to approximately 60% of this level in the adult (Sorg 
et al., 1987). In the myelinated CNS, Pip isoform transcripts predominate as the 
major product of the Pip gene. Dm20 isoform expression is also upregulated during 
myelination but transcript levels never reach more than 50% of Pip-mRNA levels 
(Nave et al., 1987a). Although peak Pip gene expression occurs during 
myelination, Dm20 transcripts can be identified as early as embryonic day 9.5 in the 
developing murine CNS (Timsit et al., 1992; Spassky et al., 1998) and DM20 
protein is identified from embryonic day 12 (Dickinson et al., 1996). Initially Dm20 
isoform expression localises in the basal plate of the diencephalon and the caudal 
hypothalamus but later this spreads into the major white matter tracts. Unlike 
previously described oligodendrocyte progenitors, the Dm20 transcript-positive cells 
do not express platelet-derived growth factor a-receptor (PDGFRa) although they 
do develop into mature oligodendrocytes. Dm20+, PDGFRa- cells are thought to 
represent a distinct lineage of oligodendrocyte precursors indicating that
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oligodendrocytes may arise from two distinct populations of progenitor cells 
(Spassky et al., 1998). The significance of Dm20 isoform expression in these cells 
is unclear but its presence may indicate that the DM20 protein has roles early in 
oligodendrocyte development.
In the developing CNS, srPlp and srDm20 transcripts show similar spatio-temporal 
expression patterns to Pip and Dm20 transcripts respectively but are also expressed 
in neurones (Bongarzone et al., 1999). Further analysis of the early srDm20 
transcript patterns in the developing CNS is necessary to establish if the expression 
of this isoform is confined to the same neural precursor cells as Dm20 transcripts.
1.3.4 Expression of the Pip gene in the PNS
The Pip gene is expressed in the myelin-forming and non-myelin-forming Schwann 
cells of the PNS (Griffiths et al., 1995). Both PLP and DM20 proteins are produced 
(Kamholz et al., 1992) and appear to undergo similar post-translational 
modifications as in the CNS (Tetzloff and Bizzozero, 1993). However, the level of 
gene expression is much lower in Schwann cells and is uncoupled from the 
expression of other myelin genes suggesting that, in the PNS, the Pip gene may be 
under different transcriptional control than in the CNS.
In contrast to the CNS, the PLP isoform constitutes only a small proportion of the 
Pip gene products of the Schwann cell and appears to be localised to the perinuclear 
region (Griffiths et al., 1995). DM20 is the major protein isoform produced in the 
PNS and locates to the non-compacted regions of the Schwann cell cytoplasm 
including the cell body, the Schmidt-Lanterman incisures, the paranodes and the 
outer Schwann cell cytoplasm. Although the presence of PLP or DM20 proteins 
cannot be demonstrated readily in peripheral compacted myelin there is some 
evidence to suggest that there may be low levels of each isoform present (Agrawal 
and Agrawal, 1991; Garbem et al., 1997). In particular, Garbern et al. (1997) have 
demonstrated a low level of PLP immunoreactivity in peripheral compact myelin. 
Garbem et al. (1997) also described a family with a point deletion leading to a PLP 
gene-null allele. This family unusually developed a peripheral demyelinating 
neuropathy suggesting that the Pip gene does have roles in forming or maintaining 
peripheral myelin (see 1.4 Pip gene mutations, page 19). These results mean that 
the role of the Pip gene in the PNS may need to be re-evaluated.
The DM20 protein isoform is also expressed in the satellite cells of the peripheral 
ganglia and the olfactory bulb ensheathing cells (Griffiths et al., 1995).
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1.3.5 Translation and post-translational modification of PLP/DM20 
protein
1.3.5.1 Translation and post-translational modification
Pip and Dm20 message isoforms are translated on the rough endoplasmic reticulum 
and the proteins progress through the secretory pathway to the plasma membrane 
where they incorporate into myelin (Gow et al., 1994a). Two post-translational 
events occur, the amino-terminal methionine is lost and the proteins undergo 
acylation. Some proteins, for example the myelin protein PO, require cleavage of an 
amino-terminal signalling peptide before the protein can be translocated to the 
plasma membrane (D'Urso et al., 1990). PLP/DM20 proteins do not have a cleaved 
targeting sequence (Milner et al., 1985) but the minor isoforms srPLP and srDM20 
appear to have a targeting sequence encoded by exon 1.1 (Bongarzone et al., 1999). 
The twelve peptide sequence shows some homology to known soma-restrictive 
targeting sequences and may restrict these proteins to the cell body of 
oligodendrocytes and neurones but does not undergo post-translational cleavage 
(Bongarzone et al., 1999).
The PLP protein is acylated at six cysteine residues (see Figure 2, page 17) 
increasing its overall hydrophobicity. The DM20 protein is also acylated but lacks 
two of the acylation sites that are located in the peptide region unique to the PLP 
isoform (Weimbs and Stoffel, 1992). The two isoforms are acylated by similar 
ratios of long chain fatty acids predominantly comprising palmitic, palmitoleic, 
oleic and stearic acids (Bizzozero and Lees, 1999). The function of these fatty acids 
is unknown but alterations in their composition do lead to changes in protein 
conformation. Some evidence exists to suggest that the long-chain fatty acid 
composition of the proteolipids is linked to gene function. The relative proportions 
of fatty acids acylating the Pip gene products are highly conserved between species 
despite diversity in the proportions of other cell lipids. This implies that the pattern 
of acylation is also important for normal protein function (Bizzozero and Lees, 
1999). Additionally, aberrant proteolipid acylation has been identified in at least 
one neurodegenerative disorder, X-linked adrenoleukodystrophy, although its 
significance in disease pathogenesis is uncertain (Bizzozero and Lees, 1999).
1.3.5.2 PLP and DM 20 protein topology
Although several different models of PLP protein membrane topology have been 
proposed, the one suggested by Popot et al. (1991) is the most widely accepted (see 
Figure 2, page 17). The DM20 protein isoform lacks the hydrophilic, highly
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charged, basic region unique to the PLP isoform (Weimbs and Stoffel, 1992) and 
may adopt a different topology. This may indicate that DM20 and PLP proteins 
have different roles as protein function can be intimately linked to conformation.
1.3.6 Proposed functions of the Pip gene
1.3.6.1 Structural roles
The abundance of the PLP protein in compacted CNS myelin and its proposed 
transmembrane topology provide strong circumstantial evidence for an important 
structural role in the formation and maintenance of compact myelin. Further 
evidence comes from the Pip gene mutants that characteristically have CNS 
hypomyelination with altered myelin periodicity, predominantly showing condensed 
intraperiod lines (1.4.2 Pip gene mutations in animal, page 22). In particular, the 
Pip gene products may act as adhesive struts supporting the intraperiod line and 
hence contributing to myelin compaction and stability (Duncan et al., 1987a; 
Sinoway et al., 1994). In vitro studies provide evidence that the extracellular 
domains of the Pip gene protein isoforms may have adhesive properties possibly 
through the formation of homophilic or heterophilic interactions between PLP and 
DM20 proteins (Sinoway et al., 1994). Sinoway et al. (1994) specifically suggest 
that DM20 may be necessary to allow PLP transport to the cell surface and hence its 
incorporation into compact myelin although this view is not supported by other 
work (Thomson et al., 1997).
1.3.6.2 Non-structural roles
The expression of the Pip gene before the formation of myelin in the CNS and in 
non-neural tissues has lead to the suggestion that it may have functions other than as 
a structural component of compact myelin. The presence of Dm20 transcripts in 
early embryonic tissues (Timsit et al., 1992) and the reduction in mature 
oligodendrocyte numbers in most Pip mutants (Knapp, 1996) provide some 
evidence for a role, particularly of the DM20 protein isoform, in oligodendrocyte 
differentiation and survival. Yamada et al. (1999) reported from in vitro studies that 
a secreted Pip gene product may act as a mitotic factor increasing astrocyte and 
oligodendrocyte numbers. They suggested that this product may have autocrine or 
paracrine roles in the CNS but were unable to demonstrate its presence directly.
As the Pip gene products and other members of the DM  gene family show 
considerable similarity to channel-forming proteins (see 1.3.2.2 Phylogenetic 
evolution o f the Pip gene and the DM gene family, page 12), a role in regulating the 
ion permeability of myelin has been proposed. Experimental data from artificial
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lipid bilayers provides support for the Pip gene protein isoforms acting as 
ionophores (Diaz et al., 1990).
The isolation of srDm20 transcripts to developing neural tissue and of srPLP and 
srDM20 proteins to the soma of oligodendrocytes and subpopulations of neurones 
suggests potential roles in early neural development and in mature oligodendrocyte 
and neuronal function (Bongarzone et al., 1999).
1.3.7 Lower molecular weight proteolipid proteins in the CNS
Biochemical fractionation of CNS tissue has shown small amounts of low molecular 
weight proteolipids that may represent rare protein isoforms of the Pip gene. One of 
these peptides (Mr 20 kDa) has been identified in bovine foetal tissue (Schindler et 
al., 1990). Two other proteolipids (Mr 14 kDa and 16 kDa) have been isolated from 
adult bovine brain (Lepage et al., 1986) and embryonic murine tissue (Nussbaum 
and Mandel, 1973). The presence of these proteins with the DM20 protein isoform 
in pre-myelinating CNS tissue may indicate a non-structural role for the Pip gene. 
However, to date, no reports of transcripts coding these putative isoforms have been 
published and they may represent artefacts of biochemical fractionation.
1.4 Pip gene mutations and disease
Spontaneous Pip gene mutations cause severe dysmyelinating disease in man and in 
animals. The study of these disorders and the generation of Pip transgenic animals 
have provided valuable insights into the functions of the Pip gene and its role in 
neurological disease.
1.4.1 PLP gene-related disorders in man
Two dysmyelinating diseases have been described in man that have an X-linked 
recessive mode of inheritance and have been shown to map to the PLP gene locus; 
Pelizaeus-Merzbacher disease (PMD) and X-linked Spastic Paraplegia type 2 
(SPG2). Both were originally defined by their clinical features and are now 
considered allelic disorders of the PLP gene.
1.4.1.1 Pelizaeus-M erzbacher Disease
PMD (OMIM 312080) was first described in 1885 by Pelizaeus and in 1910 by 
Merzbacher. It produces a progressive clinical syndrome of nystagmus, delayed 
psychomotor development, spasticity, cerebellar ataxia, optic atrophy, laryngeal 
stridor, seizures and mental deterioration that leads to death in adolescence or early 
adulthood (Hodes et al., 1993; Seitelberger, 1995). Marked variation in the severity
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of disease has been noted both between unrelated families and within related 
families and three classifications of disease have been proposed (Seitelberger,
1995). These are PMD type I (“classic PMD”, onset within the first 5 years), PMD 
type II (congenital or “connatal” PMD, onset from birth), and PMD type III 
(“transitional PMD” with an intermediate phenotype between type I and II). Due to 
its X-linked mode of inheritance, males are predominantly affected while females, 
heterozygous for the disease allele, act as asymptomatic carriers. Occasionally, 
disease is reported in females from affected families (see 1.4.5 Clinically affected 
female carriers, page 33).
Pathologically, PMD is characterised by diffuse, symmetrical CNS hypomyelination 
that is most marked in late myelinating areas such as the cerebellar and cerebral 
white matter. Oligodendrocytes are reduced in number with ultrastructural 
abnormalities and there is a dense fibrillary astrocytosis. Myelin, when present, is 
poorly compacted and there is some evidence of demyelination. Complete 
amyelination, which is seen in connatal (Type II) PMD, is reflected clinically by 
early disease onset and death (Seitelberger, 1995). Although PLP gene mutations 
are not classically considered to affect the PNS, one report describes a 
demyelinating peripheral neuropathy in a family with a PLP gene-null mutation and 
alludes to possible similar pathology in other PMD families (Garbem et al., 1997) 
(see also 1.3.4 Expression o f  the Pip gene in the PNS, page 15).
1.4.1.2 X-Linked Spastic Paraplegia Type 2
X-linked spastic paraplegia is a rare disorder that occurs in two clinically distinct 
forms. The pure spastic form is characterised by spasticity of the lower limbs with 
normal mental function. Most cases reported take on a more complicated phenotype 
of spasticity, cerebellar ataxia, mental retardation and, occasionally, congenital 
malformations. Some cases of complicated SPG with congenital abnormalities 
result from mutations of the L1CAM  gene at Xq28 locus (SPG 1; OMIM 312920). 
Other cases of complicated SPG and uncomplicated (pure) SPG map to the PLP 
gene locus and are classified as SPG2 (OMIM 312920). Some of the clinical 
features of SPG2 are similar to those of PMD including mental retardation, 
nystagmus and optic atrophy. In most reports, only male patients are clinically 
affected while females act as asymptomatic carriers (Saugier-Veber et al., 1994). 
As with PMD, there are occasional reports of clinical disease in females from 
affected families and there can be marked heterogeneity of disease within families 
(Bonneau et al., 1993; Sivakumar et al., 1999). Pathologically, most of the CNS 
white matter is spared but the longitudinal spinal tracts are severely dysmyelinated 
(Seitelberger, 1995).
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1.4.1.3 Genetic basis o f P L P  gene-related disorders in man
Point mutations of the PLP gene were first reported by Hudson et al. (1989) , 
Gencic et al. (1989) and Trofatter et al. (1989) who described three separate 
mutations leading to PMD. Trofatter et al. (1989) noted genetic heterogeneity of 
PMD as these point mutations could not be identified in six additional affected 
families and these findings have subsequently been supported by the numerous 
reports of novel mutations leading to disease. To date, at least 62 point mutations 
have been described in coding regions of the PLP gene leading to PMD or SPG2 
(Table 1, page 24) but only two PLP gene polymorphisms have been found (Table 
2, page 25) (for reviews see OMIM 312080; Garbern, 2000; Hodes et al., 1993). 
Although some of these mutations are predicted to lead to protein truncation or 
aberrant splicing (for example G434A, C700T), others lead to conservative amino 
acid substitutions that are not expected to dramatically alter protein conformation 
(for example C728T, Ala243Val). The intolerance of even conservative amino acid 
changes adds weight to the argument that the functions of the PLP gene are 
dependent on the primary peptide sequences indicating a possible role in protein- 
protein interactions (see 1.3.2.1 Conservation o f  the Pip gene, page 11). Other 
mutations affecting non-coding regions have been described and some families with 
linkage to the PLP gene locus but no observed mutation are thought to have 
mutations in non-transcribed regulatory regions (Cambi et al., 1996; Inoue et al., 
1997). These findings suggest that altered gene regulation can also lead to disease.
One of the major groups of PLP gene mutations leading to disease involve 
alterations in copy number of the PLP gene (Sistermans et al., 1998; Mimault et al., 
1999) (Table 2, page 25). Interphase fluorescence in situ hybridisation has shown 
that many, perhaps even the majority, of cases of PMD result from duplication of 
the PLP gene (Osaka et al., 1996; Woodward et al., 1998). In addition, several 
families, often with milder PMD phenotypes, have been described that have PLP 
gene deletions (Raskind et al., 1991; Osaka et al., 1996) or mutations in exon 1 
predicted to cause functional null alleles (Garbern et al., 1997). These findings 
show that at least one subgroup of PMD results from alterations in PLP gene dosage 
and suggest that null mutations of the PLP gene lead to comparatively mild 
phenotypes.
Heterogeneity of disease within affected families may be the result of modifying 
genes (see 1.4.6 Modifying loci, page 34). Tables 1 and 2 (pages 24 and 25) list the 
known PLP gene mutations that cause PMD and SPG2. Point mutations in the 
coding regions of the gene are demonstrated graphically in Figure 3 (page 23).
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1.4.2 Pip gene mutations in animals
Pip gene mutations have been described in the mouse (PlpiP, Plp)P-4j , PlpiP~msd, 
Plpjp~rsh), rat (Plpmd), dog (Plpsh) and rabbit (PlpP{) (see Table 3, page 26) (for 
review see Knapp, 1996). The jimpy mouse results from a point mutation in intron 
4 that disrupts the 3' acceptor splice site (Hudson et al., 1987; Nave et a l,  1987b). 
This leads to the deletion of exon 5 from the Pip gene transcripts and is predicted to 
produce a truncated protein with a novel, cysteine-rich carboxy terminus. The other 
mutants result from point mutations causing amino acid substitutions (see Table 3, 
page 26 and Figure 3, page 23) (Plpmd\ Boison & Stoffel, 1989; Plp)P-msd\ Gencic & 
Hudson, 1990; Plps^\ Nadon et al., 1990; PlpJP~rsh\ Schneider et al., 1992; PlpPl 
Tosic et al., 1994; Plpjp~4j\ Pearsall et al., 1997).
Most of these mutants develop fatal dysmyelinating phenotypes (Knapp, 1996). 
The CNS is severely hypomyelinated with a paucity of mature oligodendrocytes. 
Microglia proliferate in response to oligodendrocyte death (Vela et al., 1996) and 
astrocyte hypertrophy contributes to a general gliosis (Billings-Gagliardi et al., 
1995; Duncan, 1995). The animals develop a marked tremor as they start to 
ambulate (from 10 to 12 days in the mouse) and seizures are common. Affected 
individuals usually die in the late post-natal period (around 25 to 30 days in the 
mouse). PLP and DM20 are often absent from the few myelin sheaths that do form 
and all the myelin proteins are reduced (Sorg et al., 1987; Billings-Gagliardi et al., 
1995; Nadon and Duncan, 1996). Pip gene expression is reduced in the PNS of at 
least some of these mutants (Tosic et al., 1996) but this has no effect on Schwann 
cell function and the peripheral myelin is normal.
Unlike other Pip gene mutants, rumpshaker mice and paralytic tremor rabbits have 
mild clinical phenotypes that are non-lethal and partially regress with time. Both 
dysmyelinate but partially recover as they age (Taraszewska, 1988; Fanarraga et al., 
1992; Tosic et al., 1996).
1.4.2.1 Dysmyelination
In the CNS of most Pip gene mutants, only a minority of axons is myelinated, the 
proportion reflecting the severity of the phenotype. The sheaths that form are thin 
and occur as solitary internodes (Ransom et a l, 1985; Billings-Gagliardi et al., 
1995; Duncan, 1995). What little myelin that is present is loosely compacted and 
ultrastructurally abnormal (Duncan et al., 1987a; Billings-Gagliardi et al., 1995). 
Most of the lamellae have abnormal intraperiod lines that condense to a single 
electron-dense band indistinguishable from the major dense line. This leads to a
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Table 1 PLP  gene point mutations causing PMD and SPG2
(numbering starts from the methionine translation initiation codon)
Classification Region Nucleotide Amino acid Disease
missense exon 1 G 003 A Met 001 lie PMD-I
exon 2 C 044 T Pro 015 Leu PMD-I
exon 2 T 094 G Phe 032 Val PMD-I PMD-II
exon 2 C 128 T Thr 043 He PMD-I
exon 2 T 137 G Leu 046 Arg PMD-I
exon 2 T 137 C Leu 046 Pro PMD-II
exon 3 G 220 A Gly 074 Arg PMD-I
exon 3 C 337 A Thr 116 Lys PMD-I
exon 3B C 384 G Gly 128 Gly PMD-II
exon 3B C 418 T His 140 Tyr SPG2
exon 3B A 441 T Gly 147 Gly PMD-I
exon 3B C 442 T His 148 Tyr SPG2
exon 3B G 453 C Lys 151 Asn PMD-I
exon 3B G 453 T Lys 151 Asn PMD-I
exon 4 C 467 T Thr 156 He PMD-I
exon 4 T 487 C Trp 163 Arg PMD-II
exon 4 T 497 A Val 166 Glu PMD-I
exon 4 T 497 G Val 166 Gly PMD-I
exon 4 T 505 C Cys 168 Arg PMD
exon 4 C 509 T Ser 170 Phe SPG2
exon 4 T 515 C Val 172 Ala PMD-II
exon 4 A 524 G Tyr 175 Cys PMD
exon 4 G 542 A Trp 181 Ala PMD
exon 4 A 544 C Thr 182 Pro PMD-II
exon 4 C 548 A Thr 183 Asn PMD
exon 4 T 560 C lie 187 Thr SPG2 (Pftp rsh)
exon 4 G 607 C Asp 203 His PMD-I
exon 4 A 608 T Asp 203 Val PMD-I
exon 4 A 608 G Asp 203 Gly PMD
exon 4 T 609 A Asp 203 Glu PMD
exon 4 A 613 G Arg 205 Gly PMD-I
exon 4 A 620 G Tyr 207 Cys PMD-I
exon 5 T 626 A Val 209 Asp PMD-I
exon 5 T 629 A Leu 210 His PMD
exon 5 C 632 T Pro 211 Leu PMD-I
exon 5 T 214 C Trp 212 Arg PMD
exon 5 C 641 G Ala 214 Pro PMD-I
exon 5 C 646 T Pro 216 Ser PMD-I
exon 5 G 649 A Gly 217 Ser PMD-I
exon 5 G 655 T Val 219 Phe PMD-I
exon 5 G 659 A Cys 220 Tyr PMD-I
exon 5 G 661 T Gly 221 Cys PMD-II
exon 5 C 670 A Leu 224 He PMD-II
cont/....
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Table 1 continued
Classification Region Nucleotide Amino acid Disease
missense exon 5 T 671 C Leu 224 Pro PMD-II
exon 5 T 676 C Ser 226 Pro SPG2
exon 5 T 682 C Cys 228 Tyr PMD
exon 6 A 234 T Gin 234 Pro PMD
exon 6 T 710 C Phe 237 Ser SPG2
exon 6 G 724 C Ala 242 Pro PMD-I
exon 6 C 728 T Ala 243 Val PMD-II (P //’w )
exon 6 G 737 A Gly 245 Glu PMD
exon 6 C 743 A Ala 248 Glu PMD
exon 6 G 745 C Ala 249 Pro PMD-I
exon 6 C 758 T Ser 253 Phe PMD-I
deletion exon 1 G 003 no translation PMD-I
nonsense exon 3B G 434 A Trp 145 Stop SPG2
exon 6 C 700 T Gin 234 Stop SPG2 PMD-I
exon 7 insert G 775 frameshift stop 268 PMD-II
splice site exon 3 C 347 A Thr 116 Lys SPG2 PMD-I
substitution 5'-Hanking C -442 G regulatoiy PMD-I
5'-UTR C -031 T regulatory PMD-I
Table 2 PLP gene duplications, deletions and polymorphisms 
a) Duplications and deletions of the PLP gene locus; b) Partial PLP gene 
deletions; c) PLP gene polymorphisms (numbering starts from the 
methionine translation initiation codon)
Classification Region Disease
gene duplication entire locus PMD-I
gene deletion entire locus PMD-I
b) Classification Region Nucleotide Amino acid Disease
deletion 5'flank-intron 1 frame-shift SPG2
exon 3B A3 52 to T497 Thr 118 to Val 166 PMD-I
exon 3B to 4 in frame Val 117 to Leul65 PMD-I PMD-II
deletion/ insertion intron 5 T 675+2—>G 5' splice site PMD-I
c) Region Polymorphism Amino acid
exon 2 A 168 G Gin 056 Gin
exon 4 T 609 C Asp 203 Asp
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Table 3 Spontaneous Pip gene mutations in animal models
(numbering starts from the methionine translation initiation codon)
Species Mutant Allele Region Classification Nucleotide Amino acid
mouse jim py pipip 3'splice site 
o f  exon 4
missense with 
frameshift
A621 -2—»G 
splice site 4
jim py-4j p ip ip -fi exon 2 missense G 117 T Ala 039 Ser
rumpshaker pipjp-rsh exon 4 missense T 562 C lie 187 Thr
myelin synthesis 
deficient
Plpjp-msd exon 6 missense C 730 T Ala 243 Val
rabbit paralytic tremor PlpPt exon 2 missense T 113 A His 037 Gin
dog shaking pup pipsh-pup exon 2 missense A 112 C His 037 Pro
rat myelin deficient Plpmd exon 3 missense A 225 C Thr 075 Pro
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reduction of myelin periodicity from llnm  in the wild type to 9nm in the mutants 
(Duncan et al., 1987a). Myelin lamellae occasionally form with normal intraperiod 
lines but these are rare and could represent areas of myelin containing very low 
levels of the abnormal Pip gene proteins (Duncan et al., 1987a). Most axons are 
naked and have no association with oligodendrocyte processes (Thomson et al., 
1997).
The rumpshaker mouse is hypomyelinated with increased numbers of unmyelinated 
small axons and thin sheaths surrounding larger axons. The small diameter (late 
myelinating) axons of the optic nerve have normal-thickness myelin sheaths when 
present but a large proportion of axons remains unmyelinated. As the animal 
matures, the clinical phenotype recovers and most of the axons acquire myelin 
sheaths although these still remain comparatively thin (Fanarraga et al., 1992). 
Although many sheaths have normal periodicity, others have condensed intraperiod 
lines (Griffiths et al., 1990). The paralytic tremor rabbit has delayed and 
incomplete central myelination predominantly affecting the small diameter fibres 
(Taraszewska, 1988; Tosic et a l, 1996).
1.4.2.2 Oligodendrocyte abnormalities and death
Mature oligodendrocyte numbers are severely reduced in the jimpy, jimpy-4j and 
myelin synthesis deficient mice, the myelin deficient rat and the shaking pup 
(Billings-Gagliardi et al., 1995; Knapp, 1996). Death of mature oligodendrocytes 
probably accounts for this in most mutants as immature oligodendrocyte numbers 
are not reduced (Nadon and Duncan, 1995; Skoff, 1995; Gow et al., 1998; Lipsitz et 
al., 1998; Grinspan et al., 1998). Oligodendrocytes in the shaking pup do not die 
but remain immature and fail to produce many myelin sheaths (Nadon and Duncan,
1996). Some of the mutants have abnormal oligodendrocyte morphology with 
distension of the rough endoplasmic reticulum and swollen Golgi vesicles (Billings- 
Gagliardi et al., 1995; Knapp, 1996). Oligodendrocytes from myelin synthesis 
deficient and jimpy mice show PLP/DM20 immunoreactivity in the rough 
endoplasmic reticulum but no evidence of protein in the Golgi or at the cell surface 
(Roussel et al., 1987; Gow et al., 1998). These results suggest a disruption of 
protein trafficking in oligodendrocytes leading to an inability to incorporate 
abnormal Pip gene products into myelin.
The rumpshaker mouse and paralytic tremor rabbit are notable as they maintain 
normal oligodendrocyte numbers despite having disrupted protein trafficking 
pathways. DM20 protein levels are maintained and this isoform is incorporated into 
the myelin sheath (Griffiths et al., 1990; Karthigasan et al., 1996). Only small 
amounts of the abnormal PLP isoform are produced and these are retained in the
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rough endoplasmic reticulum (Karthigasan et al., 1996).
1.4.2.3 Axonal changes
Axonal pathology is seen in jimpy and rumpshaker mice (Rosenfeld and Friedrich, 
Jr., 1983; Fanarraga et a l , 1992), the paralytic tremor rabbit (Taraszewska, 1988) 
and the myelin deficient rat (Dentinger et al., 1982; Duncan et a l, 1995). Axonal 
swellings are found with accumulations of cytoskeletal elements and membrane 
bound organelles such as dense bodies. In the longer-lived mutants, degenerate 
axons can also be identified.
1.4.3 Pip transgenic animals
Several lines of transgenic mice have been generated that express PLP transgenes. 
Both genomic transgenic constructs encoding PLP and DM20 proteins and cDNA 
transgenic constructs expressing one or other of the two isoforms have been used. 
There is little correlation between the transgene copy number and the transcript and 
protein levels in the transgenic mice when compared to levels of endogenous Pip 
gene expression. This indicates that some of these transgenes are less efficiently 
transcribed than the endogenous Pip gene (Johnson et a l, 1995) and that transcript 
and protein processing may be altered.
1.4.3.1 Expression o f genomic Pip  transgenes
Three transgenic lines of mice containing two separate transgenes have been 
produced that express both major splice variants of the Pip gene (lines #66 and #72: 
Readhead et al., 1994; line #4e: Kagawa et a l, 1994a). The constructs include 
fragments encompassing all the known exonic sequence of the murine Pip gene 
covalently linked to 5' and 3' Pip gene flanking sequences (see Table 4, page 29). 
These produce transcripts that undergo normal splicing.
Transgenic mice from these lines develop dysmyelinating and demyelinating 
phenotypes that are influenced by gene dosage. Homozygous #4e and #66 mice 
develop severe dysmyelinating phenotypes that cause tremor, seizuring and death by 
60 days of age (Readhead et a l, 1994; Kagawa et a l, 1994a; Inoue et a l, 1996). 
Homozygous #72 mice have lower transgene copy numbers than homozygous #66 
mice and develop a milder dysmyelinating phenotype that leads to death by 4 
months of age (Anderson et a l, 1998). Hemizygotes from all three lines myelinate 
well initially but develop late phenotypes associated with subsequent demyelination 
(Kagawa et a l, 1994a; Inoue et a l, 1996; Anderson et a l, 1998). Occasional
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swollen and degenerate axons are seen as late changes in #66 homozygotes and are 
prominent features of #72 homozygotes, along with some demyelination, prior to 
death (Anderson et a l, 1998). Axonal pathology is also seen in hemizygous mice 
from these two lines (Anderson et a l, 1998). The axonal changes predominantly 
affect tracts with small diameter fibres such as the optic nerve, corticospinal tract 
and fasciculus gracilis.
1.4.3.2 Expression o f P/p-cDNA and D m 20-cD NA  transgenes
Several lines of Dm20-cDNA transgenic mice and one line of Plp-cDNA transgenic 
mice have been generated (see Table 4, page 29) (Nadon et a l, 1994; Johnson et a l, 
1995). The ND4 and ND3A lines of Dm20-cDNA transgenic mice generated by 
Johnson et a l (1995) offer further examples of the influence of gene dosage on Pip 
gene-related disease. ND4 hemizygous mice (70 transgenic cassettes) develop 
central demyelination leading to death at 10 months of age (Mastronardi et a l,
1993). ND3A homozygous mice (34 transgenic cassettes) have similar pathological 
features to the ND4 hemizygous mice but a milder clinical phenotype that develops 
from 12 to 16 months of age (Mastronardi et a l, 1996). ND3A hemizygous mice 
(17 transgenic cassettes) do not develop CNS pathology at all.
1.4.3.3 Targeted gene replacements of the Pip  gene
Boison and Stoffel (1994) attempted to generate mice that expressed only the 
Z)ra20-mRNA isoform by targeted mutation of the endogenous Pip gene. The 
targeting construct removed exon 3B from the Pip gene and introduced a selectable 
marker, the neomycin resistance gene (neo), into intron 3. During splicing, because 
of the presence of the neo cassette, the Pip gene transcripts retained intron 3 and no 
proteins were translated. From this targeting strategy, two lines of mice with 
functional null alleles of the Pip gene were generated. Poorly compacted myelin 
sheaths surround the larger diameter CNS axons of these mice but many of the small 
diameter axons remain unmyelinated (Boison and Stoffel, 1994; Boison et a l, 
1995). The myelin that does form shows variable ultrastructural abnormalities. The 
intraperiod lines are often condensed or the extracellular interface between adjacent 
myelin lamellae may be disrupted (Rosenbluth et a l, 1996).
These mice are notably different from the missense Pip gene mutants as they show 
only subtle clinical phenotypes and produce large amounts of myelin. This is 
comparable to the milder forms of PMD with deletions and functional null alleles of 
the PLP gene (Raskind et a l, 1991; Osaka et a l, 1996; Garbern et a l, 1997). There 
are some common features between the Pip gene-null mutants and the other Pip 
gene mutants such as ultrastructural abnormalities of myelin. However, some of the
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features of missense Pip gene mutants must arise through mechanisms other than 
the loss of functional Pip gene products.
1.4.4 Pathogenesis of Pip gene-related disorders
Several mechanisms, including gain of function, loss of function and gene dosage 
effects, could account for the pathogenesis of Pip gene-related disease. Several 
different pathogenic pathways may lead to disease in Pip gene mutants as evidence 
exists supporting each of these mechanisms.
1.4.4.1 Gain of function o f mutated gene products
The accumulation of Pip gene protein isoforms in the rough endoplasmic reticulum 
of mutant oligodendrocytes probably results from conformational changes within 
altered proteins leading to ineffective protein trafficking. It has been suggested that 
oligodendrocyte death and dysmyelination results from the abnormal trafficking 
(Gow et al., 1998). Alternatively, an inability of mutant polypeptides to form 
multimeric complexes may directly prevent their integration into myelin (Gow et 
al., 1994b). In vitro studies demonstrate that the degree of disruption of protein 
trafficking correlates with phenotypic severity in mutant animals (Gow and 
Lazzarini, 1996; Thomson et a l, 1997). In addition, the inability of transgenic 
complementation to rescue jimpy mice adds weight to the theory that novel gains of 
function of abnormal Pip gene products prove toxic to the oligodendrocyte (Nadon 
et al., 1994; Kagawa et al., 1994a; Schneider et a l, 1995).
However, jimpy oligodendrocytes can survive longer and reach mature phenotypes 
when cultured in normal astrocyte-conditioned medium (Knapp et al., 1996) and 
their survival is also enhanced by transplantation into normal and shiverer CNS 
tissue (Lachapelle et al., 1991). These findings suggest that jimpy oligodendrocytes 
are intrinsically viable and die only because the local environment is not permissive 
to their survival. The contradictory findings in these mutants must be clarified 
before toxic properties can be ascribed to mutated Pip gene products.
1.4.4.2 Loss o f function o f Pip  gene products
The ultrastructural abnormalities of myelin in Pip-null mice (Boison and Stoffel,
1994) and in the spontaneous Pip gene mutants that express low levels of potentially 
non-functional protein provide evidence that PLP and DM20 are structural 
components of myelin. The condensation of the intraperiod lines and poor 
maintenance of myelin compaction in these mutants are consistent with PLP and 
DM20 proteins acting as adhesive struts supporting the extracellular interface 
between adjacent myelin lamellae. Transgenic complementation of the jimpy mouse
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can reverse these ultrastructural changes although the rescued mice remain severely 
hypomyelinated (Schneider et al., 1995). This provides evidence that these 
ultrastructural abnormalities are the direct result of loss of functional Pip gene 
products. In addition, PMD cases with deletions or effective null alleles of the PLP 
gene show that at least some of the disease features result from loss of normal PLP 
and DM20 proteins (Raskind et al., 1991; Osaka et al., 1996; Garbern et al., 1997).
The proposals that PLP/DM20 proteins are important for oligodendrocyte survival 
and maturation will be expanded in relation to the results of this study (page 125).
1.4.4.3 Effect of Pip gene dosage
1.4.4.3.1 Stoichiometric relationship to other myelin constituents
Gene dosage as a pathogenic mechanism has been well documented in mutations of 
the peripheral myelin protein 22 (PMP22) gene, a minor component of compacted 
PNS myelin (Gabriel et al., 1997; Hanemann and Muller, 1998). A severe 
peripheral neuropathy, Charcot-Marie-Tooth type 1A (CMT1A), results from 
duplications of the PMP22 gene. In contrast, deletions of this gene lead to the mild 
disease, hereditary neuropathy with liability to pressure palsies (HNPP). PMP22 
protein levels in these disease groups correlate well with gene dosage and disease 
severity (Gabriel et al., 1997). The correlation between PMP22 protein levels, gene 
copy number and disease has lead to speculation that these peripheral neuropathies 
are a feature of abnormal PMP22 protein stoichiometry in peripheral myelin 
(Gabriel et al., 1997).
A similar phenomenon is seen in Pip gene-related disease in which deletions, 
duplications and transgenic over-expression of the gene can have similar effects to 
missense mutations (Hodes and Dlouhy, 1996). A strong correlation between gene 
dosage and severity of disease is particularly well documented in mice harbouring 
additional copies of the Pip gene (see 1.4.3.1 Expression o f genomic Pip transgenes, 
page 28). The stoichiometric relationship both between PLP and DM20 proteins 
and between PLP/DM20 and the other myelin proteins may prove to be important in 
elaborating and maintaining central myelin (Mastronardi et al., 1993; Johnson et a l, 
1995; Inoue et al., 1996).
1.4.4.3.2 Abnormal protein processing due to increased Pip gene dosage
Homozygous #4e transgenic mice have striking similarities to the spontaneous Pip 
gene mutants with ultrastructural evidence of disrupted protein trafficking and 
increased oligodendrocyte apoptosis (Kagawa et al., 1994a; Inoue et al., 1996). 
However, unlike missense Pip gene mutants, oligodendrocyte dysfunction cannot
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occur through gains of function of mutated gene products. Instead, increased 
protein turnover in over-expressing cells blocking protein trafficking may disrupt 
oligodendrocyte function sufficiently to affect myelination (Inoue et al., 1996; Gow 
et al., 1998).
ND4 transgenic mice that express high levels of Dm20 transcripts develop 
demyelination as they mature (Barrese et al., 1998). The Pip gene products from 
the ND4 mice undergo abnormal post-translational modifications. Acylation is 
increased several-fold, a different population of fatty acids is esterified and the 
amino-terminal glycine becomes methylated (Barrese et al., 1998). These changes 
increase the hydrophobicity of the proteins and may affect their cellular processing 
and integration into myelin. The altered characteristics of PLP and DM20 proteins 
could be pivotal in the demyelination process making abnormal post-translational 
modification a potential mechanism for disease pathogenesis in cases of increased 
Pip gene dosage.
1.4.4.4 Pathogenesis o f axonal changes
Axonal pathology may reflect a specific response to disrupted Pip gene function in 
the oligodendrocyte or to disrupted gene function in the neuron itself as the srPLP 
and srDM20 proteins are located in some subpopulations of neurons (Bongarzone et 
al., 1999). However, the identification of axonal pathology in other myelin mutants 
such as the quaking mouse (Friedrich, Jr. et al., 1980) indicates that axonal changes 
could be a general response to abnormal oligodendrocyte function.
1.4.5 Clinically affected female carriers
Female carriers of X-linked disease rarely develop severe phenotypes due to the 
process of X-inactivation. Mice heterozygous for the jimpy  mutation demonstrate 
the influence of this process in suppressing the development of clinical disease. In 
these mice, X-inactivation creates a mosaic pattern of Pip gene expression; a 
proportion of oligodendrocytes expresses the jimpy allele, the remainder expresses 
the wild type Pip allele. The majority of oligodendrocytes expressing the jimpy 
allele appear to die during post-natal development (Kagawa et al., 1994b). This 
leaves predominantly cells that express the wild type allele and that are capable of 
adequately myelinating the CNS (Skoff and Ghandour, 1995). Pockets of 
dysmyelination are present presumably created by the small percentage of 
oligodendrocytes expressing the jimpy allele that survive. However, these patches 
resolve as the animal matures reflecting the ability of oligodendrocytes expressing 
the wild type Pip allele to compensate by myelinating these regions (Bartlett and 
Skoff, 1986; Skoff and Ghandour, 1995). Both the death of cells expressing the
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disease allele and the ability of cells expressing the wild type allele to compensate 
may suppress the development of clinical disease in female carriers of X-linked 
disease (reviewed by Belmont, 1996).
Despite these mechanisms, female carriers of X-linked disease can show clinical 
phenotypes and some reports describe both juvenile-onset (C044T; Hodes et al., 
1995; G434A; Hodes et al., 1997) and adult-onset (C037A; Nance et al., 1996) 
disease in females with PLP gene mutations. Extreme skewing of X-inactivation 
develops normally in 5 to 10% of females. If X-inactivation skews heavily towards 
the mutated allele remaining active, female carriers are likely to develop clinical 
disease, a syndrome called “unfortunate Lyonisation” (Willard, 1995). Female 
animals heterozygous for the shaking pup allele demonstrate the link between 
skewing of X-inactivation and the development of clinical phenotypes. These 
animals develop a range of phenotypes that varies depending on the degree of 
myelin mosaicism present (Cuddon et al., 1998). A severe phenotype develops if 
large numbers of axons remain nonmyelinated. This is assumed to reflect skewing 
towards expression of the mutated allele by the majority of oligodendrocytes. 
Conversely, milder phenotypes correlate with a lower percentage of nonmyelinated 
fibres.
The myelin deficient rat demonstrates a further potential cause of disease in females. 
This line of rats has a high incidence of phenotypically silent X-chromosome 
monosomy (XO). In female rats that exhibit monosomy in combination with 
carrying the Plpmd allele (Plpmd/0 ) all somatic cells express the mutant allele and 
these female rats develop a phenotype that is indistinguishable from affected males 
(Plpmd/Y ) (Koeppen et al., 1992). To date, there are no reports of disease in human 
female carriers of PLP gene-related disease who have concurrent X-chromosome 
monosomy (Turners syndrome).
1.4.6 Modifying loci
More severe phenotypes seen with some large intrachromosomal duplications that 
include the PLP gene locus (Isenmann et al., 1997; Inoue et al., 1999) and 
heterogeneity within families with point mutations of the PLP gene (Bonneau et al., 
1993; Sivakumar et al., 1999) have highlighted the potential role of modifying loci 
in affecting disease severity. Both the myelin deficient rat (Duncan et al., 1995) and 
the rumpshaker mouse (I.R. Griffiths, personal communication) develop two 
different phenotypes that can be selected for by breeding and probably result from 
different modifying alleles.
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1.5 Experimental strategies for studying the roles 
of myelin proteins
1.5.1 Traditional transgenic technology
The evaluation of spontaneous mutants has been the mainstay of myelin research 
but advances in recombinant DNA technology have enabled more controlled 
investigations into the roles of myelin genes. Transfection studies allow gene 
function and disease pathogenesis to be examined in vitro (for example Filbin et al., 
1990; Filbin and Tennekoon, 1991; Gow et al., 1994b; Thomson et al., 1997) but 
cannot replicate the complex intercellular interactions and temporal changes seen in 
vivo. Transgenic systems overcome these problems by stably altering the 
mammalian genome in vivo. However, incomplete transgenic regulation and 
insertional mutagenesis can lead to misleading results. Poor transgenic regulation 
occurs if  the transgenic cassette does not include the necessary regulatory elements 
or if the transgene inserts into a transcriptionally inactive region o f the genome. 
The level of transgenic expression is also difficult to predict as there is no control 
over the number of copies of the transgenic cassette that insert into the genome and 
because of the effects of repeat-induced gene silencing (Garrick et al., 1998). One 
limitation of these studies is that the endogenous gene remains active largely 
limiting their use to increased gene dosage studies. However, reporter genes driven 
by myelin gene promoters can overcome the problems of endogenous gene activity 
(for example Plp-LacZ  fusion protein: Wight et al., 1993 and Mbp-promoter LacZ  
transgene: Wrabetz et al., 1998) and the use of antisense transgenic technology can 
prevent translation of endogenous gene products (for example the Mbp gene: 
Katsuki et al., 1988).
1.5.2 Targeted gene replacement
Targeted gene replacement overcomes many of the problems of traditional 
transgenic systems by avoiding random transgenic integration and by preventing 
endogenous gene expression (reviewed by Capecchi, 1994). The targeting cassette 
contains the desired genetic defect flanked by sequences homologous to regions of 
the endogenous target gene. The cassette integrates into the genome by 
homologously recombining with these regions on the target gene replacing a section 
of the target gene with the transgene construct. Disrupting transcriptional or 
translational control elements of the target gene generates null alleles, so called 
“gene knockouts”. Alternatively, additional genetic information can be introduced 
into the target locus, "gene knock-ins". The targeting constructs contain positive 
selectable markers embedded within the homologous regions and negative
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selectable markers on non-homologous flanking sequences. After the constructs 
have been introduced into embryonic stem-cells, isolated homologous integration 
events can be identified by using these positive and negative selectable markers.
1.5.2.1 Problems o f targeted gene replacement systems
One frustrating feature of many knockout models is the high incidence of normal 
phenotypes produced. Many examples of genetic redundancy have been reported 
where the roles of the targeted gene are replaced probably by closely related 
members of the same gene family (Hummler et al., 1994; Gibson and Spring, 1998). 
Other examples exist where unrelated genes may have convergent functions that 
lead to genetic redundancy. The Mbp gene shows this form of genetic redundancy 
in the PNS where both MBP and PO proteins in isolation are capable of supporting 
the major dense line (Martini et a l, 1995). Although genetic redundancy shows that 
these genes are not vital per se, it is difficult to comment on the importance of the 
roles that the genes fulfil.
Other problems of gene targeting relate to the targeting strategy. Targeted 
mutations that prove lethal to the embryo may provide little information about gene 
function. A subtler problem may arise through the retention of selectable markers 
within the mutated gene that can influence gene regulation. One example of this is 
the targeted Pip gene mutation described by Boison & Stoffel (1994) that was 
designed to express Dw20-mRNA in isolation (see 1.4.3.3 Targeted gene 
replacements o f the Pip gene, page 30). The retention of the neo gene within the 
mutated allele led to aberrant transcript splicing and produced a functional null 
allele.
The limited number of embryonic stem-cell lines available for gene targeting leads 
to problems of mixed genetic backgrounds in these systems (reviewed by Crawley, 
1996; Gerlai, 1996; Lathe, 1996) . Embryonic stem cell lines are chosen because 
they are capable of producing viable embryos, not because they offer a suitable 
genetic background in which to maintain a transgenic line. For example, the svl29 
line is associated with poor fertility, behavioural abnormalities and neuro- 
anatomical defects. Chimeric animals produced using this line generally are crossed 
into more robust strains such as C57BL/6 and C3H/101. This produces a mixed 
genetic background that requires at least twenty generations of back-crossing until a 
fully inbred strain is produced. Until this is achieved, modifying loci can lead to 
misleading phenotypic variation even between littermates. In addition, the targeted 
gene is selected for as part of a locus of up to thirty topographically linked alleles 
from the embryonic stem-cell line. Even with successive generations crossed into 
the new background strain, these linked genes separate almost exclusively with the
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targeted allele and will not be present in wild type littermate controls.
1.5.2.2 Transgenic complementation o f gene knockouts
Many of the problems of mixed genetic strains and the uncertain influence of 
modifying genes can be overcome by transgenic complementation to replace the 
functions of the disrupted gene in knockout animals (Gerlai, 1996). If the 
phenotype of the knockout is reversed by transgenic complementation, it is the 
direct result of loss-of-function of the targeted gene. Examples of similar 
complementation experiments within the context of myelination come from shiverer 
(Readhead et al., 1987; Kimura et al., 1998) and myelin deficient (Popko et al., 
1987) mice. The phenotypes of these spontaneous Mbp gene-null mutants can be 
reversed by complementation with Mbp transgenes. Clearly, these systems are 
limited by the availability of appropriately expressed complementary transgenes.
1.5.3 Targeted gene replacement using recombinase systems
Recent advances in targeted gene replacement technology overcome many of the 
problems of simple gene targeting strategies. The utilisation of recombinase 
technology in transgenic systems produces high rates of enzyme-mediated 
homologous recombination between specific recombination sites. The CrQ-loxP 
system derived from PI phages, for example, drives Cre-recombinase mediated 
recombination at loxP sites (reviewed by Pluck, 1996; Kuhn and Schwenk, 1998). 
The loxP sites are introduced into target genes allowing easy insertion and deletion 
of genetic material and making gene targeting much more efficient by exposure to 
Cre-recombinase during embryonic stem-cell manipulation. LoxP sites are also 
used to flank selectable markers so that these can be excised. More sophisticated 
systems allow spatio-temporal control of genetic modification by activating Cre- 
mediated recombination in vivo using Cre-recombinase transgenes driven by 
inducible or tissue-specific promoters. Although the targeted allele still shows 
strong linkage to other genes at that locus, by not exposing it to Cre-recombinase 
activity an effective wild type allele is retained allowing the influence of linked 
genes to be evaluated.
1.6 Aims of thesis
This study aims to dissect some of the roles of the Pip gene by describing the 
pathological changes that develop in the Pip gene knockout mouse (Klugmann et 
al., 1997). In addition to a detailed histological description of the changes that 
developed, morphometric analysis has been used to investigate the ability of 
PLP/DM20-deficient mice to elaborate and maintain myelin within the CNS. A
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survey of the PNS has been undertaken to establish if the Pip gene is necessary for 
maintaining peripheral myelin as suggested by Garbem et al. (1997). The axonal 
changes that develop have been described ultrastructurally and quantified using 
morphometric analysis and their relationship to PLP/DM20-defIcient myelin sheaths 
has been investigated. The significance of findings from these studies is discussed 
within the context of myelin disease and oligodendroglial function.
To confirm that the phenotype that develops in Pip gene knockout mice is the direct 
result of loss of Pip gene function, these mice have been supplemented with 
genomic Pip transgenes (Readhead et al., 1994). The role of the major Pip gene 
isoforms in oligodendrocyte function and in the formation of myelin has been 
investigated through transgenic complementation using Pip-cDNA and Dm20- 
cDNA transgenes (Mastronardi et al., 1993; Nadon et al., 1994). In the final 
discussion, the findings from this study are critically appraised and future areas of 
work that may expand on some of the points raised by this thesis are discussed.
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2. Materials and Methods
2.1 Miscellaneous
Inorganic chemicals were of AnalaR® or molecular biology grade and were sourced 
from Sigma or BDH. Solutions were sterilised as appropriate: bulk solutions were 
autoclaved; small volumes and fluids that could not be autoclaved were filter 
sterilised using a Flowpore 0.22pm filter (Biomedicals Ltd.). Gloves, eye 
protection and other protective clothing were worn when appropriate. Fixatives and 
other volatile liquids and toxic powders were prepared in a fume cupboard.
The Appendix (page 177) gives details of the preparation of fixatives, stains, buffers 
and bacteriological media and of staining and processing protocols. These are 
cross-referenced by page number in this section. The production of 
3-aminopropyltiethoxy-saline (APES)-coated slides and diethyl pyrocarbonate 
(DEPC)-treated water are detailed in the Appendix but are not cross-referenced in 
the text.
2.2 Mouse Breeding
2.2.1 Animal breeding facilities
Mice were bred at the Glasgow Parasitology Unit, University of Glasgow 
Veterinary School and at the animal breeding facilities, ZMBH, Heidelberg. The 
breeding facility at Glasgow is known to have evidence of murine hepatitis virus 
and picorna virus infections both of which have been associated with neurological 
disease in mice (Lipton et al., 1994; Fujiwara, 1994). During the period of this 
study, there was no evidence of clinical disease and the phenotypes and pathology 
identified in transgenic mice were not identified in wild type controls also bred in 
this facility. Similarly, mice bred at ZMBH, a specific-pathogen free facility, had 
phenotypes and pathology that were consistent with those seen in the mice bred at 
Glasgow. This suggests that these viruses did not contribute to the phenotypes and 
pathology described in this study.
2.2.2 Transgenic lines of mice
2.2.2.1 Pip  gene knockout mice
Pip gene knockout transgenic mice were generated by Klugman et al. (1997) at
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ZMBH, Heidelberg (Figure 4, page 42). The endogenous Pip gene was disrupted by 
introducing a targeting vector designed to disrupt the ATG translation start codon in 
exon 1. The targeting vector is also predicted to disrupt exon 1.1, preventing the 
transcription of srPlp and srDm20 mRNA (Bongarzone et al., 1999). The targeting 
vector replaced exons 1 to 3 of the wild type allele by homologous recombination 
and was introduced into R1 embryonic stem cells by electroporation. The neo gene, 
in reverse orientation to the Pip gene and under the control of the herpes simplex 
virus (HSV) promoter, was used to disrupt the translation start codons. It replaced 
the 3' end of exon 1 and 2.5kb of intron 1 between the BamYll site in exon 1 and the 
Kpn\ site in intron 1. A negative selector, the thymidine kinase (tk) gene also under 
the HSV promoter, was used to select against random (non-homologous) vector 
insertion as it was located immediately upstream of the 5' homology region of the 
targeting vector. Construct-mediated G418 resistance positively selected for stem 
cells containing the targeting construct and cells that had random vector insertion 
were negatively selected against using gancyclovir. Homologous recombination 
and a single integration event were confirmed by Southern blot analysis. Cells 
containing the Pip gene-null allele (Plptmknl) were microinjected into blastocysts 
from C57BL/6J mice to produce chimeras. The chimeras were used to establish 
founder stock of Pip gene knockout mice containing the Plptmknl allele by back 
crossing onto C57BL/6J mice (Klugmann et a l, 1997).
2.2.2.2 #66 and #72 transgenic mice
#66 and #72 transgenic mice were generated by Readhead et al. (1994) (Figure 5, 
page 43). The murine Pip gene was isolated from a cosmid library and used to 
construct a 26.6kb transgene insert. The transgenic cassette is predicted to include 
all eight exons of the Pip gene, 3.5kb of the 5' regulatory region and a small vector 
fragment containing the T7 promoter sequence at the 3' end of the transgene. This 
was introduced into B6D3F2-fertilised ova by pronuclear microinjection and 
produced two lines of transgenic mice containing the intact Pip transgene (#66 and 
#72). These were assessed by Southern blot analysis and were estimated to 
respectively contain seven and three copies of the transgene per haploid genome. 
The transgene copies co-segregated in subsequent generations following an 
autosomal inheritance pattern suggesting that, in both lines, the transgenes had 
inserted in tandem at autosomal sites (Readhead et al., 1994).
2.2.2.3 P lp T g l and Dm20Tg2  transgenic mice
PlpTgl and Dm20Tg2 transgenic mice were generated by Nadon et al. (1994) 
(Figure 6, page 44). PlpTgl mice carried thirty copies of a human PLP-cDNA 
construct. The PLP-cDNA construct was flanked on the 5' side by a 4.2kb fragment
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of the human Pip gene promoter and on the 3' side by a 1.5kb fragment from the 
3'-UTR of the human PLP gene that provided a polyadenylation signal. Dm20Tg2 
mice carried an unknown number of copies of a DM20-cDNA transgene construct. 
This construct was similar to the PlpTgl transgene but a portion of the PLP-cDNA 
clone from the BamTTl site in exonl to the Ncol site in exon 5 was replaced with a 
fragment from a rat Dm20-cDNA clone. The PlpTgl and Dm20Tgl transgenic lines 
were produced by pronuclear microinjection of the transgenes into B6C3F2 
fertilised ova (Nadon et al., 1994).
2.2.2.4 #ND3A transgenic mice
#ND3A transgenic mice were generated by Johnson et al. (1995) (Figure 7a, page 
45). The transgene construct contained a human DM20-cD'NA covalently linked at 
the BamRl site in exon 1 to 2.9kb of the human PLP gene promoter. An SV40 
polyadenylation signal was inserted at the EcoRl site in exon 7. The transgene was 
introduced into CD1 fertilised ova by pronuclear micro injection to produce 
transgenic mice. Of the four stable lines produced, the ND3A line was estimated by 
Southern analysis to have 17 copies of the transgene inserted in tandem at an 
autosomal site (Johnson et al., 1995).
2.2.2.5 Pip-LacZ fusion protein transgenic mice
Plp-LacZ transgenic mice were generated by Wight et al. (1993) (Figure 7b, page 
45). The transgene comprised 2.4kb of 5' upstream sequence, exon 1, intron 1 and 
the first 37bp of exon 2 (to the Apal site) from the murine Pip gene. The Apal site 
in Pip exon 2 was converted to a Sphl site and fused in frame with a LacZ fusion 
gene with SV40 polyadenylation signals. The transgene was introduced into 
B6D3F2 fertilised ova by pronuclear microinjection to produce transgenic mice 
(Wight et al., 1993).
2.2.3 Maintenance of transgenic lines of mice
The #72, #66, PlpTgl, Dm20Tg2 and #ND3A lines of transgenic mice were 
maintained by creating harems containing transgene positive and negative animals 
from the same background. Brother-sister matings were avoided and background 
strains were not mixed. The Plp-LacZ mice were maintained through homozygous 
mating. The Pip gene knockout transgenic line was maintained by creating harems 
of Plptmknl hemizygous male and homozygous female mice. In addition, harems 
containing wild type mice from this line and mice carrying the Plptmknl allele 
ensured the production of Plptmknl heterozygotes and wild type littermate controls.
41
a)
Endogenous Pip allele
s  =* eS  «  ea  co aoa . J.
■n-n-n-n-n—n-----h-
1 1.1 2 3 4 5 6
Targeting vector
tk
b>
s  x
5 S« «so 03
sa*
3 - E £ H = h
2 3
Ptp,mk"' allele
«  33i  sC S3
£  CO
— IT
Q.*
2 3 4 5 6
b) 1.1 — [21—  endogenous 
Pip allele
E x lf PLP5’anti
1 neo —§ —  allele
E x lf M Kneol
Figure 4 a) Targeting strategy used to create the Plptmknl allele: the negative 
selectable m arker (tk gene) is lost during homologous recombination; the 
positive selectable m arker (neo gene) is retained (relevant restriction sites are 
shown)
b) PCR prim er positions for identification of the endogenous and m utated Pip 
gene alleles (positions of forw ard prim er in red and reverse prim ers in blue)
(exons are represented by num bered boxes, coding regions are shaded grey; 
selectable m arkers are denoted by green boxes, black arrow s show orientation)
4 2
E r a -
1 1.1
0 3
b)
endogenous Pip allele
7 T7
#66 and #72 
transgene construct
PI P nrT7
Figure 5 a) Transgene construct from the #66 and #72 lines (relevant 
restriction sites are shown)
b) PCR positions for identifying the transgene construct from the #66 and #72 
lines (positions of forw ard prim er in red and reverse prim er in blue)
(exons are represented by numbered boxes, coding regions are shaded grey; 
the transgene-specific T7 prom oter sequence is represented by a green box, a 
black arrow  indicates the orientation of this sequence)
4 3
a)
PlpTgl construct
03
C / 5
SC
sC5
CO
3
oya
QC
©wW
I lA  B |
4 5 6
Dm20Tg2 construct
a<n
X
E
03
CO
T ~ | a | i i
1 2 3 4 5 6
QC©oW
DC
©wW
b)
-CD 3A 3B ■] 4 | ^ en d o g en o u sPip allele
Ex2 aEx4.2
------1 lFI 2 3A 3B| 4 15 16 7
---II 3A| 4 Is  6 .7 . 1—
PlpTgl construct
Dm 20Tgl construct
Figure 6 a) PlpTgl and Dm20Tg2 transgene constructs (relevant restriction 
sites are shown)
b) PCR prim er positions for identification of the PlpTgl and Dm20Tgl 
transgene constructs: the endogenous Pip gene allele produces a ~2168bp PCR 
product using these prim ers which can rarely be dem onstrated (positions of 
forw ard prim er in red and reverse prim er in blue)
(exons are represented by num bered boxes; coding regions are shaded; exon 3 
is shown divided into exon 3A and exon 3B)
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Figure 7 a) ND3A transgene construct: exon 7 is truncated  by the addition of 
a SV40 polyadenylation signal; PC R  p rim er positions are  dem onstrated  
(fo rw ard  p rim er in red and reverse p rim er in blue)
b) PLP-LacZ  fusion protein  transgene construct: the first 14 codons of exon 2 
are  spliced in-fram e w ith the LacZ gene coding region (shaded green) linked to 
a SV40 polyadenylation signal
(relevant restriction sites are  shown; exons are  represented  by num bered 
boxes, coding regions are  shaded grey; SV40 polyadenylation signals are  
shaded blue)
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2.2.4 Crossing o f transgenic lines o f mice
For transgenic complementation o f the Pip gene knockout mice, hemizygous 
transgene positive males were bred with Plptmknl homozygous females. This 
ensured that all F 1 males were Plptmknl hemizygotes and that a number were also 
transgenic hemizygotes. Transgene negative littermates from the same breeding 
programme were used as internal controls.
2.3 Isolation and quantification of nucleic acids
2.3.1 Tail biopsy and mouse identification
Mice were anaesthetised using halothane (Rhone-Poulenc Chemicals Ltd.). 1.2cm 
o f the tip o f the tail was removed using aseptic techniques and the wound was 
cauterised. The tail biopsy was cut into 3mm pieces, placed in a labelled Nunc 
cryotube (GibcoBRL), rapidly frozen in liquid nitrogen and stored at -20°C.
Mice were marked for future identification using a numeric ear punching system.
2.3.2 Extraction of genomic DNA (gDNA) from m ouse tails
gDNA for genotyping was isolated from tail samples collected at biopsy and at post 
mortem. The QIAmp Tissue Kit (Qiagen) was used for all gDNA preparations as it 
provided a speedy and reliable method o f gDNA extraction. The kit also offered the 
advantages o f safety and ease when handling large numbers o f samples over 
traditional phenol extraction methods. The QIAmp Tissue Kit utilises a spin column 
containing a silica membrane to bind nucleic acids. Residual protein and other cell 
debris are washed from the column before nucleic acid elution. All buffers used 
were provided as part o f the commercial kit and manufacturers' recommendations 
were followed.
2.3.2.1 Use of the QIAmp Tissue Kit
Tissue samples were lysed for 3 to 5 hours at 55°C in the manufacturers' sodium 
dodecyl sulphate (SDS) buffer containing 2mg.ml~l proteinase K (see 2.3.2.2 
Preparation o f  Proteinase K, page 47). SDS caused cell membrane lysis and 
proteinase K denatured proteins including endogenous and contaminating 
deoxyribonucleases (DNases). Salt and pH conditions o f the cell lysate were altered 
to ensure preferential binding to the silica membrane o f nucleic acids over protein 
and other cellular debris by the addition o f a second buffer. The lysate was loaded 
onto the QIAmp spin column, centrifuged to remove unbound residues and washed 
twice to remove remaining contaminants. Nucleic acids were eluted by incubation
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at 70°C in elution buffer. To prevent degradation by contaminating DNases during 
long-term storage, gDNA was stored at -20°C. For short-term storage before 
polymerase chain reaction (PCR) analysis gDNA was stored at 4°C to prevent 
physical degradation of samples through repeated thermal insults.
2.3.2.2 Preparation of Proteinase K
Proteinase K was supplied lyophilised with the QIAmp Tissue Kit. This was 
reconstituted in sterile distilled water (SDW) at 20mg.ml'l and stored at -20°C in 
110pl aliquots until required.
2.3.2.3 Assessment of gDNA quality
Yields in excess of 40pg of gDNA in a final volume of 400pl of elution buffer were 
attained using the QIAmp Tissue Kit. gDNA up to 50kb in length was eluted but 
the predominant population was in the range of 20-30kb (Figure 9, page 49). 
Purified gDNA was initially assessed to ensure that it was free from contaminating 
DNase activity and capable of enzymatic manipulation. 500ng samples of gDNA 
were incubated at 37°C for 2 hours in the presence 20U £coRl (BRL) and the 
appropriate manufacturers' buffer to assess gDNA digestibility. To determine that 
gDNA degradation was not due to contaminating DNases, a control was performed 
using gDNA incubated under similar conditions but in the absence of exogenous 
enzyme. A second control consisting of gDNA in the presence of enzyme and 
buffer incubated at 4°C for 2 hours was included to demonstrate that degradation did 
not occur due to other physical or chemical factors. These samples were compared 
on a 0.7% agarose gel (Figure 9, page 49).
2.3.3 Extraction of RNA from mouse tissue
2.3.3.1 Prevention of ribonuclease (RNase) activity
In order to prevent endogenous RNase activity, freshly dissected tissues were 
immediately frozen and stored in liquid nitrogen until use. Non-sterile equipment 
was soaked in DEPC-treated water overnight to remove contaminating RNases. 
Plastic-ware was guaranteed RNase-free (Anachem) negating the need to pretreat it 
with DEPC-treated water. All steps were carried out on ice unless otherwise stated.
2.3.3.2 RNA extraction
RNA was extracted using RNAzol B (Biotech Laboratories Inc.) solution following 
the manufacturers’ recommendations. This method is a modification of a one step 
procedure described by Chomczynski & Sacchi (1987). RNAzol B contains a
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Figure 8 Genomic DNA extracted  from  mouse tail using the QIA m p Tissue 
K it (Qiagen). The p redom inant population of gDNA species separated  with the 
23kb m ark er indicating th a t gDNA had been extracted with m inim al 
degredation using this protocol (200ng aliquots of gDNA separated  on a 0.7%  
agarose gel; size m ark er >o-DNA/f//7idIII).
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Figure 9 Assessm ent of quality of gDNA extracted  from  mouse tail using the 
Q IA m p Tissue Kit (Qiagen)
To assess gDNA quality, 500ng aliquots of gDNA were com pared after 
incubation for 2 hours in an ap p ro p ria te  enzyme buffer (BRL) with or w ithout 
20units of EcoRX restriction endonuclease (BRL) and a t 37°C or 4°C (size 
m ark er: X-DNA/////fdIII).
Lanes 1 and 2: sam ples incubated at 37°C w ithout enzyme; the gDNA did not 
degrade indicating th a t the sam ples w ere not contam inated with DNAses.
Lanes 3 and 4: samples incubated a t 37°C in the presence of enzyme; the 
gDNA was digested indicating th a t the sam ples w ere suitable for enzym atic 
m anipulation.
Lanes 5 and 6: sam ples incubated a t 4°C in the presence of enzyme; the gDNA 
did not degrade indicating th a t digestion of DNA in the sam ples (lanes 3 and 4) 
did not result through non-enzym atic mechanisms.
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Figure 10 Total cellular RNA and cDNA from  20 day-old mouse brain .
Lanes 1 to 3 show 200ng aliquots of to tal cellular RNA and  lanes 4 to 6 show 
the corresponding aliquots of cDNA populations synthesised from  RNA 
sam ples (estim ated to contain 200ng of cDNA). The 28S and 18S bands of 
ribosom al RNA are  m arked , the 5S band  could not be identified. The samples 
w ere separated  on a 1.3% nondenatu ring  agarose gel.
monophasic solution of guanidium and phenol chloroform. Guanidium rapidly 
inactivates RNase activity and forms complexes with RNA and water allowing RNA 
to be retained in the aqueous phase while DNA and proteins separate with the 
phenol phase.
The sample was broken into fine grit using a liquid nitrogen-cooled pestle and 
mortar, transferred to an appropriate volume of RNAzol B (2ml RNAzol B.lOOmg"! 
of sample) at 4°C and thoroughly mixed by vortexing. To ensure complete 
separation of RNA from endogenous RNases and other contaminants, the 
suspension of tissue was needle homogenised through a series of increasingly fine 
needles (16 to 23 gauge). A one tenth volume of chloroform was added to remove 
traces of phenol from the aqueous phase. The solution was emulsified by vortexing, 
incubated on ice for 5 minutes and centrifuged at 13,000rpm for 15 minutes at 4°C. 
The aqueous phase was collected and RNA was precipitated by the addition of 
500pl of propan-2-ol and incubation on ice for 15 minutes. RNA was pelleted by 
centrifugation at 13,000rpm for 15 minutes at 4°C, washed in 70% ethanol/ DEPC- 
treated water, air-dried and resuspended in a small volume of DEPC-treated water. 
The sample was quantified and adjusted to 2pg.pl"l before storage at -70°C to 
minimise RNase activity. Before use, the total cellular RNA samples were assessed 
to ensure they had not degraded (Figure 10, page 50).
2.3.4 Quantification and standardisation of nucleic acids
2.3.4.1 Quantification of nucleic acids
RNA and gDNA samples were quantified using a GeneQuant RNA/DNA calculator 
(Pharmacia Biotech) with a 70pl spectrophotometer cell. Small volumes of pDNA 
extracted from gels were quantified by comparison at gel analysis against a series of 
dilutions of pDNA of known concentration.
2.3.4.2 Dilution of nucleic acids
Nucleic acids were diluted to working concentrations in SDW or TE Buffer (see 
Appendix page 189). For PCR analysis, gDNA samples were diluted to a 
concentration of 25ng.p,l~l. RNA was diluted to 2pg.pl-1 for cDNA synthesis.
2.3.4.3 Ethanol precipitation and concentration of nucleic acids
Nucleic acid samples were precipitated to enable concentration and purification. 
Precipitation was performed in the presence of 0.3M sodium acetate (pH 5.2) and 
two to three times the sample volume of 100% filtered ethanol chilled to -20°C. 
The sample was stored at -70°C for 2 hours, pelleted by centrifugation at 13,000rpm
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for 10 minutes at 4°C and washed in 70% ethanol at room temperature to remove 
traces of salt. The nucleic acids were repelleted by centrifugation, the supernatant 
was removed and the pellet was air-dried for 5 to 10 minutes. The pellet was 
resuspended in an appropriate volume of SDW or TE buffer to give the desired final 
concentration allowing for an estimated 10% loss of nucleic acid during the 
precipitation process. The sample was requantified and the concentration was 
adjusted as necessary.
2.3.5 Nucleic acid electrophoresis
2.3.5.1 Agarose gels
Routine analysis of DNA and RNA was performed on 0.7 to 2% agarose gels in tris 
acetate ethylene-di-amine-tetra-acetate (TAE) buffer (see Appendix page 189). 
0.7% agarose was used for the analysis of gDNA; 1% for the analysis of RNA; 1.3% 
for the separation of digested plasmids; 2% for the analysis of PCR products. Gels 
were made from ultra pure, electrophoresis grade agarose (GibcoBRL) melted in 
TAE buffer. Ethidium bromide (from a stock of lmg.ml"l) was added to the cooled 
gel to give a final concentration of 0.5pg.mH. Samples were loaded with 6x gel 
loading buffer (see Appendix page 190) and TAE was used as the electrophoresis 
buffer.
2.3.5.2 Gel imaging and photography
Gels were viewed with a “Fotoprep I” ultraviolet (UV) transilluminator (Fotodyne 
Inc.). Gels were recorded using a Polaroid MP4 land camera (Polaroid) on Polaroid 
667 (ASA 3000) film through a Wratten 22A filter (Kodak) or using a Kaiser RA1 
CCD camera and a Sony UP-890CE video graphic thermal printer.
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2.4 PCR Genotyping
2.4.1 PCR core programme
Amplifications for genotyping were performed on a Perkin Elmer DNA thermal 
cycler or on a PHC-3 (Techne) thermal cycler.
1) Initial cycle denaturing temperature 94°C 3 min
annealing temperature 58°C 1 min
extension temperature 72°C 2 min
2) Step cycle (35 cycles) denaturing temperature 93°C 40 sec
annealing temperature 58°C 1 min
extension temperature 72°C 30 sec
3) Final cycle denaturing temperature 93°C 40 sec
annealing temperature 58°C 1 min
extension temperature 72°C 2 min
2.4.2 Genomic PCR
25pi PCR reactions were carried out in 0.5ml thin-walled microcentrifuge tubes 
(Anachem). Reactions contained 50ng target, 0.25mM dNTP Master Mix (Bioline) 
and forward and reverse primers at 0.2pM. All reactions apart from those using the 
Ex2/aEx4.2 primer pair were performed with 1.5mM MgCl2- For Ex2/aEx4.2 
primer pair reactions, 3mM MgCl2 was used. Reactions were performed in the 
presence of 1 unit of Taq DNA polymerase (Bioline) and an ammonium buffer 
(Bioline) and overlaid with 25pi of molecular biology grade mineral oil (Sigma) to 
prevent evaporation of the reaction mix. The reaction was stopped by adding 6x gel 
loading dye (see Appendix page 190) and by storing at 4°C before analysis. PCR 
products were harvested by pipetting beneath the oil layer and analysed on 2% 
agarose gels.
2.4.3 Primers for PCR genotyping and sexing
Primer sequences and product sizes are listed in Table 5 (page 55) and the PCR 
products are demonstrated in (Figure 11, page 56). Primer positions are represented 
graphically in the figures describing the transgenes and are cross-referenced in the
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text. Positive and negative controls were included with each set of samples. A 
control reaction with the sample replaced by SDW was included to ensure that there 
were no contaminating nucleic acids.
2.4.3.1 Pip gene knockout mice
The transgenic status of the Pip  gene knockout mice was assessed using one forward 
and two reverse primers (Figure 4, page 42). The E x lf forward primer recognised a 
region at the start of exon 1 and was common to both the wild type and mutant 
alleles. The aMkNeol reverse primer recognised a region in the neo gene and 
produced a 429bp product from the Plptmknl allele. The reverse primer, 
ocPLP5'anti, recognised a region in exon 1 that was deleted in the Plptmknl allele but 
produced a 389bp product from the wild type allele (Figure 11, page 56). The 
reverse primers were taken from a protocol initially described by Klugman et al. 
(1997). The forward primer was designed in house (DA Vouyiouklis, personal 
communication).
These primers did not distinguish between the endogenous Pip  gene and the #66 and 
#72 transgenes. This led to false wild type bands in mice hemizygous for the 
Plptmknl allele that had been crossed with the #66 and #72 mice and contained 
copies of these transgenes. This pattern was indistinguishable from heterozygosity 
for the Plptmknl allele. To avoid confusion, only male animals were examined in 
the study of transgenic complementation of the Pip  gene knockout mouse.
2.4.3.2 PlpTgl, Dm20Tg2 and ND3A transgenic mice
The transgenic status of the PlpTgl, Dm20Tgl and ND3A transgenic mice was 
assessed using primers that recognised regions in exon 2 (Ex2 forward primer) and 
exon 4 (aEx4.2 reverse primer) (Figure 6, page 44) (Griffiths et al., 1995). These 
primers differentiated the PlpTgl transgene product (506bp) from the Dm20Tg2 and 
ND3A transgene products (401 bp) as exon 3B (105bp) was only present in the 
PlpTgl transgene (Figure 11, page 56). The endogenous Pip gene product 
(~2168bp estimated from human PLP gene sequence data) was rarely identified as it 
was too large to be reliably amplified using this protocol.
2.4.3.3 #66 and #72 transgenic mice
A transgene-specific portion of the T7 promoter from the original plasmid was 
retained at the 3' end of the #66 and #72 transgenic cassette (Figure 5, page 43). 
The primers used recognised the T7 promoter region and a region at the 3' end of 
the murine Pip gene producing a ~400bp PCR product from the transgene (Figure 5, 
page 43) (Readhead et al., 1994; Anderson, 1997). This PCR reaction was
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Figure 11 Genotyping transgenic mice by PCR analysis 
(PCR product lengths in brackets; size m arker: DNA/Haelll)
Lanes 1 and 2 show PCR products from the PCR strategy to distinguish Pip 
gene knockout and wild type Pip alleles: lane 1 from knockout mouse DNA 
(429bp) and lane 2 from wild type mouse DNA (389bp) (see page 54)
Lanes 3 and 4 show PCR products from the PCR strategy to identify #66 and 
#72 transgenes: lane 3 from #66 transgenic line DNA and lane 4 from #72 
transgenic line DNA (both ~400bp) (see page 54)
Lanes 5 to 7 show PCR products from the PCR strategy to identify PlpTgl, 
Dm20Tgl and ND3A transgenes: lane 5 from PlpTgl transgenic line DNA 
(506bp); lane 6 from Dm20Tgl transgenic line DNA and lane 7 from ND3A 
transgenic line DNA (both 401 bp) (see page 54)
particularly sensitive to target concentration requiring gDNA to be accurately 
quantified before PCR.
2.4.3.4 Y-chromosome specific primers
Y-chromosome specific primers were used to confirm the sex of neonatal animals 
that had been culled for tissue collection. The primers described by Schneider et al. 
(1995) recognised the sex-determining region o f  the Y chromosome (Sry) gene, one 
of a group of sex determining genes located on the Y-chromosome. They produced 
a 347bp product by amplifying a region at the start of the open reading frame of the 
Sry gene (bp228 to bp575) that included the high-mobility-group-protein box, a 
highly conserved DNA binding region.
2.5 Tissue fixation
2.5.1 Fixatives
2.5.1.1 Buffered neutral formaldehyde, 4% (BNF)
BNF (see Appendix page 177) was used for the preservation of tissues for paraffin 
embedding and in situ hybridisation, immunohistochemistry and routine 
haematoxylin and eosin (H & E) staining.
2.5.1.2 Karnovsky’s modified fixative (paraformaldehyde/glutaraldehyde
4%/5%)
Karnovsky's modified fixative (see Appendix page 178) was used for the 
preservation of tissues for resin embedding before light and electron microscopy.
2.5.1.3 Periodate-lysine-paraformaldehyde (P-L-P) fixative
P-L-P fixative (see Appendix page 178) was used for the preservation of tissues 
destined for staining with the microglia marker F4/80. After perfusion, tissues were 
post-fixed and cryoprotected before rapid freezing for cryostat sectioning (see
2.6.3.2 Cryopreservation o f  P-L-P fixed material, page 59).
2.5.1.4 4% Paraformaldehyde in PBS
4% paraformaldehyde in PBS (see Appendix page 179) was used for the 
preservation of tissues destined for immunohistochemistry using vibratome sections 
of agar-embedded tissue and for post-fixation of cryopreserved and paraffin 
sections.
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2.5.2 Fixation techniques
2.5.2.1 Cardiac perfusion
Mice over 10 days of age were killed in a carbon dioxide chamber. Mice less than 
10 days of age were killed in a halothane (Rhone-Poulene Chemicals Ltd.) chamber. 
Once death had been confirmed, the thoracic cavity was opened and the right atrium 
of the heart was incised to allow blood and perfusion fluids to escape. Perfusion 
was carried out by instilling solutions into the left ventricle through a 21 to 25 gauge 
1.5-inch hypodermic needle (depending on body size). 0.85% saline was instilled to 
flush blood from the circulatory system followed by fixative. 20 to 60ml of fixative 
were used depending on carcass size and degree of fixation was assessed by carcass 
rigidity.
2.5.1.2 Tissue Dissection
Tissues were dissected using a low power dissection microscope and microsurgical 
instruments. Skin and muscle were reflected from the head and dorsum and the 
calvarium and vertebral arches were removed to reveal the brain and spinal cord. 
The cord was severed using a razor blade as it entered the brain stem and the brain 
was removed by incising the cranial nerves and meninges. The optic nerve tracts 
were incised just caudal to the optic chasm allowing the optic nerves and globes to 
be removed separately and intact. The cord was removed by incising the meninges 
and spinal nerve roots.
2.5.2.3 Tissue storage
Carcasses were stored at 4°C in fixative until tissues were dissected. P-L-P fixed 
tissue was dissected within 1 hour and post-fixed in fixative for 4 to 6 hours before 
sucrose protection and freezing. BNF fixed tissue was dissected within 24 hours 
and processed. Kamovsky’s modified fixative tissue was dissected within 7 days 
and stored in fixative at 4°C until processing. 4% paraformaldehyde/ PBS fixed 
tissue was dissected within 24 hours and stored for up to 7 days in fixative before 
being processed.
2.6 Tissue processing and sectioning
2.6.1 Paraffin wax processing and sectioning
Neural tissue and muscle from mice perfused with BNF were wrapped in pieces of 
filter paper, placed in processing cassettes and loaded in the basket of a Shandon 
Elliot automatic processor (Histokinette). The tissues were passed through
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dehydrating solutions and infiltrated with wax at 60°C (see Appendix page 179) 
before being embedded in wax. 8 pm sections were cut using a Biocut 2035 
microtome (Leica) and mounted onto APES-coated slides that were baked overnight 
at 56°C to ensure good adherence of the sections.
2.6.2 Resin processing and sectioning
Neural tissues from mice perfused with Karnovsky’s modified fixative were 
processed for resin embedding using a Lynx microscopy tissue processor (Leica) 
that automated the dehydration and resin infiltration steps (see Appendix page 180). 
Once processed, the tissues were placed in resin filled rubber moulds for 
polymerisation at 60°C overnight. Blocks were cut on an Ultracut-E Reichert-Jung 
ultratome producing 1pm ‘thick5 sections for light microscopy and 70nm ‘ultra-thin5 
sections for electron microscopy. Thick sections were cut using a glass knife and 
mounted on plain slides for light microscopy or on APES-coated slides for 
immunohistochemistry. Ultra-thin sections were cut with a diamond knife and 
mounted on 200-mesh 3.06mm-diameter copper grids.
2.6.3 Cryopreservation and sectioning
2.6.3.1 Cryopreservation of fresh neural tissue
Tissues required for immunohistochemistry and in situ hybridisation were 
cryopreserved. Nervous tissue was dissected from freshly culled mice, suspended in 
Tissue-Tek O.C.T compound (Miles Inc) and frozen in 2-methylbutane cooled to at 
least -80°C in liquid nitrogen. Frozen O.C.T blocks were wrapped twice in 
NescoFilm (Bando Chemical Ind. Ltd.) to prevent dehydration and stored at -20°C.
2.6.3.2 Cryopreservation of P-L-P fixed material
Cryopreserved, P-L-P fixed tissue was collected for F4/80 immunostaining. 
Immediately after perfusion, neural tissues were removed and post-fixed in 
P-L-P fixative for 4 to 6 hours at 4°C. The tissues were then cryoprotected by 
immersion in 20% sucrose in PBS for 24 to 48 hours at 4°C and frozen in O.C.T as 
described above.
2.6.3.3 Cryopreservation of fresh muscle
Skeletal muscle samples from freshly culled mice were dissected maintaining 
tension during and after dissection to limit contraction artefact. They were 
orientated on strips of 3MM filter paper (Whatman), dusted with talcum powder to 
reduce ice artefact and snap frozen in liquid nitrogen for sectioning on the day of
59
collection.
2.6.3.4 Sectioning of cryopreserved tissue
Cryopreserved tissue was cut on an OTF cryostat (Bright Instrument Company) at 
15pm. The sections were thaw-mounted onto APES-coated slides and stored at 
-20°C. Sections for in situ hybridisation were not allowed to thaw before use (see 
Appendix page 181).
2.6.4 Agar embedding and vibratome sectioning of 
paraformaldehyde fixed tissue
Neural tissue dissected from mice that had been perfused with 4% 
paraformaldehyde/ PBS was embedded in 4% low gelling temperature agarose type 
IV (Sigma) melted in PBS. Sections were cut on a D.S.K Microslicer DTK-1000 
vibratome (Polaron) with cutting speed and frequency optimised to reduce artefact. 
Sections of spinal cord were cut at 50-75pm and sagittal hindbrain was cut at 75- 
100pm. These were stored free-floating in fixative at 4°C until required.
2.7 Staining techniques
2.7.1 Light microscopy
2.7.1.1 Haematoxylin and Eosin (H & E)
Paraffin sections and cryopreserved muscle sections were stained with H & E to 
assess tissue morphology and preservation (see Appendix page 185). Once stained, 
sections were mounted in DPX (BDH).
2.7.1.2 Haematoxylin
Cryosections for in situ hybridisation and paraffin sections for immunostaining were 
counterstained with haematoxylin to show nuclear detail (see Appendix page 186)
2.7.1.3 Methylene blue/ azur II
Resin sections for light microscopy were stained with methylene blue/ azur II (see 
Appendix page 187). Sections were heated on a hot plate to 60°C, flooded with stain 
for 1 minute and washed in running water. These were mounted in DPX after 
drying overnight.
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2.7.2 Electron microscopy
Copper grid-mounted, thin resin sections were stained with uranyl acetate and lead 
citrate for electron microscopy (see Appendix page 186).
2.8 Morphological studies
2.8.1 Quantification of corrected glial cell densities
Quantification o f glial cells was performed on 1pm resin sections stained with 
methylene blue/azur II. Sections were cut at 14pm intervals to avoid sectioning 
individual nuclei in multiple sections and thus counting the same cell twice. A 6.3x 
eyepiece with a lOOx oil immersion lens was used to visualise cells within a 
100-square graticule (Graticules Ltd.).
Transverse sections o f the second to third cervical spinal cord segments (C2-3) and 
o f the mid-optic nerve were counted. On cord sections, glial cell nuclear profiles 
were counted within an area o f the white matter adjacent to the ventromedian 
fissure. Two fields, one on each side o f the fissure, were examined and at least four 
sections from each animal were counted giving a total o f eight hundred graticule 
squares. On optic nerve sections, one and a half fields could be counted per section 
and three sections were counted from each animal giving a total o f four hundred and 
fifty graticule squares. Nuclear profiles were selected if  they lay within the area o f 
the graticule squares using an inclusion/ exclusion technique; all profiles completely 
within the boundaries o f each square and those profiles crossing the upper and left- 
hand boundaries o f the square were counted. Those profiles crossing the bottom 
and right-hand boundaries o f the square were excluded. Endothelial cell and 
pyknotic nuclear profiles were excluded.
In both areas, longitudinal sections were taken immediately caudal to the counting 
area in order to estimate the mean and maximum nuclear lengths. The mean nuclear 
lengths were used in the calculation o f glial cell densities and total glial cell counts 
(see below). The maximum nuclear lengths were used to determine the interval 
between sections to prevent sectioning o f the same nucleus twice. The white matter 
area was calculated for each section from Polaroid light microscopy images using 
Sigma Scan/Image measurement software (Jandel Scientific Software) and a 
SummaSketch III graphics tablet (Summagraphics). Corrected glial cell densities 
and corrected total cell glial counts were calculated using Abercrombie's correction 
factor (Sturrock, 1983). Three to six animals were counted from each group and the 
results were plotted using Graphpad Prism software (Graphpad Software Inc.).
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2.8.2 Quantification of swollen axons and degenerate fibres
Densities of swollen axons and degenerating fibres were measured using an 
adaptation of a point counting method described by Williams (1977) for calculating 
myelin density. Measurements were made from electron-micro graphs of ultra-thin 
transverse sections of mid-optic nerve that were taken at 7,500 times magnification 
and magnified 2 times at printing. Tissue from at least three animals from each 
group was included and 10 to 12 electron micrographs from each tissue sample were 
counted.
2.8.2.1 Measurement of swollen axon densities
A ruled transparency with a grid of 1 .5cm ^  squares was placed over each electron 
micrograph. The numbers of swollen and normal axons crossed by the grid 
intercepts were recorded. The densities of normal and swollen axons were 
expressed respectively as a ratio of the number of intercepts hit by each group to the 
total number of possible intercept hits. This gave values of axonal density that had 
arbitrary units but that were directly comparable with each other.
2.8.2.2 Measurement of degenerate fibre densities
A ruled transparency with a grid of 2cm^ squares was placed over each electron 
micrograph. The numbers of degenerate and normal myelinated fibres crossed by 
the intercepts were recorded and fibre densities were calculated as above.
2.8.3 Assessment of axonal size and myelination status
Measurements were made from electron micrographs of ultra-thin sections of mid­
optic nerve and of spinal cord ventral columns (C2-3). Electron micrographs were 
taken from randomly selected fields of optic nerve and cervical cord. Optic nerve 
micrograph images were collected at 7,500 times magnification at all ages and 
cervical cord images were collected at 5,000 times (20 days of age) and 3,000 times 
(60 and 120 days of age) magnification respectively. To resolve the axon profiles 
and their associated glial processes, these electron micrographs were printed at 5 
times magnification. A diffraction grating with 2160 lines per mm was 
photographed for calibration. A rectangle was drawn on each electron micrograph 
to define an area that only contained axons completely included within the field of 
view of the electron micrograph. Axons for assessment were selected using an 
inclusion/ exclusion system to include all axons completely contained within the 
rectangle and those axons that crossed either of two adjacent boundaries of the 
rectangle. Axons crossing the remaining two boundaries of the rectangle were 
excluded. All the selected axons were numbered. Two to three hundred axons were
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selected from each mouse and four mice were assessed from each group. Swollen 
axons or those associated with degenerating fibres and cross-sections o f nodes and 
paranodes were excluded.
2.8.3.1 Assessment of axonal diameter
Few axons are truly circular in cross-section at electron microscopy and a direct 
comparison o f axonal diameters, and hence axonal size, is impossible. In this study, 
a projected axonal diameter was used as the measurement o f  axonal size. The 
cross-sectional area o f each axon was calculated using Sigma Scan/Image 
measurement software (Jandel Scientific Software) and a SummaSketch III graphics 
tablet (Summagraphics). The projected axonal diameter was calculated by assuming 
that all axons were circular in cross-section and extrapolating a projected axonal 
diameter from the measurement o f axonal area.
2.8.3.2 Assessment of myelination status
The myelination status o f each axon was assessed. Axons were classified as 
myelinated if  they were encircled by one or more compacted myelin lamellae. 
Ensheathed axons were fully encircled at least once by an oligodendrocyte process 
but no compacted myelin was present. Axons associated with but not ensheathed by 
oligodendrocytes and those associated with astrocyte processes were classified as 
unmyelinated. Data from non-myelinated axons encompasses data collected from 
unmyelinated and ensheathed axons.
2.8.4 Presentation of data and statistical analysis
Data have been presented graphically and, where group sizes permit, the 
non-parametric two-tailed Mann-Whitney test has been used to compare data sets 
statistically. Statistical significance has been set at P less than 0.05 throughout this 
study.
Axon diameter data are presented as mean relative frequency distributions. These 
are calculated for each time point from the relative frequency distributions o f axon 
diameters for each data set. The bin values are collated from the data sets by 
plotting the mean values with the standard error o f the mean.
Myelinated (or non-myelinated) axon diameter frequency distributions are presented 
in proportion to the total population o f axon diameters. To achieve this, the relative 
frequency distribution bin values for each data set are adjusted by multiplying by the 
percentage o f myelinated (or non-myelinated) fibres in that data set and the separate
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data sets are collated as above.
2.9 Immunohistochemistry
Descriptions of the standard immunohistochemical techniques are followed by 
modified techniques employed for staining of agar embedded tissue and for 
microglial staining. Incubation steps were performed in a humidity chamber and 
control sections with the primary antibodies omitted were included to ensure 
specificity.
2.9.1 Immunohistochemical markers
The sources and titres of antibody used are described in Table 6 (page 65).
Anti-PLP C-terminal antibody (NP Groome, Oxford, UK) recognises the carboxy 
terminus (amino acids 271 to 276) of the Pip gene protein isoforms (Fanarraga et 
al., 1993). This antibody was used to identify endogenous and transgenic Pip gene 
products by immunohistochemistry and western blotting. Anti-PLP isoform specific 
antibody (NP. Groome, Oxford, UK) recognises the 35 amino acid epitope encoded 
by exon 3B that is unique to the PLP protein isoform. Anti-MBP antibody 
(NP. Groome, Oxford, UK) was used to identify central compact myelin. Anti-CAII 
antibody (AM. Butt, London, UK) recognises carbonic anhydrase II, an 
oligodendrocyte-specific marker in mature CNS white matter defining a 
subpopulation of cells that myelinate small diameter axons (Butt et al., 1995). It 
also recognises neurones in grey matter and a wider range of glial cells in immature 
animals but was used to confirm comparative oligodendrocyte densities in white 
matter tracts between mature mice in this study. Anti-F4/80 hybridoma supernatant 
(Serotec) recognises a macrophage-specific epitope (F4/80) (Austyn and Gordon, 
1981; Perry et al., 1985) and was used to identify microglia. Anti-glial fibrillary 
acidic protein (GFAP) antibody (Dako) was used to identify astrocytes (Bignami et 
al., 1972). Anti-SMI-31 antibody (Affiniti Research Products Ltd.) recognises a 
phosphorylated neurofilament epitope and was used to identify axons and 
phosphorylated neurofilaments in neuronal cell bodies. Anti-(3-galactosidase 
antibody (Promega) was used to identify the PLP-LacZ fusion protein.
2.9.2 Peroxidase anti-peroxidase (PAP) immunohistochemistry
2.9.2.1 Preparation of slides
2.9.2.1.1 Resin sections
Resin was removed from the sections by immersion with rotation in sodium
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ethoxide (50% ripened sodium ethoxide in 50% absolute alcohol) for 30 minutes. 
The slides were washed in absolute alcohol (6 changes in 30 minutes) to remove 
traces of sodium ethoxide and then in running water for 30 minutes. Endogenous 
peroxidase activity was quenched by immersion in 3% hydrogen peroxide in water 
for 30 minutes. Sections were washed again in running water for 30 minutes before 
blocking.
2.9.2.1.2 Paraffin sections
Paraffin sections were dewaxed in xylene and hydrated through alcohols (see 
Appendix page 184). Endogenous peroxidase activity was quenched by immersion 
in 3% hydrogen peroxide in alcohol for 30 minutes. Sections were washed in 
running water for 30 minutes before blocking.
Table 6 Primary antibodies used for immunohistochemistry with 
appropriate dilutions (dilutions for western blotting in the text)
Primary antibody Dilution
anti-PLP C-terminal rabbit polyclonal IgG 1:600
anti-PLP isoform specific rabbit polyclonal IgG 1:600
anti-MBP rat monoclonal IgG 1:500
anti-CAII rabbit polyclonal IgG 1:1500
anti-F4/80 rat monoclonal IgG 1:1000
anti-GFAP rabbit polyclonal IgG 1:1000
anti-SMI-31 mouse monoclonal IgGl 1:1500
anti-(3-galactosidase mouse monoclonal IgM2a 1:1000
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Table 7 Link antibodies, PAP complexes and dilutions used for PAP 
immunostaining (sourced from Sigma)
Link antibody PAP complex Source
goat-anti-rabbit 1:10 rabbit 1:40 ICN
goat-anti-mouse 1:10 mouse 1:1250 Sigma
Table 8 Fluorescent secondary antibody dilutions for immunohistochemistry 
(sourced from Southern Biotech)
Secondary antibody Dilution
goat-anti-rabbit IgG FITC 1:80
goat-anti-rat IgG FITC 1:50
goat-anti-mouse IgGl FITC 1:80
goat-anti-mouse IgGM2a FITC 1:25
goat-anti-rat IgG TxR 1:50
goat-anti-mouse IgGl TxR 1:75
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2.9.2.2 PAP staining
Non-specific binding of antibodies was blocked by incubation of the sections with 
1% normal goat serum (NGS) in PBS for 2 hours at room temperature. Excess 
blocking solution was removed and the primary antibody was applied diluted in 
more blocking solution. The sections were incubated in the primary antibody 
overnight at 4°C.
Once the sections had warmed to room temperature, they were washed in PBS (6 
changes in 30 minutes). The appropriate link antibody (Table 7, page 66) was 
applied diluted in blocking solution for 1 hour at room temperature and then washed 
off with PBS (6 changes in 30 minutes). Sections were incubated in PAP complex 
(Table 7, page 66) for 30 minutes at room temperature and then washed in PBS (6 
changes in 30 minutes). The chromogen was developed in filtered PBS containing 
0.5 mg.ml'l 3,4,3',4',-tetraminobiphenyl hydrochloride (DAB) and 0.003% 
hydrogen peroxide until the required colour change was seen (30 seconds to 5 
minutes). DAB was removed by washing in PBS for 2 minutes and running water 
for 5 minutes.
Paraffin sections were counterstained with haematoxylin (see Appendix page 186). 
Resin sections were immersed in 1% osmium/caccodylate buffer for 2 min before 
washing. All sections were dehydrated through alcohols, cleared (see Appendix 
page 184) and mounted in DPX.
2.9.3 Immunofluorescence of fresh, cryo-preserved tissue
After thawing, cryostat sections were soaked in PBS for 10 minutes to remove the 
embedding medium and fixed in 4% paraformaldehyde/ PBS at room temperature 
for 20 minutes. Depending on the antibody used, sections were permeabilised by 
immersion in methanol for 10 minutes at -20°C. The sections were washed twice in 
PBS for 5 minutes and incubated in a humidity chamber with the primary antibody 
diluted in 1% NGS/ PBS at 4°C overnight. The primary antibody was removed by 
washing twice in PBS for 5 minutes and the appropriate secondary antibody was 
applied for 30 minutes at room temperature (Table 7, page 66). The sections were 
washed and mounted in Citifluor antifade mountant (UCK Chem Lab) under sealed 
coverslips. Sections were stored in the dark at 4°C to limit fading.
Secondary antibodies were labelled with fluorescein isothiocyanate (FITC) and 
Texas red (TXR) (Table 7, page 66) and sections were examined by 
epifluorescence. FITC absorbs light with a wavelength 495nm and emits it at
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525nm that can be visualised as green light using a blue filter. TXR absorbs light at 
596nm and emits it at 620nm that can be visualised as red light using a green filter.
2.9.4 Agar-embedded tissue staining
Immunofluorescence on agar-embedded, formaldehyde-fixed tissue was performed 
using a technique modified from Trapp et al. (1997). The main factor that 
determined the efficacy of staining was the primary antibody incubation step. 
Sections were washed 3 times in PBS for 5 minutes between each step. Except for 
the primary antibody incubation step, all steps were performed at room temperature. 
The steps were performed on free-floating sections in microwell plates containing 
300pi of reagent.
The sections were washed, permeabilised in 5% Triton X-100/ 3% hydrogen 
peroxide for 30 minutes, washed again and blocked in 3% NGS in PBS for 30 
minutes. Excess blocking solution was removed and the sections were incubated 
with the primary antibody diluted in 3%NGS in PBS at 4°C. Sections were 
incubated in anti-SMI-31 or anti-MBP primaries for 3 days; sections were incubated 
in anti-PLP C-terminal primary for 5 days.
Sections were washed and incubated for 1 hour with the secondary antibody (Table 
7, page 66). After further washing, the sections were mounted in Citifluor antifade 
mountemt under vocvlod covcrilipi, If nuclear counterstaining was required, sections
were washed and incubated in 4',6-diamidino-2-phenyl-indole (DAPI) (Sigma) 
diluted to 1:400 for 30 seconds before washing and mounting. Sections were stored 
in the dark at 4°C to limit fading. Any remaining agar was removed by gentle 
traction before mounting.
2.9.5 F4/80 Microglial staining
Immunostaining with the F4/80 hybridoma supernatant was performed on cryostat 
sections of P-L-P perfusion fixed tissue that had been cryoprotected before freezing 
(see 2.6.3.2 Cryopreservation o f P-L-P fixed material, page 59). Sections were 
washed thoroughly in PBS (6 changes in 20 minutes) between steps and reagents 
were diluted in PBS. All incubations were performed at room temperature.
Sections were thawed and washed to remove the embedding medium before being 
blocked in 1% NGS for 30 minutes. Excess blocking medium was removed and the 
F4/80 antisera was applied at 1:20 for 60 minutes. The sections were washed and 
biotinylated rabbit anti-rat IgG secondary antibody at a 1:100 dilution was applied 
for 45 minutes. After further washing, endogenous peroxidase activity was 
quenched by soaking the slides in 0.3% hydrogen peroxide in ethanol for 20
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minutes. The sections were washed in PBS and incubated in avidin-biotin complex 
(Elite ABC) for 45 minutes. The chromogen was developed in filtered PBS 
containing 0.5 mg.ml- ! DAB and 0.003% hydrogen peroxide until the required 
colour change was seen (30 seconds to 5 minutes). After excess chromogen had 
been removed by washing, the sections were exposed to 0.01% osmium tetroxide 
for 30 seconds to enhance the chromogen intensity. The sections were washed, 
counterstained with haematoxylin (see Appendix page 186), cleared through 
alcohols (see Appendix page 184) and mounted in DPX.
2.10Plasmid DNA (pDNA) preparation
2.10.1 Plasmids
Digoxigenin labelled anti-sense and sense P/p-riboprobes were generated from an 
836bp P/p-cDNA that encompassed most of the coding region of the P/p-cDNA 
inserted into a pGEM4 vector (Promega) (Figure 8, page 47) (Milner et a l,  1985). 
This plasmid, pPLP-1, was linearised by BamHl digestion for anti-sense probe 
production (T7 promoter) and by Hindlll digestion for sense probe production (SP6 
promoter).
Digoxigenin labelled anti-sense and sense M?g-riboprobes were generated from a 
780bp Mog-cDNA that included all eight exons of the murine Mog gene (Daubas et 
a l, 1994). This had been subcloned from the pCL642 plasmid into a pGEM-4Z 
expression vector (Promega) denoted pG4MOG (Figure 8, page 47) (King, 1998). 
This was linearised by Hindlll digestion for anti-sense probe production (T7 
promoter) and by EcoKX digestion for sense probe production (SP6 promoter).
2.10.2 Preparation of competent cells
Escherichia Coli Dh5a {endAl hsdRl7(r~icm+^ ) supE44 thi-1 recAl gyrA (Nalr) 
relAl k(lacZYA-argF)ui69 ($%0lacZAMl5)} was used for competent cell 
preparation. A single colony was seeded into 10ml Luria-Bertani (LB) medium (see 
Appendix page 191) and incubated at 37°C with agitation overnight. 2ml of the 
overnight culture were inoculated into a 1 litre flask containing 200ml LB medium. 
This was incubated at 37°C with agitation until an OD^qq of 0.2 to 0.3 was 
obtained. The cultures were left on ice for 10 minutes before centrifugation at 
5,000rpm for 5 minutes at 4°C. The harvested cells were gently resuspended in 
50ml of lOOmM calcium chloride, incubated on ice for 20 to 60 minutes, 
centrifuged at 5,000rpm for 5 minutes at 4°C and resuspended in 10ml of lOOmM 
calcium chloride with 15% glycerol. The suspension was aliquoted, placed in liquid
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nitrogen and stored at -80°C.
2.10.3 Transformations
In a 40ml polypropylene tube, a lOOpl aliquot of ice-thawed competent cells was 
added to 5ng of pDNA in lOOpl of TE buffer. This was incubated on ice for 30 
minutes then heat shocked at 42°C for 2 minutes. Following the addition of 800 pi 
of LB medium, the tubes were incubated at 37°C with gentle agitation. 200pl 
aliquots were spread onto ampicillin-LB agar plates (see Appendix page 191), 
inverted and incubated at 37°C overnight.
2.10.4 Plasmid preparation
A single colony was seeded into 2ml ampicillin-LB medium (see Appendix page 
191) and incubated at 37°C with agitation for 6 to 8 hours. 50pi of the starter 
culture was seeded into 25ml ampicillin-LB medium and incubated overnight at 
37°C with gentle agitation. The cells were pelleted by centrifugation at 5,000rpm 
for 5 minutes at 4°C. pDNA was prepared using the Hybaid R e c o v e r y  TM Quick 
Flow Midi Kit (Hybaid) according to manufacturers’ instructions and using the 
manufacturers’ buffers (see Appendix page 189). Briefly, the pellet was 
resuspended in 4ml of Cell Resuspension Buffer (Hybaid) containing RNase 
followed by the addition of 4ml of Cell Lysis Buffer and incubated at room 
temperature for 5 minutes. Following the addition of 4ml Neutralisation Buffer 
(Hybaid), the mixture was centrifuged at 18,000rpm for 10 minutes at 22°C. The 
supernatant was applied to a pre-equilibrated column under gravity flow. The 
bound material was washed twice in 10 ml Wash Solution (Hybaid) and eluted in 
5ml of Elution Buffer. pDNA was precipitated by the addition of a 0.7 volume of 
propan-2-ol and immediately centrifuged at 18,000 rpm for 10 minutes at 4°C. The 
pellet was washed in 70% ethanol, collected by centrifugation at 18,000 rpm for 10 
minutes at 4°C, air dried for 15 minutes and resuspended in 250pl of TE buffer. 
Yields in the range of 50 to lOOpg of pDNA were obtained.
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Figure 12 Plasmids used for riboprobe production
a) pPLP-1 plasmid for generation of anti-sense and sense /7/?-riboprobes
b) pG4M OG plasmid for generation of anti-sense and sense Mog-ri bop robes
(dark green boxes represent cDNA fragments; light green boxes represent T7 
and SP6 vector prom oters; restriction sites for cDNA insertion and for plasmid 
linearisation are shown; arrow s denote direction of transcription of anti-sense 
and sense riboprobes; sizes of cDNA inserts and riboprobes are given)
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2.11 Semi-quantitative reverse transcription PCR 
(RT-PCR)
The semi-quantitative RT-PCR method described has been used extensively in this 
laboratory to study Pip gene transcript ratios and previously established conditions 
were adopted for this study (Dickinson, 1995).
2.11.1 cDNA Synthesis
2pg of total cellular RNA was heat denatured at 65°C for 5 minutes and quenched 
on ice. First strand cDNA synthesis was performed from this RNA in a reaction 
mix containing 3pg random oligo d(N)6 (GibcoBRL), 0.5mM dNTP, lOmM DDT, 
20U RNase inhibitor (RNasin, Promega) and 400U Moloney murine leukaemia 
virus reverse transcriptase in the manufacturers buffer (GibcoBRL). This was 
incubated first at 37°C for 30 minutes, then at 42°C for 60 minutes and finally 
quenched by the addition of EDTA to a concentration of 25mM. Nucleic acids were 
precipitated at -80°C over 2 hours in the presence of 0.3M sodium acetate (pH5.2) 
and a 2x volume of ethanol. The nucleic acids were pelleted by centrifugation at 
13,000 rpm for 30 minutes at 4°C, washed in 70% ethanol, air dried and 
reconstituted to 0.5ng/pl cDNA assuming maximal reverse transcription. cDNAs 
were gel checked to ensure efficient reverse transcription and accurate 
quantification (Figure 10, page 50).
2.11.2 RT-PCR
2.11.2.1 RT-PCR reaction Mix
RT-PCR was performed on lng and 2ng aliquots of cDNA in 50pl reaction 
volumes. Each reaction contained 0.25mM dNTP Master Mix (Bioline), 3mM 
MgCl2, forward and reverse primers at 0.2pM, 2 units of Taq DNA polymerase 
(Bioline) and an ammonium buffer (Bioline). The reactions were overlaid with 50pl 
of molecular biology grade mineral oil (Sigma) to prevent evaporation. The Ex2 
and aEx4.2 primer pair (see 2.4.3.2 PlpTgl, Dm20Tg2 and ND3A transgenic mice, 
page 54) were used to amplify P//?-cDNA and Dw20-cDNA species. To assess 
consistency of sample loading and PCR conditions between tubes, primers that 
amplified cDNAs of transcripts from the ubiquitously expressed housekeeping gene, 
cyclophylin, were included in separate reactions (Table 5, page 55) (Danielson et al., 
1988).
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2.11.2.2 RT-PCR Programme
To ensure consistency all amplifications were performed on the same thermal cycler 
(Perkin Elmer) and each experiment was repeated at 25 and 30 cycles of step 2.
1) Initial cycle denaturing temperature 94°C 3 min
annealing temperature 58°C 1 min
extension temperature 72°C 2 min
2) Step cycle denaturing temperature 93°C 40 sec
(25 and 30 cycles) annealing temperature 58°C 1 min
extension temperature 72°C 30 sec
3) Final cycle denaturing temperature 93°C 40 sec
annealing temperature 58°C 1 min
extension temperature 72°C 2 min
2.12/n Situ Hybridisation
2.12.1 Preparation of apparatus and solutions
To minimise RNase activity, all solutions were made using DEPC-treated water. 
Glassware was cleaned by soaking overnight in 6% sulphuric acid/ 6% potassium 
dichromate, washed in DEPC-treated water and baked at 180°C for 4 hours loosely 
wrapped in foil. Plastic-ware was guaranteed RNase free (Anachem).
2.12.2 Preparation of digoxigenin-labelled riboprobes
2.12.2.1 Riboprobe production
Digoxigenin-labelled-UTP riboprobes were generated using the DIG RNA 
Labelling Kit (SP6/T7) (Boehringer Mannheim). Each 20pl reaction contained 
0.5pg of linearised pDNA template, NTPs at ImM, ImM digoxigenin-labelled UTP, 
10U RNase inhibitor and 10U of either SP6 or T7 RNA polymerase in transcription 
buffer supplied with the kit. The reaction mixture was incubated at 37°C for 1 hour 
and then quenched on ice. Template was treated with 5U of RNase-free DNase 
(Boehringer Mannheim) by incubation at 37°C for 10 minutes followed by the 
addition of lp l of 0.2M EDTA. RNA was ethanol precipitated in the presence of
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0.3M lithium chloride and resuspended in 50pl of DEPC-treated water in the 
presence of 0.5U.pl"l RNase inhibitor. The reconstituted riboprobe was stored at 
-70°C until use.
2.12.2.2 Assessment of riboprobe activity
To assess digoxigenin-labelled riboprobe activity, dot blots of dilutions of the 
riboprobe were compared to standards supplied by the manufacturers. The test 
samples of probe were dot blotted onto a Hybond N+ nylon membrane (Hybaid). 
The membrane was air-dried for 10 minutes, baked at 80°C for a minimum of 2 
hours and washed in maleate buffer (0.1M maleic acid, 0.15M NaCl, pH 7.5). A 
blocking solution of 10% foetal calf serum diluted in maleate buffer was applied to 
the membrane for 30 minutes. Sheep-derived, alkaline phosphatase-labelled anti- 
digoxigenin antibody (Anti-Digoxigenin-AP Fab fragments, Boehringer Mannheim) 
was applied to the membrane for 30 minutes at 1:4500 in 0.1M Tris/ 0.15M NaCl 
(pH7.5) buffer. After two 15 minute washes in 0.1M Tris the enzymatic reaction 
was developed by adding the alkaline phosphate substrate buffer (see Appendix page 
183). Once the reaction had started to develop (taking up to 30 minutes) the filter 
was washed and the activity of the riboprobe dilutions was compared to standards. 
Riboprobes were used at dilutions that corresponded to 0.5 to 5ng.ml"l.
2.12.3 Prehybridisation of sections
Paraffin sections were dewaxed by washing in xylene for 10 minutes followed by 5 
minute washes in ethanol, methylated spirits, 0.85% saline and PBS. Both paraffin 
and cryosections then went through a series of washes (see Appendix page 182) 
including two fixation steps in 4% paraformaldehyde, proteinase K treatment to 
destroy RNase activity and acetylation in triethanolamine/acetic anhydride. The 
sections were dehydrated through alcohols and left to dry before hybridisation.
2.12.4 Hybridisation
Probe was diluted to final concentration of 0.5 to 5ng.ml'l in hybridisation buffer 
containing 50% formamide, 10% dextran sulphate, lx Denhardf s, 20mM Tris HC1 
pH8, 0.3M NaCl, 5mM EDTA, lOmM NaP04 pH8 and 0.5mg.ml-l yeast tRNA. 
The probe were heated to 80°C for 2 minutes to denature secondary RNA structures 
and cooled on ice before being applied to sections under coverslips. Slides were 
placed horizontally in a holding box that contained a sponge reservoir of 50% 
formamide in 5x SSC to maintain humidity. This was sealed and placed in a 
humidified oven at 50°C for overnight hybridisation.
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2.12.5 Slide development and mounting
Slides were passed through a series of increasingly stringent washes and 
equilibrated with the substrate buffer conditions (see Appendix page 183). After 
blocking, sheep-derived, alkaline phosphatase-labelled anti-digoxigenin antibody 
(Anti-Digoxigenin-AP Fab fragments, Boehringer Mannheim) was applied at 1:500 
in 0.1M Tris/ 0 .15M NaCl (pH7.5) buffer for 1 hour at room temperature. Antibody 
was removed by washing in TBS and the reaction was developed by adding 
substrate buffer (see Appendix page 183) for 5 minutes to 12 hours. Once the 
reaction had developed, slides were washed in running water for at least 10 minutes, 
counterstained and mounted in glycerol under sealed coverslips.
2.13Western Blotting
2.13.1 Extraction of Protein from Tissue
Protein was extracted from whole spinal cords and brain that had been dissected 
from freshly killed animals and stored in liquid nitrogen. During the extraction 
process, all steps were performed at 4°C and the protein extracts were stored at 
-20°C until required
2.13.1.1 Isolation of protein from whole brain and spinal cord
Tissue samples were homogenised in 75 pi aliquots of tissue lysis buffer containing 
lOmM Tris (pH6.0), 150mM NaCl, ImM EDTA, ImM ethylene-glycol-bis-(beta- 
amino-ethylether)-N,N'-tetra-acetic acid, 0.2mM phenylmethylsulfonyl fluoride, 
0.5% NP-40, 1% TritonX-100. The homogenate was centrifuged at 13000rpm for 
30 minutes to pellet the cell debris and the supernatant was retained. Total protein 
concentration was measured using the BCA assay (Pierce).
2.13.1.2 Isolation of protein from myelin extracts of brain and spinal cord
Tissue samples were homogenised in buffer containing 0.85M sucrose, lOmM 
Hepes (pH7.4), 3mM dithiothreitol (DTT), ImM Na-p-tosyl-l-lysine chloro-methyl 
ketone (TLCK). Additional buffer was added to give a final volume of 7.4ml 
(approximately 20x that of the tissue sample). This was overlain with 4.6ml of 
buffer containing 0.25M sucrose, lOmM Hepes (pH7.4), 3mM DTT, ImM TLCK 
and centrifuged at 70,000g for 90 minutes. This produced a biphasic solution with 
cellular debris left in the lower phase (0.85M sucrose), lipid floating on top of the 
upper phase (0.25M sucrose) and myelin protein trapped at the interface between the 
two phases. The protein layer was removed and osmotically challenged to solublise 
any remaining cellular organelles. 12ml of SDW was added to the sample and this
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was centrifuged at 23,000g for 30 minutes to sediment the protein. The supernatant 
was discarded and the process was repeated 3 times with the final centrifugation at 
17,000g to ensure that only protein sedimented. The protein pellet was washed in a 
small volume of SDW before being resuspended in 50pl of SDW. Total protein 
concentration was measured using the BCA assay (Pierce).
2.13.2 SDS-Polyacrylamide gel electrophoresis
2.13.2.1 SDS-Polyacrylamide gel preparation
Proteins were resolved on a 40ml vertical SDS-polyacrylamide gel produced by 
polymerisation of acrylamide cross-linked with N,N'-methylene bisacrylamide at a 
ratio of 30:8. The catalyst for the reaction was ammonium persulphate and the 
accelerator was N,N,N,N',-tetramethylethylenediamine (TEMED). A 5 to 20% 
gradient gel was poured using a Biorad mode 385 gradient former from 5% and 
20% solutions of acrylamide-bisacrylamide containing 0.375M Tris (pH 8.8), 0.1% 
SDS, 0.05% TEMED, 0.075% ammonium persulphate. Once this had polymerised 
a stacking gel (2.5% acrylamide-bisacrylamide, 0.125M Tris (pH 6.8) 0.1% SDS, 
0.05% TEMED, 0.075% ammonium persulphate) with wells was lain on top.
2.13.2.2 Protein electrophoresis
Aliquots of the protein samples (25pg of myelin extracts and 50pg of whole 
extracts) were made up to a volume of 25pl in a buffer containing 62.5mM Tris 
(pH6.8), 40mM DTT, 5% 2-mercaptoethanol, 0.002% bromophenol blue, 2% SDS, 
10% glycerol and denatured by boiling for 5 minutes. This allowed the SDS to bind 
to the denatured polypeptides in a constant weight ratio so that they had similar 
charges and would separate on the basis of size. The samples were loaded onto the 
gel with equine myelin and size markers as controls.
The samples were electrophoresed in a discontinuous buffer system using a buffer 
containing 25mM Tris (pH8.3), 19.2mM glycine, 0.1% SDS at 4°C. The samples 
were electrophoresed for 45 minutes at 125mA to stack the samples and then at 
35mA overnight to resolve the proteins.
2.13.3 Western Blotting
2.13.3.1 Electrophoretic protein transfer
The gel was washed in SDS-transfer buffer (25mM Tris (pH8.3), 150mM glycine, 
20% methanol, 0.1% SDS). The proteins were transferred onto Hybond ECL 
nitrocellulose membrane (Amersham Life Sciences) in a transblot cell (Bio-Rad).
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The cell was run for 4 hours at 300mA in the SDS-transfer buffer that was cooled to 
4°C. The gel was stained with Comassie blue R250 to check for loading accuracy 
and efficiency o f transfer.
2.13.3.2 Immunostaining
The membrane was blocked overnight at 4°C by soaking in blocking buffer 
containing 0.2% gelatin, 5% dried milk, 0.1% TritonX-100 in TBS (pH 7.6). 
Primary antibodies were diluted in blocking buffer and applied for 1 hour at room 
temperature. The membrane was washed repeatedly in blocking buffer over 2 hours 
and the link antibody, diluted at 1:2500 in blocking buffer, was applied for 60 
minutes. The membrane was washed again in blocking buffer and rinsed in TBS 
(pH 7.6). The membrane was incubated in equal volumes o f luminol enhancer 
solution and stable peroxide solution (both from Pierce Chemical Co.) for five 
minutes at room temperature and wrapped in Saran wrap. X-omat imaging film 
(Kodak) was exposed to the membrane for 30 seconds and the film was developed 
in an automatic processor (Dupont Cronex CX-130).
Anti-PLP C-terminus antibody was applied at 1:5000 and anti-MBP antibody (rabbit 
polyclonal supplied by JM. Matthieu, Lausanne, Switzerland) was applied at 1:2000; 
both were detected with goat anti-rabbit IgG antibody conjugated to peroxidase. 
Anti-actin antibody was applied at 1:2000 and detected with anti-mouse IgG 
antibody conjugated to peroxidase.
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3. The phenotype and pathology of 
the P i p  gene knockout mouse
3.1 Introduction
Much of the evidence supporting roles for the Pip gene in oligodendrocyte 
development and survival comes from studies of spontaneous Pip gene mutants. 
These are characterised by early-onset, dysmyelinating phenotypes with reduced 
numbers of mature oligodendrocytes and small numbers of thin myelin sheaths 
(reviewed in introduction to this thesis). Two disease mechanisms have been 
proposed for the pathogenesis of these phenotypes. The Toss-of-function’ 
hypothesis (page 31) proposes that Pip gene products play vital roles in 
oligodendrocyte development and myelin stability and that, without these, the 
oligodendrocyte is not viable. This is supported by similar disease in humans with 
deletions and functional null alleles of the PLP gene and by the paucity of gene 
products in people and animals with missense mutations of the Plp/PLP gene. The 
‘gain-of-function’ hypothesis (page 31) proposes that mutated Pip gene products 
gain toxic properties disrupting oligodendrocyte function. The inability of 
transgenic complementation to rescue the phenotypes of some spontaneous Pip gene 
mutants and evidence of abnormal protein trafficking within mutant 
oligodendrocytes adds weight to this theory.
In order to clarify some of these points and provide a model to examine the effects 
of gene dosage, a targeted mutation of the Pip gene was induced producing mice 
with null alleles of the Pip gene (Klugmann et al., 1997). Surprisingly, despite the 
complete absence of Pip gene products, these mice myelinated well showing no 
evidence of gross dysmyelination. They remained clinically normal into adulthood 
and were indistinguishable from unaffected littermate controls. On closer 
examination however, they did show evidence of neurodegeneration that was 
characterised by a progressive axonopathy with fibre degeneration. Two further 
mouse models described by Boison and Stoffel (1994) that had functional Pip gene 
null-alleles also showed few clinical signs but appeared to have selective 
dysmyelination, small diameter axons remaining unmyelinated (Boison and Stoffel, 
1994; Boison et al., 1995). In addition, they reported poor compaction of central 
myelin with abnormalities of the intraperiod lines (Rosenbluth et al., 1996) and 
reduced optic nerve conduction velocities (Boison and Stoffel, 1994).
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3.2 Aims
One o f the major aims o f this study was to characterise the Pip gene knockout 
mouse generated by Klugman et al. (1997) and thus elucidate the roles o f the Pip 
gene. These mice are referred to as knockout mice in this text and a description of 
the targeting strategy is given in Chapter 2 Materials and Methods {2.2.2.1 Pip gene 
knockout mice, page 39). This section describes the clinical and pathological 
features o f the knockout mice in comparison to age-matched controls from the same 
breeding programme that lack the targeted mutation (wild type mice). In addition to 
CNS dysfunction, humans with deletions and functional null-alleles o f the PLP  gene 
show evidence o f demyelinating peripheral neuropathies (Garbem et a l ,  1997). 
This suggests that the PLP  gene plays a role in maintaining peripheral myelin. In 
order to investigate a similar role for the murine Pip  gene products, a 
histopathological survey o f the PNS o f knockout mice was undertaken.
In this chapter, molecular analysis o f the knockout mice is described to show that 
the targeted mutation prevents endogenous Pip gene activity. A summary o f the 
clinical and pathological findings in the knockout mice is given followed by more 
detailed descriptions o f the axonal, glial and myelin changes. Electron microscopy, 
immunostaining and morphometric analyses are included where relevant to 
highlight the changes that developed. Results from the survey o f the peripheral 
nervous system are included at the end.
A separate description o f female animals heterozygous for the targeted allele 
(.Plptmknl) is given in Chapter 4 Plptmknl heterozygous animals (page 132).
3.3 Materials and methods
3.3.1 Anim al breeding
Over 450 animals were bred as described in 2.2 Mouse Breeding (page 39) during a 
three year period. Both male and female mice were used for survey histopathology 
and molecular analyses. Only male mice were used for morphometric analyses and 
body weight measurements, to control for differences between genders. Genotypes 
o f knockout mice were confirmed by PCR (see 2.4 PCR Genotyping, page 53).
3.3.2 M olecular analysis o f the knockout animals
Mice were compared by RT-PCR and western analysis at the peak o f normal Pip 
gene expression (20 days of age).
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3.3.2.1 Tissue collection
Total cellular RNA was extracted from whole brain homogenates as described in 
2.3.3 Extraction o f  RNA from  mouse tissue (page 47). Protein was extracted from 
whole brain homogenates and from the myelin fraction o f brain as described in
2.13.1 Extraction o f  Protein from  Tissue (page 75).
3.3.2.2 Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was performed as described in 2.11 Semi-quantitative 
reverse transcription PCR (RT-PCR) (page 72) to assess the level o f Pip gene 
transcription.
3.3.2.3 Western analysis
Western analysis o f protein samples from whole tissue and myelin extracts o f  brain 
and spinal cord were compared using the anti-PLP C-terminal antibody as described 
in 2.13 Western Blotting (page 75).
3.3.3 Histopathology
A histological survey o f CNS tissue was performed from 1pm resin sections stained 
with methylene blue/ azur II (see 2.6.2 Resin processing and sectioning , page 59). 
Tissues were collected from 20, 60, 120, 240, 360 and 540 day-old wild type and 
knockout mice. Occasional knockout mice surviving for more than 540 days o f age 
without developing severe neurological dysfunction and wild type mice up to 2 
years o f age were included. Tissue from 98 knockout mice (o f which 39 were 360 
days o f age or older) and 62 wild type mice (of which 19 were 360 days o f age or 
older) was examined.
A  survey o f the peripheral neuromuscular system o f aged knockout mice was 
performed. Resin sections from a range o f peripheral nervous tissues (sciatic, 
peroneal, tibial, vagus and trigeminal nerves, lumbar nerve roots and brachial 
plexus) were examined from six knockout mice aged 600 days or older. 
Cryosections o f skeletal muscles (biceps brachii, triceps brachii, quadratus femoris, 
cranial tibialis, gluteals) and neuromuscular junctions from a 540 day old knockout 
mouse were compared to an age-matched control.
3.3.4 M orphometric analysis
To study neural development and maturation, glial cell quantification and myelin 
morphometry were performed on the ventral columns o f spinal cord (C2-3) and on 
mid optic nerve. Analysis at 20 days allowed glial cell development and
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myelination to be compared at the peak o f myelination but before secondary 
neurodegenerative changes had developed. By 120 days, the axonal changes and 
fibre degeneration were well established enabling the axonal changes to be 
quantified and the glial cell responses to be recorded. 60 days o f age was chosen as 
an intermediary stage when neural development was complete but degenerative 
changes had not become prominent.
3.3.4.1 Axon diameters and myelination status
Axon diameters and myelination status were calculated as described in 2.8.3 
Assessment o f  axonal size and  myelination status (page 62).
3.3.4.2 Glial cell quantification
Glial cell densities and numbers were calculated as described in 2.8.1 Quantification 
o f  corrected glial cell densities (page 61). In situ hybridisation and 
immunocytochemical markers were used to confirm these findings because o f the 
inaccuracy o f glial cell identification based on nuclear morphology and the 
inadequacies o f Abercrombie’s correction factor (Sturrock, 1983b; reviewed by 
Coggeshall, 1992; Clarke, 1992; Hedreen, 1998; Sturrock, 1983b).
3.3.5 Im munostaining
Immunohistochemistry was performed as described in 2.9 Immunohistochemistry 
(page 64). Anti-F4/80 hybridoma supernatant and anti-GFAP antisera were used to 
demonstrate microglial densities and astrocytic bulk respectively. Anti-CAII 
antiserum was used to estimate oligodendrocyte densities.
3.3.6 In situ  hybridisation
In situ hybridisation was performed as described in 2.12 In Situ Hybridisation (page 
73). 15|am cryosections were probed using digoxigenin-labelled riboprobes that
recognised transcripts from Pip and M og  genes (page 69). Oligodendrocyte 
densities were confirmed by in situ hybridisation using antisense M og  digoxigenin 
labelled riboprobes (Salvati et al., 1996; Solly et al., 1996).
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3.4 Results
3.4.1 Analysis of Pip gene activity in thePlp  gene knockout mouse
3.4.1.1 Pip gene expression
3.4.1.1.1 Semi-quantitative RT-PCR
Transcript analysis by RT-PCR of knockout and control animals are demonstrated 
in Figure 46 (page 147, Chapter 5) where these results are compared to results 
obtained from knockout animals complemented with various trans genes. 
Transcripts from the Pip gene were identified only at very low levels in knockout 
mice by RT-PCR.
3.4.1.1.2 In situ hybridisation
In situ hybridisation at 20 days of age using an anti-sense P/p-riboprobe 
demonstrated high levels of Pip gene activity predominantly in the white matter of 
wild type mice but failed to detect any transcripts in knockout mice (Figure 13, page 
83)
3.4.1.2 PLP and DM20 protein levels
3.4.1.2.1 Western blotting
Protein analysis by western blotting of knockout and control animals are 
demonstrated in Figure 47 (page 148, Chapter 5) where these results are compared 
to results obtained from knockout animals complemented with various trans genes. 
Neither PLP nor DM20 protein isoforms could be detected in knockout mice at 20 
days of age.
3.4.1.2.2 Immunostaining
No PLP/DM20 immunoreactivity could be identified in knockout mice at 20 days of 
age although the myelin of knockout mice did immunostain for other myelin 
specific proteins such as MBP (Figure 14, page 84).
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a)
b)
Figure 13 In situ hybridisation using a digoxigenin labelled antisense-P/p 
riboprobe on 15pm sections of spinal cord (C2-3) from a) wild type and b) 
knockout mice at 20 days of age. Strong hybridiation signal was detected 
predominantly throughout the white m atter regions of the spinal cord of the 
wild type mouse. In contrast, no hybridistaion signal was detected in the 
spinal cord section from the knockout mouse indicating that the Pip gene was 
transcriptionally inactive. (50x magnification)
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a)
b)
c)
Figure 14 Dorsal columns of spinal cord (C2-3) from 120 day-old wild type 
and knockout mice immunostained for (a and b) PLP/DM20 and (c) MBP 
a) Wild type mice demonstrated PLP/DM20 immunoreactivity localised to 
myelin sheaths throughout the section, b) PLP/DM20 immunoreactivity could 
not be detected in knockout mice although large volumes of myelin formed and 
imunostained for myelin markers such as MBP (c) (412x magnification)
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3.4.2 Clinical phenotype of the Pip gene knockout mouse
The knockout mice appeared to develop normally maintaining their body weights 
(Figure 15, page 86) and reaching reproductive ages without showing evidence of 
neurological dysfunction. However, aged mice developed a progressive clinical 
phenotype characterised by paresis, urinary incontinence, poor grip and weight loss. 
Most knockout mice remained clinically indistinguishable from controls until 15 to 
18 months of age. However, some mice showed signs of disease from as early as 12 
months of age while a small number did not develop a phenotype until they were 
over 20 months of age. The oldest knockout mouse recorded reached 670 days 
before being culled because of neurological dysfunction. No difference in age of 
onset or progression of signs was noted between male and female mice.
The first signs of neurological dysfunction were perineal urine staining and poor 
grip. Male mice quickly developed priapism but otherwise both sexes remained 
stable for 3 to 6 weeks. Subsequently, the mice showed rapid progression of other 
signs and deteriorated over a further 4 to 5 week period before euthanasia was 
necessary. They developed progressive paresis, muscle atrophy and weight loss. 
Although the changes were widespread, muscle wastage and paresis were most 
obvious affecting the hindlimbs. When encouraged to walk along a narrow ledge, 
affected mice developed a marked shake and generally fell off. Control animals 
were capable of walking along the ledge and showed only mild instability. Affected 
mice made no attempt to grasp the cage bars with their hindlimbs and could not 
retain their forelimb grip when gentle traction was applied. Wild type mice 
maintained strong forelimb and hindlimb grips even when the surface that they were 
holding onto was inverted. Severely affected mice made little attempt to walk 
tending to move backwards or to turn on their rumps in a tight circle when trying to 
move. Some of the more advanced cases showed evidence of faecal incontinence 
with large amounts of impacted faeces in the anus and externally caking the 
perineum. Weight loss and general debility progressed until euthanasia was 
necessary. The mice did not develop seizures or gross tremors, both common 
features of other Pip gene mutants.
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Figure 15 Grouped data from body weight measurements of male knockout 
and wild type mice taken at culling (mean body weight plotted with SEM)
Knockout mice maintained normal body weights to 360 days of age. By 540 
days of age, the knockout mice had significantly reduced body weights 
(★ equals P=0.0003 at 540 days of age). From grouped data of mice greater 
than 540 days of age (range 550 to 720 days), the body weights of wild type 
mice fell and the difference between wild type and knockout mice became less 
dramatic (P=0.0524)
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3.4.3 Pathological description of the CNS changes in thePlp gene 
knockout mouse
3.4.3.1 Gross pathology findings
The most severely affected knockout mice had little muscle bulk and no 
subcutaneous fat reserves at post mortem. The urinary bladder was distended 
suggesting that perineal urine staining resulted from defective bladder emptying 
with urinary overflow. Knockout animals culled before developing neurological 
dysfunction were grossly normal at post mortem.
3.4.3.2 Overview of histopathological findings
The knockout mice developed well myelinated central white matter tracts by 20 
days of age (Figure 16, page 89). Myelin sheaths were of an appropriate thickness 
for the size of axon, glial cell densities appeared normal and there was no evidence 
of demyelination. However, the myelin sheaths of the knockout mice were more 
irregular than in control animals and electron microscopy confirmed that they were 
poorly compacted (Figure 17, page 90).
As the animals aged, evidence of axonal pathology developed (see 3.4.3.4 Axonal 
changes and fibre degeneration, page 99). Occasional swollen axons and 
degenerate fibres were established by 60 days of age and these changes became 
progressively more prominent (Figure 18, page 91 and Figure 20, page 93). 
Initially, the lesions showed tract specificity predominantly developing in the small 
diameter (late myelinating) areas such as the optic nerve, the corticospinal tracts and 
the fasciculus gracilis (Figure 19, page 92). Changes were prominent in these areas 
at 120 days of age but steadily progressed to affect all white matter regions. 
Swollen and degenerate fibres began to appear in the ventral and lateral columns 
and swollen axons could occasionally be found in the myelinated fibres of the grey 
matter (Figure 21, page 94). The majority of swollen axons and all identified 
degenerate axons were surrounded by myelin membranes. Sheaths associated with 
larger swellings were often attenuated but could be visualised on electron 
microscopy (Figure 30, page 105). Occasional swellings were identified that had no 
associated myelin sheath but swollen axons were not identified in non-myelinated 
areas of the CNS (see 3.4.3.4.2 The lamina cribrosa, page 99).
A generalised progressive gliosis developed throughout the white matter tracts from 
120 days of age. Increased cell densities were most obvious in areas that showed 
prominent axonal changes and microglia appeared to be the predominant cell type 
(Figure 19, page 92). Although the axonal and glial cell changes became extensive
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as the animals aged, no evidence of demyelination was seen. Some aged mice 
(greater than 540 days) developed vacuolation and splitting of the myelin sheaths 
(Figure 22, page 95).
Dorsal root ganglion and retinal ganglion neurones project axons into the fasciculus 
gracilis and optic nerve respectively, the areas most severely affected by the 
knockout axonopathy. These neurones and other neurones throughout the CNS 
were examined to establish if they were affected by neurodegenerative changes. 
Although no attempt was made to quantify the neurones, no evidence of neuronal 
degeneration or death was found.
Wild type animals remained essentially normal throughout their life-span (greater 
than 2 years of age). They did develop some CNS changes characteristic of ageing, 
most notably occasional ‘dystrophic’ axonal swellings. These swellings contained 
excessive volumes of axoplasmic reticulum and were easily distinguished from the 
knockout-associated axonal changes because of their homogeneous appearance, 
ultrastructural features and low numbers.
3.4.3.3 Glial cell changes
Corrected total and differential glial cell densities and counts were calculated from 
nuclear profiles. Immunostaining and in situ hybridisation were used to confirm 
these findings.
3.4.3.3.1 Corrected total glial cell densities and numbers
Total corrected glial cell densities were calculated from sections of mid optic nerve 
and ventral columns of spinal cord (C2-3). At 20 and 60 days of age, no difference 
between knockout and control animals was seen. By 120 days of age, a significant 
gliosis (P=0.022) had developed in both areas confirming the subjective 
identification of increased glial cell numbers on light microscopy (Figure 23, page 
96). The spinal cord and optic nerve areas were equivalent between knockout and 
wild type mice at each age and the total corrected glial cell counts reflected similar 
findings.
3.4.3.3.2 Corrected differential glial cell densities
Corrected differential cell densities revealed that normal oligodendrocyte densities 
were maintained in the knockout mice at least until 120 days of age (Figure 24A, 
page 97). Microglial cells accounted for the increasing cell densities (P=0.0095 at 
120 days) (Figure 24B, page 98). The temporal and spatial association between 
increasing cell density and developing axonal pathology suggested that the two 
processes were linked.
Figure 16 Methylene blue/ azur II stained ljum resin section of mid optic nerve 
from a 20 day-old knockout mouse. The optic nerve was well myelinated with 
no gross evidence of myelin or glial abnormalities. (1300x magnification)
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Figure 17 Myelinated fibres in the optic nerve of a) knockout and b) wild type 
mice at 120 days of age. The level of myelin compaction varied greatly 
between individual fibres in the knockout mouse. However, in general, myelin 
sheaths in the knockout mouse were poorly compacted on comparison with
controls. ( 10,000x magnification)
9 0
Figure 18 Methylene blue/ azur II stained lpm  resin section from mid optic 
nerve of a 360 day-old knockout mouse demonstrated swollen axons (open 
arrows) and degenerate fibres (closed large arrows). Numerous microglia 
(closed small arrows) were identified as darkly stained nuclei with condensed 
chromatin patterns (1000 magnification)
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a)
Figure 19 Methylene blue/ azur II stained lpm  resin sections from a 640 day 
old knockout mouse: a) mid optic nerve with numerous large axonal swellings 
(arrows), b) dorsal columns of cervical spinal cord (C2-3) showing axonal 
swelling, predominantly in the fasciculus gracilis (arrows) (360x magnification)
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Figure 20 Methylene blue/ azur II stained lpm  resin sections of spinal cord 
(C2-3) showing progression of neurodegenerative changes in the fasciculus 
gracilis of knockout mice between a) 360 days of age and b) 670 days of age 
(375x magnification)
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Figure 21 Methylene blue/ azur II stained lpm  resin sections from an aged 
knockout mouse demonstrating widespread neurodegenerative changes in 
spinal cord (C2-3): a) swollen axon of a myelinated fibre (arrow) in the gray 
matter (750x magnification); b) neurodegeneration affecting the lateral 
columns (300x magnification); c) neurodegeneration affecting the ventral 
columns (300x magnification)
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Figure 22 Methylene blue/ azur II stained lpm  resin section of ventral 
columns of spinal cord (C2-3) from a 600 day-old knockout mouse showing 
vacuolation (open arrows) and splitting (closed arrows) of myelin sheaths 
(1300x magnification)
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Figure 23 Corrected total cell densities in a) mid optic nerve and b) ventral 
columns of spinal cord (C2-3) of knockout and wild type mice a t 20, 60 and 120 
days of age. A significant increase in total corrected cell densities was seen in 
the knockout mouse at 120 days of age in both areas.
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Figure 24A Corrected oligodendrocyte cell densities in a) mid optic nerve and 
b) ventral columns of spinal cord (C2-3) of knockout and wild type mice at 20, 
60 and 120 days of age. No difference in oligodendrocyte numbers was seen at 
any age between the two groups cont./
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Figure 24B Corrected microglial cell densities in a) mid optic nerve and b) 
ventral columns of spinal cord (C2-3) of knockout and wild type mice at 20, 60 
and 120 days of age. A microgliosis could be shown statistically in both areas 
in 120 day old knockout mice.
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3.4.3.3.3 Confirmation of glial cell morphometry
3.4.3.3.3.1 In situ hybridisation
Jn situ hybridisation using anti-sense Mog-riboprobes confirmed that knockout and 
wild type animals had equivalent numbers of oligodendrocytes in the cervical cord 
at 20 days of age (Figure 25, page 100).
3.4.3.3.3.2 Immunostaining
CAII immunostaining showed that oligodendrocyte numbers were maintained in 
knockout mice (Figure 26, page 101) and F4/80 immunostaining demonstrated that 
a microgliosis developed most prominently in regions containing small diameter 
fibres (Figure 27, page 102). Although astrocyte cell numbers were normal in these 
animals, a moderate increase in GFAP staining suggested a degree of astrocyte 
hypertrophy (Figure 28, page 103).
3.4.3.4 Axonal changes and fibre degeneration
3.4.3.4.1 Ultrastructural features
Swollen axons contained increased numbers of organelles and could be divided into 
two populations (Figure 29, page 104 and Figure 30, page 105). In younger 
animals, swellings contained large numbers of dense bodies and mitochondria that 
appeared to develop at the distal paranode initially. This opinion was based on 
longitudinal sections of optic nerve in which the majority of axons have their cell 
bodies in the retina and the term ‘distal’ reflects the location of the paranode relative 
to the perikaryon. In older animals, larger swellings contained predominantly 
neurofilaments located in intemodal regions. Degenerate fibres generally had 
amorphous centres surrounded by degenerating myelin sheaths. Occasionally 
remnants of axoplasmic organelles could be seen that resembled dense bodies 
(Figure 31, page 106). No active phagocytosis of myelin debris was seen on either 
light or electron microscopy.
3.4.3.4.2 The lamina cribrosa
To establish if the axonal changes were isolated to myelinated intemodes, sections 
of the optic nerve in the region of the lamina cribrosa were examined. This region 
is unusual in the CNS as it is devoid of oligodendrocytes and contains only 
unmyelinated axons. This allows in vivo examination of axons in an 
oligodendrocyte-deprived environment. As the axons pass from the retinal ganglion 
cells through this region and into the optic nerve, they acquire myelin sheaths.
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Figure 25 In situ hybridisation using digoxigenin-labelled anti-sense Mog 
riboprobes on cryostat sections (15pm) of ventral columns of spinal cord 
(C2-3) from a) wild type and b) knockout mice at 20 days of age. 
Oligodendrocyte cell densities were equivalent in knockout and wild type mice. 
(140x magnification)
b)
Figure 26 Carbonic anhydrase II immunostaining of oligodendrocyte cell 
bodies in the cerebellum of 20 day-old wild type (a) and knockout (b) mice. 
Carbonic anhydrase II positive oligodendrocyte numbers were equivalent 
between the two mice (270x magnification; haematoxylin counterstain)
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Figure 27 Dorsal columns of cervical spinal cord (a and b; 148x 
magnification) and corpus callosum and cingulate cortex (c and d; 85x 
magnification) from aged wild type (a and c) and knockout (b and d) mice 
immunostained with F4/80. Increased immunostaining was most 
prominent in the corticospinal tracts (open arrow; b) and fasciculus 
gracilis (closed arrow; b) in the spinal cord and in the corpus callosum 
(closed arrow; d) in the knockout mice. A general increase in nuclei 
indicating a microgliosis was also evident in the knockout mouse.
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a)
c)
e)
b)
d)
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Figure 28 GFAP-immunostained lpm  resin sections from wild ty pe (a, c, 
e) and knockout (b, d, f) mice at -600 days of age. A slight increase in 
staining in the fasciculus gracilis (a, b) and corticospinal tracts (c, d) in 
knockout mice is partly masked by myelin vacuolation. A moderate 
increase in immunostaining is apparent in the ventral columns of spinal 
cord (C2-3) in knockout mice (e, f) (145x magnification)
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Figure 29 Electron micrograph showing axonal lesions in the optic nerve of a 
360 day-old knockout mouse. Axonal pathology included swollen axons 
containing dense bodies (open arrow) and neurofilaments (closed arrow) and 
degenerating fibres and their remnants (arrow heads) (8000x magnification)
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a)
b)
Figure 30 Axonal swellings in knockout mice (20,000x magnification)
a) Myelinated swollen axon containing predom inantly neurofilaments and 
some mem brane bound organelles (360 days of age; ventral columns of 
thoracic cord)
b) Swollen axon containing mitochondria, dense bodies and cytoskeletal 
elements; an attenuated myelin sheath surrounds this swollen axon (160 days 
of age; mid optic nerve) 10r
TO**?;
Figure 31 Electron m icrographs of degenerate and dystrophic axons in 
knockout mice (20,000x magnification)
a) Degenerating myelinated fibre containing rem nants of m em brane bound 
organelles (160 days of age; mid optic nerve)
b) Myelinated dystrophic axon containing accumulations of smooth axoplasmic 
reticulum (540 days of age; ventral columns spinal cord)
1 0 6
lamina cribrosa myelinated region
Figure 32 Methylene blue/ azur II stained longitudinal section from the lamina 
cribrosa of a 600 day-old knockout mouse showing axonal changes in 
myelinated regions (arrow) (450x magnification)
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The majority of axonal swellings were seen in the myelinated region (Figure 32, 
page 107) although occasional swollen axons crossed the transition zone between 
the myelinated region and the unmyelinated lamina cribrosa. As these swellings 
were associated with at least the first myelinated heminode o f the axon, they 
probably arose in the myelinated region and extended into the unmyelinated axon.
3.4.3.5 Myelination and myelin structure 
3.4.3.5.1 Myelin ultrastructure and periodicity
Myelin sheaths from knockout mice were poorly compacted and had abnormal 
periodicity (Figure 33, page 109). Although the major dense line formed normally, 
the intraperiod lines were disrupted. In some areas the intraperiod lines diverged 
and separated, in others they condensed to form a single electron-dense structure. 
Occasional stretches of normal periodicity were seen interspersed between poorly 
compacted sections of myelin. The myelin sheath showed no other ultrastructural 
abnormalities. The periaxonal space, inner cytoplasmic tongue and nod o f Ranvier 
were normal. The oligodendrocyte cell body had normal ultrastructural features 
with no swelling of the rough endoplasmic reticulum or Golgi apparatus.
3.4.3.5.2 Myelination status
The percentages of myelinated and non-myelinated (ensheathed and unmyelinated) 
axons were calculated from optic nerve and ventral columns of spinal cord (C2-3) in 
20, 60 and 120 day-old mice (Figure 34, page 110 and Figure 35, page 111). The 
knockout mice had a higher percentage of non-myelinated fibres than wild type 
controls. This was statistically significant at all ages in the optic nerve (P=0.0286 at 
20 and 60 days; P=0.0159 at 120 days, n=4) and at 20 and 60 days o f age in the 
ventral columns of spinal cord (P=0.0286, n=4). However, the differences in 
percentage of non-myelinated fibres in the spinal cord were much smaller than in 
the optic nerve. At all ages, ensheathed fibres were well represented in the 
knockout optic nerve and spinal cord and accounted for approximately 20% to 30% 
of the non-myelinated fibres. Direct comparison with the proportions o f ensheathed 
and unmyelinated fibres in wild type mice was impossible because o f the low 
numbers of non-myelinated fibres in controls greater than 20 days o f age. At 20 
days of age, the proportion of non-myelinated fibres that were ensheathed appeared 
to be equivalent between the wild type and knockout mice.
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Figure 33 Electron m icrograph showing three types of myelin periodicity in 
knockout mice (120 days of age; mid optic nerve; 300,000x magnification) 
Myelin dem onstrating a) norm al periodicity interspersed with lamellae 
containing condensed intraperiod lines, b) poor compaction with separation at 
the intraperiod lines, c) condensation of the intraperiod lines
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Figure 34 Electron m icrographs of optic nerve from knockout and wild type 
mice at 60 days. A higher percentage of nonmyelinated axons (arrowheads) 
were found in knockout mice (a) when compared to wild type mice (b). 
Myelinated (m), ensheathed (ens) and unmyelinated (unm) axons were found 
in the optic nerve of knockout mice at this age (c) (16,000x magnification)
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and knockout mice at 2 0 , 60  and 120 days of age
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3.4.3.5.3 Morphometric analysis of axonal diameters
The axon diameters of all fibres, myelinated fibres and non-myelinated (ensheathed 
and unmyelinated) fibres from the mid optic nerve and ventral columns of spinal 
cord (C2-3) were compared at 20, 60 and 120 days of age.
In both areas at 20 and 60 days of age, the distributions of combined (myelinated 
and non-myelinated) axon diameters were comparable between the two groups. 
When compared to wild type mice, a significant trend towards increased mean 
axonal diameter was seen in the optic nerve of 120 day-old knockout mice 
(P=0.0286, n=4) although this was not reflected in the spinal cord at this age (Figure 
36, pages 113 and 114).
In the optic nerve at 20 days of age, the axon diameter frequency distribution for 
non-myelinated axons was similar in both groups although the knockout mice had a 
relatively greater proportion of non-myelinated fibres (Figure 37A, page 115). At 
older ages, the low numbers of non-myelinated fibres in wild type animals made 
direct comparison between the two groups difficult. In the optic nerve of 60 and 
120 day-old knockout mice, the proportion of myelinated fibres less than 0.8pm in 
diameter was lower than in wild type controls. However, the proportions of 
myelinated fibres greater than 0.8pm in diameter were comparable (Figure 37B, 
page 116).
In the spinal cord, non-myelinated axon diameter distributions showed the relative 
increase in proportion of non-myelinated fibres in the knockout mice (Figure 3 8A, 
page 117). Although the distributions of myelinated fibre diameters were not 
identical in the spinal cord of knockout and wild type mice, they were very similar 
(Figure 38B, page 118). At all ages in the knockout spinal cord, the relative number 
of myelinated fibres less than 1 pm in diameter was lower than in wild type controls 
suggesting that a similar trend of reduced numbers of small diameter myelinated 
fibres as seen in the optic nerve occurred.
In summary, knockout mice developed a full range of axon diameters by 60 days of 
age although the percentage of fibres that acquired myelin sheaths was reduced. By 
120 days of age, the mean axon diameter in the optic nerve of knockout mice was 
significantly increased compared to controls. In older knockout mice, the 
proportion of small myelinated axons (<lpm  in diameter) in both the optic nerve 
and spinal cord appeared to be reduced although larger diameter myelinated axons 
were unaffected.
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Figure 36B Axon diam eter frequency distribution (myelinated and non­
myelinated fibres) from ventral columns of spinal cord (C2-3) in a) 20, b) 60 
and c) 120 day-old knockout and wild type mice 
(n=4 at each age and genotype; bars=M +SEM)
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Figure 37B Myelinated axon diam eter frequency distribution in proportion to 
all fibres from mid optic nerve in a) 20, b) 60 and c) 120 day-old knockout and 
wild type mice (n=4 at each age and genotype; bars=M +SEM)
116
a)
i s
b)
£ s3 C 
k. <uf  oW 4-> 
Q> r -
S o
i f
VO  CL
3 .E
c)
o a
£ 53 s= 
O ' —  
2 « 
t  2a? _
S o
I I
1 1s  ?■
<  .E
0 .4 -
§  12 0.3-3 M=
f i
*T 0l. v
|  §  0.2 .
I I  
I  IO Q.
0 . 1 -
0 .0 -
r~1 wild type
knockout
di_
<0.5 <1 0 <1.5 <2.0 <2.5 <3.0 <3.5 <4.0 <4 5 <5.0 <5.5 <6 0 <6.5 <7.0 <7.5 <8 0 <8 5 <9.0 <9.5
0.4-,
0.3-
0 .2 -
0  1 -
0 .0 -
<0.5 <1.0 <1.5 <2 0 <2 5 <3.0 <3.5 <4.0 <4.5 <5.0 <5 5 <6.0 <6.5 <7 0 <7.5 <8 0 <8.5 <9 0 <9.5
03-
0 . 1 -
0 .0 -
<0.5 <10 <1.5 <2.0 <2.5 <3.0 <3.5 <4.0 <4.5 <5.0 <5.5 <6.0 <6 5 <7.0 <7.5 <8.0 <8 5 <9.0 <9.5
Axon diameter range (|^ m)
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Figure 38B Myelinated axon diam eter frequency distribution in proportion to 
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3.4.3.5.4 Comparison of fibre densities
The significant increase in mean axonal diameter in the optic nerve of knockout 
mice at 120 days of age could have represented either a generalised increase in axon 
diameter or the selective exclusion of small diameter fibres from analysis through 
neurodegeneration. In order to establish which of these two scenarios occurred, the 
densities of axons (both myelinated and non-myelinated) were calculated for both 
groups of mice from the optic nerve at each age.
The relative distributions of axon densities were comparable between wild type and 
knockout mice at 20 and 60 days of age (Figure 39a, page 120). By 120 days of 
age, although the distribution of densities of axons greater than 1pm in diameter 
were equivalent, the knockout mice had reduced densities of smaller diameter fibres 
(Figure 39A, page 120).
To demonstrate that this change represented the loss of small diameter fibres and 
not the failure of these fibres to develop, relative fibre densities were compared at 
60 and 120 days of age for each group (Figure 39B, page 121). Wild type mice 
showed a slight increase in density of larger diameter fibres over this period but 
essentially maintained similar density distributions as they aged. Although the 
knockout mice had a normal distribution of fibre densities at 60 days of age, the 
densities of fibres less than 1pm in diameter was markedly reduced by 120 days of 
age. At 120 days of age, the distribution of fibres greater than 1pm in diameter was 
similar to that at 60 days of age suggesting that small diameter fibres did develop 
but were subsequently excluded from the analyses.
The density of axons in the knockout mice was similar to wild type controls at 
younger ages but dropped as the animals aged. In order to demonstrate this, the 
total axon densities were compared at 20, 60 and 120 days of age (Figure 39C, page 
122)
Taken together, these findings show that the knockout mice developed a full range 
of axon sizes with normal densities but lost small diameter fibres as they aged. The 
loss of small diameter fibres coincided with the development of neurodegeneration 
and probably reflected the exclusion of fibres from morphometric analyses as they 
develop neurodegenerative changes.
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3.4.4 Survey o f the  PNS o f the  Pip  gene k n o ck o u t m ice
Survey histological examination of the peripheral nervous system of aged knockout 
mice (greater than 600 days) revealed no abnormalities. Resin sections from the 
proximal and distal regions of a range of peripheral and cranial nerves showed no 
evidence of myelin or axonal changes (Figure 40, page 124). Cryosections of a 
range of skeletal muscles and neuromuscular junctions showed no evidence of 
changes consistent with neurogenic atrophy or of neuromyopathy.
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Figure 40 Methylene blue/ azur II stained 1 jlxiti resin section of sciatic nerve 
from a 360-day-old knockout mouse showing no evidence of axonal 
degeneration or demyelination (566x magnification)
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3.5 Discussion
Data presented in this chapter demonstrated that the targeting strategy used to create 
the Plptmknl allele prevented Pip gene expression in hemizygous mice. These mice 
were capable of elaborating large volumes of myelin and maintaining mature 
oligodendrocyte numbers into adulthood. Unlike other Pip gene mutants, knockout 
mice remained comparatively normal until they became aged when progressive 
neurological deficits led to severe debility. From early adulthood (60 days), 
progressive neurodegenerative changes developed characterised by axonal swelling 
and fibre degeneration. Coincident with this, a microgliosis developed. Unlike 
human cases of PMD resulting from PLP gene-null alleles, knockout mice had no 
PNS changes.
The maintenance of mature oligodendrocytes in knockout mice showed that Pip 
gene products are not necessary for the maturation or survival of these cells. It 
seems unlikely, therefore, that the increased apoptosis and reduced numbers of 
mature oligodendrocytes seen in the majority of spontaneous Pip gene mutants 
result from the paucity of Pip gene products. This study adds weight to the theory 
that mutated Pip gene products lead to oligodendrocyte death through the 
acquisition of properties that disrupt oligodendrocyte function. In this scenario, 
maintenance of oligodendrocyte numbers in the rumpshaker mouse and paralytic 
tremor rabbit (Gow and Lazzarini, 1996) would reflect the inability of the abnormal 
Pip gene products to disrupt cellular function, not a beneficial effect of continued 
targeting of DM20 protein to the cell surface. The elaboration of large volumes of 
myelin and absence of demyelination in the knockout mouse demonstrated that PLP 
and DM20 proteins are not necessary for the formation or maintenance of central 
myelin. This contrasts with severe dysmyelination seen in spontaneous Pip gene 
mutants. Dysmyelination in these mutants may result because insufficient 
oligodendrocytes survive to maturity to form myelin sheaths. An alternative 
explanation, supported by in vivo and in vitro studies, is that disrupted PLP/DM20 
protein trafficking observed in many of these mutants prevents the elaboration of 
myelin membranes.
Despite the large volumes of myelin that form in knockout mice, evidence of subtle 
oligodendrocyte dysfunction does exist. The disrupted periodicity of knockout 
myelin suggests that PLP and DM20 proteins influence the myelin ultrastructure 
particularly of the intraperiod line. Abnormalities of the intraperiod lines are 
reported in most spontaneous Pip gene mutants and in the Pip gene-null mice 
described by Boison & Stoffel (1994). The knockout mice described in this thesis 
had occasional stretches of myelin with normal periodicity interspersed between
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abnormal lamellae. More commonly, the intraperiod lines condensed to a single 
electron dense structure or separated completely. Pip gene products, although not 
essential for the formation of myelin, may stabilise the intraperiod line by acting as 
struts maintaining both adhesion and spacing between the extracellular leaflets of 
myelin lamellae. This is supported by transfection and lipid-vesicle studies 
demonstrating that Pip gene products have adhesive properties between the 
extracellular surfaces of lipid bilayers (Sinoway et al., 1994; Palaniyar et al., 1998). 
However, the ultrastructural abnormalities of myelin in knockout mice may 
represent post mortem change induced by tissue processing. Striking differences 
between the periodicity of fresh and fixed myelin demonstrate the potential for 
processing to alter myelin ultrastructure (Kirschner and Hollingshead, 1980). 
Karthigasan et al. (1996) have demonstrated that rumpshaker myelin develops more 
post mortem decompaction than wild type myelin. Although this finding suggests 
that rumpshaker myelin is unstable, it highlights the difficulty in interpreting 
ultrastructural changes of myelin in mutants.
The failure of a proportion of fibres to myelinate in the knockout mouse provides 
further evidence of oligodendrocyte dysfunction. Although a wide range of axons 
sizes remained non-myelinated, the predominance of these changes in the optic 
nerve compared to the ventral columns of spinal cord suggested that small diameter 
fibres were preferentially affected. This was supported by the trend in knockout 
mice towards relatively fewer small-diameter myelinated axons (<0.8pm) despite 
normal numbers of larger myelinated axons in the same areas. As these trends 
developed before axonal swellings and degeneration became prominent, it is 
unlikely that they resulted from selective degeneration of small diameter myelinated 
axons. On the contrary, the data support selective dysmyelination of some small 
diameter axons and suggest that this process is not linked to axonal swellings, which 
are confined to myelinated fibres. These results support a role for the Pip gene in 
the early stages of myelination, perhaps in initial axoglial contact. However, the 
disruption of normal myelination in knockout mice cannot be linked to a particular 
stage of axo-oligodendroglial interaction as both ensheathed and unmyelinated 
axons were well represented. Although the Pip gene products cannot be localised to 
the cell surface before the start of myelin compaction (Schwob et al., 1985), one 
study suggests that a secreted Pip gene product can influence glial development 
(Yamada et al., 1999). This putative peptide appears to have biological activity at 
very low concentrations and may be a candidate for influencing axoglial interaction 
before upregulation of the Pip gene (Yamada et al., 1999).
The development of progressive neurological dysfunction in aged knockout mice 
correlated with increasing axonal swellings and degeneration. Axonal changes have
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been implicated in some cases of chronic progressive relapsing multiple sclerosis 
where reasonable neurological function appears to be maintained until a threshold of 
axonal pathology is reached (Trapp et al., 1998). Knockout mice presumably have a 
similar clinical course, remaining normal throughout most of their life but 
developing neurological dysfunction when axonal changes reach a threshold limit. 
Axonal swellings also develop in some induced and spontaneous Pip gene mutants 
including the double mutant shiverer-Plp gene knockout mouse (Dentinger et al., 
1982; Rosenfeld and Friedrich, Jr., 1983; Taraszewska, 1988; Fanarraga et al., 
1992; Duncan et al., 1995; Griffiths et al., 1998; Anderson et al., 1998). No 
swellings developed in shiverer controls suggesting that the absence of the Pip gene 
products, not abnormal oligodendrocytes per se, led to the development of axonal 
swellings (Griffiths et al., 1998). The development of axonal changes in a range of 
deletion, duplication and missense mutations of the Pip gene suggests that a 
common pathogenesis may exist.
The development of axonal changes may arise through either primary neuronal or 
primary oligodendroglial abnormalities related to the loss of Pip gene function. 
Localisation of srPlp and srDm20 transcripts to some neuronal populations within 
the adult murine CNS provides the first evidence that the Pip gene may have a role 
in normal neuronal function (Bongarzone et al., 1999). The possibility that this 
putative role is disrupted resulting in the knockout axonopathy must be considered, 
however, the data in this thesis does not favour this. Axonal swellings were 
confined to myelinated regions of the CNS suggesting that their development was 
dependent on the presence of PLP/DM20-deficient oligodendrocytes. In addition, 
no evidence of neuronal pathology was found in the neurones of the dorsal root 
ganglia or the retinal ganglion cell layer, both regions that project axons into the 
most severely affected white matter tracts. Although this does not prove that a 
neuronal defect did not cause the knockout axonopathy, it does suggest a more focal 
axonal problem. The axonal changes in knockout mice eventually affected all white 
matter regions suggesting that the cellular abnormality leading to these changes was 
widespread. However, Bongarazone et al. (1999) reported that srPlp and srDm20 
transcripts were isolated to populations of neurones in the cerebellum, hippocampus 
and olfactory system predicting a more focal effect. The data presented in this 
thesis supports a primary oligodendrocyte deficit leading to secondary axonal 
dysfunction although a primary neuronal defect cannot be categorically excluded. 
In particular, if srPlp and srDm20 transcripts are identified in wider populations of 
neurones in the murine CNS, their role in the development of the knockout 
axonopathy will have to be re-evaluated.
A primary oligodendrocyte defect could lead to the development of axonal changes
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if PLP/DM2O-deflcient oligodendrocytes acquire toxic properties that prove 
deleterious to the axon. Alternatively, myelinated axons may become dependent on 
normal PLP/DM20-expressing oligodendrocytes raising the possibility that the Pip 
gene is involved in signal transduction pathways between the mature 
oligodendrocyte and axon. However, to date, no molecules that interact directly 
with the PLP or DM20 proteins have been found.
In both the PNS and CNS, the local glial environment can have a profound effect on 
neuronal structure and function. Studies in the trembler mouse demonstrated that 
Schwann cells can modulate axonal neurofilament phosphorylation and slow axonal 
transport mechanisms, possibly through a signalling pathway (De Waegh and 
Brady, 1991; De Waegh et a l, 1992). In the CNS, a similar role for the 
oligodendrocyte in modulating radial axonal growth in a myelin-independent 
manner has been proposed (Sanchez et a l, 1996). Axon ensheathment by the 
oligodendrocyte process was sufficient to induce local neurofilament accumulation 
and radial axonal growth possibly through a phosphatase or kinase mediated 
pathway (Starr et a l, 1996; Sanchez et a l, 1996). The accumulation of 
neurofilaments in swollen axons in knockout mice suggests that a similar 
mechanism could be disrupted. However, the diameters of unaffected axons in the 
knockout mouse showed nonnal radial axonal growth to 60 days of age and, 
subjectively, neurofilament densities were normal. In addition, staining for a range 
of phosphorylated and non-phosphorylated neurofilament epitopes revealed no 
abnormalities in knockout axons although occasionally Purkinje cell neurones 
stained for phosphorylated neurofilaments (Klugmann et a l, 1997). Together, these 
results point towards normal neurofilament structure in the knockout axon and 
suggest that local phosphatase and kinase systems are not primarily involved in the 
axonopathy. In the optic nerves of older knockout mice (120 days of age), the trend 
towards increased mean axonal diameter might indicate a generalised axonal 
change. However, selective exclusion of small diameter myelinated fibres affected 
by neurodegeneration, which predominates in this area, could also account for this 
finding. Similar trends were not identified in optic nerves at 60 days of age, when 
neurodegenerative changes are mild, nor in ventral columns of spinal cord at 120 
days of age, before neurodegeneration could be readily identified in this area. These 
data support normal radial axonal growth in the knockout mouse with skewing of 
data through the loss of small diameter axons leading to the changes seen in the 
optic nerves in older animals.
In transgenic models of motor neurone disease, the accumulation of neurofilament 
subunits led to reduced slow axonal transport, axonal swelling and degeneration and 
neuronal death (Cote et a l, 1993; Xu et a l, 1993a; Xu et a l, 1993b; Collard et a l,
128
1995). Some evidence of disrupted fast axonal transport in these mice (Collard et 
al., 1995) and in motor neurone disease cases (Toyoshima et al., 1998) supports 
mounting evidence that neurofilaments and microtubules form highly 
interdependent structures (Julien, 1997; Zhu et al., 1998). Although these studies 
show the potential for disrupted slow axonal transport to induce axonal changes and 
secondary fast axonal transport blocks, the balance of data from the knockout mouse 
suggests a more general disruption of axonal transport. Swellings had changes that 
were characteristic of both slow (neurofilament) and retrograde-fast (dense body) 
axonal transport blocks although individual swellings rarely showed accumulation 
of both neurofllaments and dense bodies. Subjectively, membrane bound organelles 
accumulated first followed by neurofilaments. These findings suggest that both 
slow and fast-retrograde axonal transport are equally disrupted, the temporal 
differences in axonal changes reflecting different transport speeds of organelles. 
The putative early disruption of these two mechanisms is difficult to reconcile with 
a single transport defect. It seems more likely that these changes represent 
secondary responses to an unidentified change in the axoplasmic environment that is 
related to the loss of Pip gene function.
Axonal swellings in transgenic models of neurofilament-related disease developed 
in proximal regions of large diameter axons (Xu et al., 1993a; Xu et al., 1993b). 
These axons have the highest rate of neurofilament metabolism and are clear 
candidates for developing early changes in neurofilament-related disease (Cote et 
al., 1993; Julien, 1997). In contrast, the knockout axonopathy initially affected 
small diameter fibre tracts suggesting that the axonal changes were not primarily 
related to abnormalities of neurofilament metabolism. The spatial and temporal 
association between swollen and degenerate axons in the knockout mouse suggests 
that these two processes were linked and appeared to be uniformly distributed 
throughout the corticospinal tracts and optic nerve, both areas that project axons in a 
single direction (unquantified data). The development of focal swellings at any 
point along the length of an axon is more indicative of a focal transport block and 
suggests that focal axonal function is affected. This provides further support for the 
knockout axonopathy developing in response to the influence of PLP/DM20- 
deficient oligodendrocytes rather than a primary neuronal abnormality. To test the 
hypothesis that the axonal swellings in knockout mice resulted from axonal 
constriction, axon diameters were assessed. The normal to increased range of inter- 
nodal axon diameters in knockout mice suggests that constriction of inter-nodal 
axons did not lead to disruptions of axonal transport or swelling. Microgliosis and 
astrocyte hypertrophy are commonly associated with axonal degeneration in the 
CNS (Stoll and Jander, 1999; reviewed by Aldskogius and Kozlova, 1998) and the 
lack of active demyelination in the knockout mouse suggests that myelin breakdown
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and glial responses occur secondary to axonal degeneration.
This study highlights the tract specificity of neurodegenerative changes in knockout 
mice for small fibre regions and shows that dysmyelination also affects 
predominantly small diameter axons. Similar tract specificity has been noted in 
other Pip transgenic mice (Anderson et al., 1998). These findings may reflect 
different responses of subpopulations of axons to oligodendrocyte dysfunction or 
perturbed function of neuronal subpopulations that express rare Pip gene splice 
variants. Alternatively, they may reflect disrupted Pip gene function in 
subpopulations of oligodendrocytes. Although there are no clear molecular 
divisions of mature oligodendrocytes, some evidence for functional subpopulations 
does exist. For example, oligodendrocytes can be separated into those myelinating 
large numbers of small axons and those myelinating small numbers of large axons 
(Hildebrand et al., 1993). However, as large diameter axons myelinate in advance 
of small diameter axons, this may reflect the different temporal recruitment of 
oligodendrocytes from the same population of premyelinating cells. In fact, the 
ability of oligodendrocytes from small axon regions to myelinate large diameter 
axons suggests that functional divisions of premyelinating oligodendrocytes do not 
exist (Fanarraga et al., 1998). Other divisions are made based on 
immunocytochemical markers, for example carbonic anhydrase II (Butt et al., 
1995), but, again, this may reflect differences in recruitment from a single 
oligodendrocyte population. It is not within the scope of this study to resolve these 
issues. However, axons in knockout mice appear to develop normally at least until 
20 days of age, as evidenced by normal radial axonal growth. This occurs in the 
face of oligodendrocyte dysfunction favouring an oligodendrocyte-mediated basis 
for tract specificity.
At least three PLP gene-null mutations have been reported in families suffering 
from PMD with comparatively mild phenotypes (Raskind et al., 1991; Sistermans et 
al., 1996; Garbern et al., 1997). The family described by Garbem et al. (1997) has a 
point mutation in the translation initiation codon of exon 1 preventing translation of 
PLP and DM20 proteins. Although PLP and DM20 proteins are absent from the 
CNS, the presence of other myelin proteins such as MBP indicates that large 
volumes of myelin form. Ante mortem and post mortem examination suggests that 
these patients myelinate well but subsequently lose myelin. In addition, a segmental 
demyelinating peripheral neuropathy also develops (Garbern et al., 1997). 
Although there are similarities between this family and the knockout mouse, the 
phenotypes do differ with humans developing early onset neurological dysfunction 
and peripheral neuropathies (Garbern et al., 1997). These contrasting findings are 
difficult to correlate with similar protein deficits. Early onset neurological
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dysfunction may reflect a reduced ability of human cases to compensate for early 
neurodegenerative changes because of their higher requirements for normal 
function. Alternatively, such discrepancies may be a function of the absolute 
greater age of human myelin sheaths; if Plp/PLP gene products are required for 
long-term myelin stability, knockout mice may not survive long enough to show 
evidence of myelin breakdown. A third alternative is that humans and mice 
compensate differently for the loss of PLP/ DM20 proteins.
The lack of PNS pathology in the knockout mouse suggests that the clinical features 
related to loss of upper motor neurones causing paresis and disuse muscle atrophy. 
The discordance of PNS changes between the two species is hard to correlate with 
the existing data on Pip gene expression in the PNS. Garbern et al. (1997) are the 
first workers to demonstrate Pip gene products in peripheral myelin lamellae of 
healthy mammals. The balance of data from other studies suggests that, if present, 
the Pip gene products constitute only a small proportion of the total peripheral 
myelin proteins and are unlikely to be important structural components (Griffiths et 
al., 1995). The lack of PNS changes in knockout mice does not support a role for 
the Pip gene in peripheral myelin assembly or maintenance. However, the 
peripheral neuropathy reported by Garbern et al. (1997), which may also affect 
another PLP gene-null PMD family, shared many features with HNPP, a peripheral 
neuropathy that is exacerbated by nerve compression. The failure to develop PNS 
changes in knockout mice may reflect the differences in body size and compression 
stresses on peripheral nerves between mice and humans.
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4. p i p t m k n 1  heterozygous mice
4.1 Background
Although female members of PMD families rarely develop phenotypes, clinical 
abnormalities are occasionally reported (Hodes et ah, 1995; Nance et al., 1996; 
Sivakumar et al., 1999). A proportion of oligodendrocytes in these individuals is 
predicted to express the mutated allele through the process of X-inactivation as 
evidenced by mosaic patterns of dysmyelination in heterozygous carriers of the 
PlpiP, Plpjp~rsh, Plpmd and Plpsh alleles (Rosenfeld and Friedrich, Jr., 1984; Duncan 
et ah, 1987b; Fanarraga et ah, 1991; Hodes et ah, 1995; Nezu et ah, 1996). 
However, experimental data from jimpy heterozygotes demonstrates that the 
majority of oligodendrocytes in the mature CNS express the wild type allele 
(Bartlett and Skoff, 1986). Pockets of dysmyelination exist throughout the 
immature CNS of these mice, particularly affecting the optic nerve (Skoff and 
Montgomery, 1981; Skoff and Ghandour, 1995) but, as the animals age, 
hypomyelination in the spinal cord and brain largely resolves leaving a 
predominantly well myelinated CNS (Bartlett and Skoff, 1986). These results 
indicate that oligodendrocytes expressing mutant alleles are less likely to elaborate 
myelin sheaths than their wild type counterparts and suggest that the expression of 
the mutated Pip alleles confers negative properties to oligodendrocytes (Kagawa et 
ah, 1994b; Skoff and Ghandour, 1995). In addition, the studies from the jimpy 
heterozygote (Skoff and Ghandour, 1995), mirrored in studies from other mutants 
(Fanarraga et ah, 1991; Cuddon et ah, 1998), demonstrate that the CNS 
compensates for the reduced number of functional oligodendrocytes possibly 
explaining why clinical phenotypes are rare. The effects of modifying loci or 
skewing of X-inactivation, which occurs in a minority of normal cases, may account 
for the extremes of phenotypes that are seen occasionally in female members of 
PMD families. Marked variability in neuropathological changes in animals 
heterozygous for Pip gene mutations has been reported even within individuals and 
may also reflect the random nature of X-inactivation (Duncan et ah, 1987b).
4.2 Aims
The heterozygous knockout mouse (Plp/PlptmknJ) offers a unique opportunity to 
compare the survival and function of PLP/DM2O-deficient oligodendrocytes and 
normal oligodendrocytes side-by-side in vivo. In order to establish if isolated
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expression of the Plptmknl allele could induce neurodegeneration in animals also 
expressing the wild type Pip allele, a histological and morphometric analysis of 
heterozygous knockout mice was undertaken. Immunohistochemistry was used to 
examine the contribution PLP/DM20-negative oligodendrocytes made to 
myelination.
4.3 Materials and Methods
4.3.1 Anim al breeding
Animals were bred as described in 2.2 Mouse Breeding (page 39) and genotypes 
were confirmed by PCR (see 2.4 PCR Genotyping, page 53). During the study, 88 
female mice were confirmed to be heterozygous for the Plptm knl allele.
4.3.2 Histopathology
A histological survey of CNS tissue was performed on 1pm resin sections of spinal 
cord and optic nerve stained with methylene blue/ azur II (see 2.6.2 Resin 
processing and sectioning, page 59). Tissues were collected from 20, 60, 120, 240, 
360 and 540 day-old heterozygous knockout mice and from occasional mice 
surviving past 540 days of age (n=39; 8 animals were 540 days of age or more).
4.3.3 Im m unostaining
Immunohistochemistry was performed on 1pm resin sections from spinal cord 
(cervical, thoracic and lumbar) and optic nerve as described in 2.9 
Immunohistochemistry (page 64). Tissue from at least three animals at 10, 20, 120, 
240 and 360 days of age and from 6 animals over 540 days of age was examined.
4.3.4 Quantification o f axonal changes
Axonal swelling and degeneration in mid optic nerve were assessed by point count 
analysis as described in 2.8.2 Quantification o f  swollen axons and degenerate fibres  
(page 62). Hemizygous knockout mice (n=4), heterozygous knockout mice (n=3) 
and wild type mice (n=3) were compared at 120 days of age.
4.4 Results
4.4.1 Clinical phenotype
Heterozygous knockout mice were indistinguishable from wild type controls until at 
least 360 days of age. In a proportion of older animals, neurological signs that 
mirrored those seen in older hemizygous knockout mice developed. Changes 
included perineal urine staining, poor grip, muscle wastage and paresis that 
progressed until euthanasia was necessary. The age of onset of the clinical
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phenotype was variable even between littermates. Some mice survived to 720 days 
of age without developing overt signs of neurological dysfunction while others 
developed signs before 540 days of age.
4.4.2 Histopathology
From 120 days of age, heterozygous knockout mice developed the characteristic 
neurodegenerative changes seen in PLP/DM20-deficient animals. The changes 
included axonal swellings, degeneration and microgliosis. These initially affected 
small diameter fibre tracts but progressed to involve all white matter regions as the 
mice aged. Most older heterozygous knockout mice had moderate 
neurodegenerative changes, however, extremes of neurodegeneration were seen 
occasionally. Some animals had minimal changes at 540 days of age that correlated 
with normal phenotypes; others developed much more extensive neurodegeneration 
with early clinical phenotypes (Figure 41, page 136).
4.4.3 Myelin ultrastructure
Poorly compacted myelin sheaths were interspersed between normally compacted 
sheaths in heterozygous knockout mice (Figure 42, page 137). The distribution of 
the two populations of myelin sheath appeared to be uniform each being represented 
throughout the CNS and ensheathing a full range of axon diameters (unquantified 
data).
4.4.4 Mosaicism of Pip gene expression in oligodendrocytes
The myelin sheaths in the CNS of heterozygous knockout mice showed 
heterogeneity of PLP/DM20 protein expression with the presence of both 
PLP/DM20-positive and negative sheaths. Some areas appeared to have an evenly 
distributed mix of PLP/DM20-positive and negative sheaths giving a mosaic pattern 
of expression (Figure 43, page 138). Other areas had large patches that contained 
either predominantly PLP/DM20-positive or PLP/DM20-negative sheaths (Figure 
43, page 138). The presence of PLP/DM20-deficient myelin was demonstrated by 
MBP immunoreactivity showing that the lack of PLP/DM20 staining did not 
indicate a lack of myelin (Figure 44, page 139). Quantification of myelin sheaths 
suggested that, on average, approximately 67% of sheaths were PLP/DM20-positive 
(I.R. Griffiths, personal communication), however, variability was seen both within 
and between individuals. At one extreme, some mice appeared to have 
predominantly PLP/DM20-positive myelin sheaths and this staining pattern was 
associated with minimal neurodegenerative changes in older animals (Figure 41, 
page 136).
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4.4.5 Q uan tifica tion  o f axonal changes in heterozygous k n o ck o u t 
m ice
Heterozygous knockout mice developed axonal pathology that was intermediate in 
degree between that found in hemizygous knockout mice and wild type controls 
(Figure 45, page 140). Heterozygous knockout mice developed approximately 38% 
of the volume of swollen axons than hemizygous knockout mice but a 
disproportionately lower volume of degenerate fibres (approximately 15%).
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Figure 42 Electron m icrograph of optic nerve from a 120 day-old 
heterozygous knockout mouse (20,000xmagnification)
Both well and poorly compacted myelin sheaths can be seen surrounding axons 
in this section.
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& CD '
Figure 43 Resin section of dorsal and lateral columns from mid thoracic cord 
of a 360 day-old heterozygous knockout mouse immunostained with the PLP 
C-term inal antibody (PAP method)
a) The distribution of PLP/DM20-positive myelin sheaths is variable in this 
section with both patchy and evenly distributed patterns of immunoreactivity 
(lOOx magnification): (b) some areas have evenly distributed positive and 
negative myelin sheaths; (c) some areas have patches of either positive or 
negative myelin sheaths (200x magnification)
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b)
Figure 44 Ventral column of cervical spinal cord (C2-3) from a 20 day-old 
knockout heterozygous mouse immunostained showing a) PLP/DM20 and b) 
MBP immunoreactivity (200x magnification)
a) Patchy distribution of PLP/DM20-positive myelin sheaths reflected the 
variegated expression of the Plptmknl allele in oligodendrocytes due to random  
X-inactivation
b) MBP-immunostained serial section demonstrates that PLP/DM20-deficient 
areas were not devoid of myelin
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Figure 45 Swollen axon and degenerate fibre volumes assessed by point count 
analysis of mid optic nerves from 120 day-old wild type, heterozygous 
knockout and knockout mice. Heterozygous knockout mice showed reduced 
swollen axon and degenerate fibre volumes when compared to knockout mice. 
The reduction in degenerate fibre volume was disproportionately large.
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4.5 Discussion
Data presented in this chapter demonstrated that mice heterozygous for the Plptmknl 
allele developed an intermediate level of neurodegeneration when compared to 
hemizygous and wild type mice. Heterozygous knockout mice had mosaic patterns 
of Pip gene expression that could be diffuse or patchy and were maintained into 
adulthood. On average, approximately 67% of myelinated fibres had PLP/DM20- 
positive myelin sheaths (IR. Griffiths, personal communication) but extremes of Pip 
gene expression were also seen. The variable level of neurodegeneration and 
clinical phenotypes appeared to correlate broadly with the level of Pip gene 
expression.
The development of axonal swellings in heterozygous knockout mice provides 
further evidence that interaction with PLP/DM20-deficient oligodendrocytes may 
disrupt axonal function locally. Adjacent oligodendrocyte processes expressing 
wild type phenotypes (PLP/DM20-positive) cannot rescue the putative effects of 
PLP/DM20-deficient oligodendrocytes on axonal function. This suggests that 
PLP/DM20-deficient oligodendrocyte have either a toxic effect on axonal function 
or directly influence axonal function locally. However, comparative localisation of 
axonal changes with PLP/DM20-deficient oligodendrocyte processes has not been 
performed in this study and the possibility that these changes result from a primary 
neuronal defect cannot be excluded.
Heterozygous knockout mice developed a degree of axonal swelling that correlated 
with the proportion of PLP/DM20-deflcient myelin sheaths when compared to 
hemizygous knockout mice (approximately 38%). Indirectly, this suggests that a 
relationship exists between the percentage of PLP/DM20-deficient oligodendrocyte 
processes and the severity of axonal swelling. However, the level of axonal 
degeneration did not follow a similar trend and was less than half the estimated level 
when compared with hemizygous knockout mice (approximately 15% instead of a 
predicted 33%). This may indicate that axonal degeneration depends on the 
cumulative effects of axonal compromise caused by axonal swellings along the 
length of each axon. In heterozygous knockout mice, the reduced volume of 
swollen axons may reduce the level of axonal compromise below the threshold for 
degeneration in the majority of axons. This may explain why some large swollen 
axons in the aged knockout mouse survive while other axons degenerate.
Although the majority of heterozygous knockout mice had approximately 67% 
PLP/DM20-positive myelin sheaths, variability was seen both between and within 
individual animals. The variability in neurodegenerative change and clinical
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phenotype appeared to correlate loosely with the level of Pip gene expression. In 
particular, two aged mice (540 and 720 days of age), that had no clinical phenotype 
and only mild neurodegeneration, had a very low proportion of PLP/DM20- 
deficient myelin sheaths. The most likely explanation for these extremes of Pip 
gene expression is skewing of X-inactivation that occurs normally in a minority of 
cases (Belmont, 1996). The reciprocal effect of skewing towards expression of 
mutated PLP alleles in female carriers of PMD may explain the reports of female 
cases of PMD. Similar correlation of myelin mosaicism and phenotypic severity 
has been reported in heterozygous females from shaking pup  colonies that show 
moderate, resolving clinical signs (Cuddon et al., 1998).
The majority of animals heterozygous for Pip gene mutations do not develop 
clinical disease and show resolving areas of dysmyelination. This probably occurs 
because oligodendrocytes expressing the mutated allele die or remain inactive and 
are compensated for by neighbouring oligodendrocytes expressing the wild type 
allele (Skoff and Ghandour, 1995). Expression of the Plptmknl allele does not affect 
oligodendrocyte maturation or survival but does seem to affect axonal function and 
moderately reduce the ability of mutant oligodendrocytes to elaborate myelin 
sheaths. In heterozygous knockout mice, oligodendrocytes expressing the Plptmknl 
allele are predicted to survive to compete with oligodendrocytes expressing the wild 
type Pip allele. It may be that the survival of a large percentage of oligodendrocytes 
with mutant phenotypes enables significant neurodegeneration with clinical disease 
to develop in these mice, a scenario that does not occur in most spontaneous Pip 
gene mutant heterozygotes. A similar mechanism has been proposed to explain 
clinical disease in female members of a family with a mild form of PMD 
(Sivakumar et al., 1999).
The distribution of PLP/DM20-negative oligodendrocyte processes in heterozygous 
knockout mice could be diffuse or patchy and varied both within and between 
individuals. Patchy areas devoid of Pip gene expression may reflect clonal 
expansion of oligodendrocyte progenitors that express the Plptmknl allele through 
clonal inheritance of X-inactivation patterns in heterozygous knockout mice 
(Duncan et al., 1993; reviewed by Willard, 1995). The patchy pattern mimics areas 
of dysmyelination seen in heterozygous carriers of spontaneous Pip gene mutations 
where similar distributions of two populations of oligodendrocytes may exist but are 
more difficult to detect.
142
5. Transgenic complementation of 
the P i p  gene knockout mouse
5.1 Background
Different spatio-temporal expression patterns of PLP and DM20 proteins have led to 
suggestions that these two isoforms may have different roles in neural development 
and maintenance (as reviewed in the introduction to this thesis, page 18). The PLP 
protein has been implicated as an important structural component of compact 
myelin and the DM20 protein has been implicated in oligodendrocyte development 
because of its early expression in the embryonic CNS. Some in vitro studies 
suggest that the DM20 protein, which is more lipophilic than PLP (Horvath et al., 
1990), may facilitate cellular trafficking of the PLP protein to the cell surface and its 
subsequent incorporation into myelin presumably through heteromeric interaction 
(Sinoway et a l, 1994; Gow and Lazzarini, 1996; Tosic et al., 1997). These studies 
show that both isoforms must be expressed in transfected cells before the PLP 
protein will reach the cell surface. However, other in vitro work contradicts these 
studies showing that PLP protein can reach the cell surface in the absence of DM20 
protein (Gow et al., 1994a; Thomson et al., 1997). Clarification of how in vitro 
studies correlate with in vivo interactions between these two proteins has been 
hampered by the inability to directly identify the DM20 protein because it has no 
unique epitope that is not also present on the PLP protein. As such, although DM20 
protein can be localised biochemically to the myelin sheath, it cannot be directly 
demonstrated in this compartment in situ nor can its cellular localisation to other 
compartments be confirmed. Pip gene products do not have cleaved targeting 
sequences (Milner et al., 1985); however, the amino-terminal has been implicated in 
targeting these proteins to the cell surface (Colman et al., 1982).
Although transgenic strategies have been developed to study some of these issues, 
they have been hampered by the inability to study expression of individual 
components of the Pip gene products in the absence of endogenous proteins in vivo. 
The knockout mouse provides a valuable tool for studying the roles of the Pip gene 
isoforms in isolation.
5.2 Aims
This study describes transgenic complementation of the knockout mouse. In order
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to confirm that the phenotypic changes described in the knockout mice were 
attributable directly to the loss of Pip gene function, knockout mice were 
complemented with genomic Pip transgenes. Histopathology and morphometric 
analyses were used to determine if transgenic expression of the Pip gene products 
prevented the neurodegenerative and myelin changes in the knockout mice. To 
examine the different behaviour of individual isoforms, knockout mice were 
complemented with Plp-cDNA and Dm20-cDNA transgenes. To examine the 
ability of the PLP-LacZ fusion protein to incorporate into the myelin sheath in the 
absence of endogenous Pip gene products, knockout mice were complemented with 
Plp-LacZ fusion trans gene (Wight et al., 1993).
5.3 Materials and Methods
5.3.1 Animal breeding and identification
Animals were bred as described in 2.2 Mouse Breeding (page 39). 
Complementation of the knockout mouse with genomic Pip transgenes was 
achieved by crossing with the #66 and #72 lines of mice (Readhead et al., 1994). 
Complementation of the knockout mouse individually with the PLP and DM20 
protein isoforms was achieved by crossing with the PlpTgl and Dm20Tgl 
transgenic lines (Nadon et al., 1994) and with the ND3A transgenic line 
(Mastronardi et al., 1996). The genotypes of these transgenic crosses were 
confirmed by PCR (see 2.4 PCR Genotyping, page 53). The Plp-LacZ transgenic 
mice were maintained as homozygous stock and crossed with homozygous female 
knockout mice producing male offspring that were hemizygous for both the Plp- 
LacZ transgene and the Plptmknl allele.
5.3.2 Molecular characterisation of the transgenic complementation 
models
Pip gene expression in the various mice was compared by semi-quantitative RT- 
PCR and western analysis at 20 days of age.
5.3.2.1 Tissue collection
Total cellular RNA was extracted from whole brain homogenates as described in
2.3.3 Extraction o f RNA from mouse tissue (page 47). Protein was extracted from 
whole brain homogenates and from the myelin fraction of brain as described in
2.13.1 Extraction o f Protein from Tissue (page 75)
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5.3.2.2 Semi-quantitative RT-PCR
To compare transcript levels of the endogenous Pip gene and transgenes, semi- 
quantitative RT-PCR was performed as described in 2.11 Semi-quantitative RT-PCR 
(page 71).
5.3.2.3 Western analysis
To compare translation of endogenous Pip gene and trans gene transcripts, western 
analysis o f protein samples using the anti-PLP C-terminal antibody was performed 
as described in 2.13 Western Blotting  (page 75).
5.3.3 Histopathology
A histological survey was performed on 1pm resin sections, stained with methylene 
blue/ azur II, from a range of CNS tissues including spinal cord and optic nerve (see
2.6.2 Resin processing and sectioning, page 59). Knockout mice complemented 
with the #66, #72, P lpTgl and D m 20Tg2 transgenes were compared to knockout 
and wild type controls at 120 days of age. Knockout mice up to 540 days of age 
complemented with the #72 transgene and up to 240 days of age complemented 
with the #66 transgene were also examined to establish if transgenic rescue of the 
knockout phenotype was maintained.
5.3.4 Axonal swelling and degeneration quantification
Point counts were performed on electron micrographs from mid optic nerves as 
described in 2.8.2 Quantification o f  swollen axons and  degenerate fibres (page 62). 
Data from three #72 transgene-complememented knockout mice were compared 
with data from 4.4.5 Quantification o f  axonal changes in heterozygous knockout 
mice (page 135).
5.3.5 Glial cell quantification
Glial cell quantification was performed on ventral columns of spinal cord (C2-3) 
and mid optic nerve as described in 2.8.1 Quantification o f  corrected glial cell 
densities (page 61). Data from three #72 transgene-complememented knockout 
mice were compared with data from 5.43.3.1 Corrected total glial cell densities and  
numbers (page 88).
5.3.6 Immunostaining
Immunostaining was performed as described in 2.9 Immunohistochemistry (page 
64).
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5.4 Results
5.4.1 #66 and #72 transgenic complementation of knockout mice
5.4.1.1 Clinical description
Knockout mice complemented with the #66 transgene (n=9) up to 240 days of age 
and complemented with the #72 transgene (n=19) up to 540 days of age were 
examined. Both groups of mice appeared to develop normally showing no evidence 
o f neurological dysfunction. In particular, #72 transgene-complemented knockout 
mice maintained normal clinical phenotypes at least until 540 days o f age (n=5) 
despite the development of typical knockout phenotypes in transgene-negative 
littermate controls that were hemizygous for the Plptmknl allele (n=4).
5.4.1.2 #66 and #72 transgene expression in knockout mice
Transcript (Figure 46, page 147) and western analysis (Figure 47, page 148) showed 
that #66 and #72 transgenic complementation of knockout mice led to high levels of 
Pip gene expression at both transcript and protein levels.
5.4.1.3 Histological changes
Transgenic complementation with either transgene prevented the development of 
the neurodegenerative changes characteristic of knockout mice at 120 days of age. 
The mice developed well myelinated CNS white matter tracts (Figure 48, page 150) 
with no evidence of axonal swelling, axonal degeneration or microgliosis.
By 18 months of age, occasional swollen axons could be identified in the optic 
nerve and spinal cord of #72 transgene-complemented knockout mice. However, 
marked neurodegeneration similar to that seen in the knockout mice did not develop 
and extensive axonal changes, microgliosis and demyelination that have been 
reported as late changes in hemizygotes from the #66 and #72 transgenic line 
(Anderson et al., 1998) were not seen (Figure 49, page 151).
146
Pip (506bp) 
DM20 (401 bp)
603bp ^
603bp—W 
310bp—W
Figure 46 Semi-quantitative RT-PCR analysis of Pip gene isoform expression 
in knockout and transgene-complemented knockout mouse brain at 20 days of 
age. Lanes 1) wild type, 2) knockout, 3) #66 transgene-complemented 
knockout, 4) #72 transgene-complemented knockout, 5) PlpTgX transgene- 
complemented knockout, 6) Dm20Tgl transgene-complemented knockout, 
(size m arker: DNA/Z/a^lIl).
a) On comparison to wild type: no Pip or Dm20 isoform PCR products were 
detected in the knockout mouse; low (#66) and comparable (#72) Pip and Dm20 
PCR products were detected in #66 and #72 transgene-complemented 
knockout mice; low levels of Pip and no Dm20 isoform PCR products were 
detected in the PlpTgl transgene-complemented knockout mouse; no Pip and 
low levels of Dm20 PCR products were detected in the Dm20Jg2 transgene- 
complemented knockout mouse (30 cycles)
b) RT-PCR using prim ers designed to detect cyclophylin cDNAs were used to 
determine equivalency of sample loading and PCR conditions between samples 
(30 cycles)
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Figure 47 a+b) W estern blot of 20 and 60pg aliquots of protein extracted from 
whole brain of 20 day-old mice.
a) W estern blot probed for PLP and DM20 proteins.
Lane 1 - wild type mouse: PLP and DM20 proteins separated in the region of the 
23kD marker. Higher molecular weight bands separated below the 51kD marker 
and above the 125kDa marker and may have represented aggregates o f PLP and 
DM20 proteins.
Lanes 2 and 8 - knockout mouse: no PLP or DM20 protein could be detected in 
whole brain even at maximal loading (lane 8).
Lane 3 - #72 transgene-complemented knockout mouse: #72 transgenic 
complementation produced PLP and DM20 protein levels approaching those found 
in controls (lane 1).
Lanes 4 and 9 - P/pTgl transgene-complemented knockout mouse: PLP protein 
was detected but did not approach levels found in controls (lane 1). DM20 protein 
was not detected even at maximal loading (lane 9).
Lanes 5 and 10 - ND3A transgene-complemented knockout mouse: DM20 
protein could be detected in levels approaching those found in controls (lane 1). 
PLP protein was not detected even at maximal loading (lane 10).
Lanes 6 and 11 - PlpTgl and ND3A transgenes-complemented knockout mice: 
Co-expression o f PlpTgl and ND3A transgenes failed to increase PLP protein 
expression although higher molecular weight bands were seen.
Lanes 7 and 12 - Dm20Tg2  transgene-complemented knockout mouse: no 
DM20 protein could be detected.
b) Western blot probed for actin; lanes 1 to 7 as above: Probing for actin 
demonstrated that sample loading and detection were equivalent between samples.
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Figure 47 c+d) W estern blots of 2 and lOpg aliquots of myelin protein extracts 
from 20 day-old mouse brain.
a) W estern blot probed for PLP and DM20 proteins.
Lane 1 - wild type mouse: PLP and DM20 proteins and higher molecular weight 
bands are identified in myelin protein extracts.
Lanes 2 and 8 - knockout mouse: no PLP or DM20 protein could be detected in 
myelin even at maximal loading (lane 8).
Lane 3 - #72 transgene-complemented knockout mouse: PLP and DM20 proteins 
were present in myelin protein extracts in similar levels to controls (lane 1).
Lanes 4 and 9 - P/pTgl transgene-complemented knockout mouse: PlpTg\ 
transgene products were identified in myelin extracts indicating that the transgene 
products enter the myelin sheath. No DM20 protein was detected even at maximal 
loading (lane 9) and the level o f PLP protein was less than in controls (lane 1). 
Lanes 5 and 10 - ND3A transgene-complemented knockout mouse: ND3A 
transgene products were identified in myelin extracts indicating that the transgene 
products enter the myelin sheath. Even at maximal loading, PLP protein was not 
detected but high molecular weight bands were identified (lane 10) suggesting that 
DM20 protein without PLP protein may be able to form aggregates.
Lanes 6 and 11 - P lpTgl and ND3A transgenes-complemented knockout mice: 
Both transgene products were identified in myelin protein extracts.
Lanes 7 and 12 - Dm20Tg2  transgene-complemented knockout mouse: no 
DM20 protein was detected even at maximal loading.
b) W estern blot probed for MBP proteins; lanes 1 to 7 as above:
Probing for MBP proteins demonstrated that sample loading and detection were 
equivalent between samples.
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Figure 48 M ethylene blue/ azu r II stained section of mid optic nerve from  120 
day-old knockout mice com plem ented with a) #72 transgenes and b) #66 
transgenes showing no evidence of neurodegeneration o r microgliosis
(lOOOx m agnification)
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Figure 49 M ethylene blue/ azu r II stained lp m  resin sections of a) dorsal 
colum ns of spinal cord (C2-3) from  a 540 day-old #72 transgene-com plem ented 
knockout mouse and b) mid optic nerve from  a 568 day-old hemizygous #72 
transgenic mouse (expressing the endogenous Pip allele) dem onstrating  the 
paucity of axonal swellings (filled arrow s) in #72 transgene-com plem ented 
knockout mice com pared to older anim als from  the #72 transgenic line. O lder 
#72 hemizygotes also develop red u n d an t myelin sheathes (large open arrow s) 
and myelin vacuolation (small open arrow s) (1400x m agnification)
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5.4.1.4 Immunohistochemistry
Knockout mice complemented with the #66 and #72 transgenes had Pip gene 
products localised to myelin sheaths in the CNS (Figure 50, page 153 and Figure 
51a and b, page 154). Although the majority o f myelin sheaths in the #72 
transgene-complemented knockout mice showed PLP/DM20 immunoreactivity, a 
proportion did not. This feature was most obvious in the larger diameter fibres o f 
the ventral columns o f spinal cord (C2-3) (Figure 51c, page 154) but could be 
identified throughout the CNS. Despite this finding, the occasional swollen axons 
in aged #72 transgene-complemented knockout mice could not be localised with 
PLP/DM20-deficient myelin sheaths (Figure 5 Id, page 154).
5.4.1.5 Myelin ultrastructure
Ultrastructural examination revealed that the myelin sheaths in #72 transgene- 
complemented knockout mice showed no decompaction or intraperiod line 
abnormalities (Figure 52, page 155).
5.4.1.6 Analysis of axonal swelling and degeneration
Point count analysis revealed that the #72 transgene-complemented knockout mice 
(n=3) had no axonal swellings at 120 days o f age. These mice did have occasional 
degenerate fibres at 120 days o f age that were similar in quantity to wild type 
controls (n=3) and markedly lower than in knockout animals (n=4) (Figure 53, page 
156).
5.4.1.7 Glial cell quantification
At 120 days o f age, #72 transgene-complemented knockout mice had glial cell 
densities in the ventral columns o f spinal cord (C2-3) and mid optic nerve that were 
indistinguishable from wild type controls and that were significantly lower than 
knockout controls (P=0.0238) (Figure 54, page 157).
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Figure 50 50jj.ni v ibratom e section of cervical cord from  20 day-old #72 
transgene-com plem ented knockout mice showing transgene expression in a 
c luster of m yelinated fibres in the grey m atter. The section has been 
im m unostained to show a) PLP/DM 20 protein (green) in the myelin sheath, b) 
phosphorylated neurofilam ents (red) in the axon and c) both dem onstrating  
th a t transgene products localised to the myelin sheath (1300x m agnification)
Figure 51 PLP/DM 20-positive myelin in 1pm resin sections (PAP m ethod) 
from  #66 and #72 transgene-com plem ented knockout mice
V entral colum ns of spinal cord (C2-3) from  120 day-old knockout mice 
com plem ented with a) #72 transgenes and b) #66 transgenes dem onstrating  
transgene products in myelin (615x m agnification)
V entral colum ns of spinal cord (C2-3) from  a 540 day-old #72 transgene- 
com plem ented knockout mouse (c) dem onstrating  several PLP/D M 20-negative 
myelin sheaths (arrow s). M id optic nerve from  the same anim al (d) showing 
two swollen axons su rrounded  by PLP/DM 20-positive myelin (arrow s) 
(1067x m agnification)
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Figure 52 Myelin periodicity in #72 transgene-com plem ented knockout mice is 
norm al (240,000x m agnification)
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Figure 53 Swollen axon and degenerate fibre volumes assessed by point count 
analysis of mid optic nerve from  120 day-old wild type, knockout and 
#72 transgene-com plem ented knockout mice. #72 transgene-com plem ented 
knockout mice w ere indistinguishable from  wild type contro ls and  had no 
axonal swellings a t this age.
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Figure 54 Total corrected cell densities of mid optic nerve and ventral 
columns of spinal cord (C2-3) from wild type, knockout and #72 transgene- 
complemented knockout mice at 120 days of age. #72 transgene-complemented 
knockout mice, unlike knockout mice, did not develop a gliosis and were 
indistinguishable from wild type controls.
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5.4.2 Plp-cD N A  and D m 20-cDNA  transgenic com plem entation of  
knockout mice
5.4.2.1 Clinical description
PlpTgl and D m 20Tgl transgene-complemented knockout mice developed 
progressive neurological dysfunction from 12 months o f age that was 
indistinguishable from the knockout phenotype. Early in the course o f the 
investigation, it became apparent that the Dm20Tg2 transgene-complemented 
knockout mice did not produce detectable levels o f the DM20 protein isoform in 
central neural tissue (see below). The ND3A transgenic line was obtained from 
FG. Mastronardi (Department o f Biochemistry, University o f Toronto) in the hope 
that this line would produce the DM20 protein in knockout mice. As these mice 
only became available towards the end o f this project, a more detailed description o f 
their clinical features was not possible.
5.4.2.2 PlpTgl transgene-complemented knockout mice
5.4.2.2.1 Transgene expression
PlpTgl transgenic expression in knockout mice produced levels o f Pip-mRNA 
considerably lower than in the wild type controls, when compared by semi- 
quantitative RT-PCR (Figure 46, page 147). PLP protein isoform was detected in 
the myelin fraction on Western analysis (Figure 47, page 148). The Dm20 isoform 
was not expressed at either transcript or protein levels in P lpTgl transgene- 
complemented knockout mice.
5.4.2.2.2 Histological changes
P lpTgl transgene-complemented knockout mice developed neurodegenerative 
changes by 120 days o f age that were indistinguishable from the pathology in 
knockout mice (n=5) (Figure 55, page 160).
5.4.2.2.3 Immunohistochemistry
Tissue collected at 20 days o f age for cryostat sections and from a range o f ages for 
perfusion fixation was immunostained using both fluorescent and PAP techniques. 
At 120 days o f age, resin sections were immunostained using the PAP technique. 
At both ages, PLP protein could be identified in myelin sheaths surrounding small 
diameter axons in the spinal cord (C2-3) and mid optic nerve. Occasional profiles 
o f larger myelin sheaths immunostaining for transgene products were seen but large 
diameter myelin sheaths in general appeared to be devoid o f transgene products
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(Figure 56, page 161).
5.4.2.2.4 Myelin ultrastructure
The ultrastructural features o f myelin in the CNS o f PlptTgl transgene- 
complemented knockout mice were indistinguishable from myelin in knockout 
controls (Figure 57, page 162). Myelin periodicity ranged from myelin with normal 
periodicity to myelin with condensation or splitting o f the intraperiod lines.
5.4.2.3 Dm20Tg2 transgene complemented knockout mice
5.4.2.3.1 Transgene expression
RT-PCR indicated that low levels o f Dm20T g2 transgene transcripts were expressed 
in D m 20Tg2 transgene-complemented knockout mice (Figure 46, page 147) and Pip 
isoform transcripts were not detected. However, the DM20 protein isoform could 
not be detected in the CNS on western analysis at 20 days o f age (Figure 47, page 
148) or by immunohistochemistry at any age examined (embryonic day 16 and 
postnatal day 1,5,  10, 20, 120) (data not shown).
5.4.2.3.2 Histological changes
Dm20Tg2 transgene-complemented knockout mice developed neurodegenerative 
changes that were indistinguishable from knockout mice by 120 days o f age (n=6) 
(Figure 55, page 160).
5.4.2.4 PlpTgl/ Dm20Tg2 double transgenic complementation of the knockout 
mouse
Knockout mice complemented with both the PlpTgl and Dm20Tg2 transgenes 
developed neurodegenerative changes and progressive clinical phenotypes that were 
indistinguishable from knockout mice or from the P lpTgl transgene-complemented 
knockout mice (n=10).
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a)
b)
Figure 55 Methylene blue/ azur II stained ljim  resin sections of mid optic 
nerve from 120 day-old knockout mice complemented with the a) PlpTgl 
transgene and b) Dm20Tg2 transgene. Both sections show evidence of axonal 
swelling (small arrows) and axonal degeneration (large arrows)
(lOOOx magnification)
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Figure 56 PLP/DM20 immunoreactivity in lpm  resin section of fasciculus 
gracilis from spinal cord (C2-3) of a PlpTgl transgene-complemented knockout 
mouse at 120 days of age. PLP/DM20-positive myelin sheaths can be seen 
surrounding some small diam eter fibres (1300x magnification)
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Figure 57 Myelin periodicity in PlpTgX transgene-complemented knockout 
mice (240,000x magnification)
a) PlpTgX transgene-complemented knockout mice had myelin lamellae with 
both condensation and splitting at the intraperiod line although some regions 
of individual lamellae appeared to have norm al periodicity
b) Occasional myelin sheaths were found that were ultrastructurally  normal
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5.4.2.5 ND3A transgene-complemented knockout mice
5.4.2.5.1 Transgene expression
ND3A transgene-complemented knockout mice produced high levels o f DM20 
protein but no PLP protein. The transgene products were detected in the myelin 
fraction on western analysis (Figure 47, page 148).
5.4.2.5.2 Histological changes
ND3A transgene-complemented knockout mice develop neurodegenerative changes 
by 120 days o f age that were indistinguishable from the knockout phenotype (n=4) 
(Figure 58, page 164).
5.4.2.5.3 Immunohistochemistry
The DM20 protein isoform incorporated into a full range o f myelin sheaths by 20 
days o f age in ND3A transgene-complemented knockout mice (Figure 59, page
165). This was demonstrated by demonstrating PLP/DM20 immunoreactivity using 
the anti PLP C-terminal antibody and failing to demonstrate PLP protein isoform 
immunoreactivity using the anti PLP-specific antibody (Figure 59, page 165). By 
inference, DM20 protein isoform incorporated into a wide range o f myelin sheaths 
within the CNS but no PLP protein isoform was produced.
5.4.2.5.4 Myelin ultrastructure
M yelin from ND3A transgene-complemented knockout mice showed the same 
range o f ultrastructural abnormalities as that from knockout mice (Figure 60, page
166)
5.4.3 P LP-L slcZj transgenic complementation o f knockout mice
Knockout mice expressing the PLP-LacZ fusion protein produced detectable levels 
o f  the fusion protein that was expressed in the same spatial expression pattern as the 
Pip  gene. In addition, the fusion protein incorporated into the myelin sheath (Figure 
61, page 167).
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Figure 58 Methylene blue/ azur II stained ljum resin section of mid optic nerve 
from a ND3A transgene-complemented knockout mouse at 120 days of age. 
Swollen axons and a microgliosis were seen by this age indicating that 
neurodegeneration developed in ND3A transgene-complemented knockout 
mice (1300x magnification)
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Figure 59 PAP immunostained sections from ND3a transgene complemented 
knockout mice at 20 days of age
a) ljum resin section showing PLP/DM20-immunoreactivity localised to myelin 
sheaths of ventral columns of spinal cord (C2-3) (PLP C-terminal antibody) 
(740x magnification)
Serial 15pm paraffin sections showing the lateral columns of spinal cord (C2-3) 
counterstained with haematoxylin (65x magnification)
b) white matter immunostained using the anti PLP C-terminal antibody
c) no positive staining was seen using the anti PLP isoform-specific antibody 
This confirmed that only DM20 protein was produced in ND3A transgene- 
complemented knockout mice and that it incorporated into a wide range of 
myelin sheaths.
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Figure 60 Myelin ultrastructure in ND3A transgene-complemented knockout 
mice (300,000x magnification)
Myelin was indistinguishable from that in knockout mice showing normal 
periodicity and both compaction and splitting at the intraperiod line.
Figure 61 15pm cryosection of sagittal hindbrain from a 20 day-old 
PLP-LacZ transgene-complemented knockout mice (140x magnification)
a) Staining with anti (3-galactosidase antibody linked to a FITC-labelled 
secondary antibody demonstrates high levels of transgene expression 
throughout myelinated regions of the cerebellum indicating fusion protien 
incorporation into myelin
b) Immunoreactivity against the PLP/DM20 carboxy terminus cannot be 
detected demonstrating that the fusion protein incorporates into myelin in the 
absence of endogenous Pip gene products (anti PLP C-terminal antibody 
detected using a TxR-labelled secondary)
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5.5 Discussion
5.5.1 #66 and #72 transgenic complementation of knockout mice
Transcript and protein analysis showed that transgenic complementation using 
either the #66 or #72 transgene induced high levels of Pip gene activity in the 
knockout mouse approaching the level of endogenous Pip gene expression. At 120 
days of age, #72 transgenic complementation was shown to prevent the 
development of axonal and glial changes in knockout mice and #72 transgene- 
complemented knockout mice produced compacted central myelin sheaths of 
normal periodicity. These results indicate that the neurodegenerative changes and 
altered myelin ultrastructure in the knockout mouse are the direct result of loss of 
Pip gene products.
Aged #72 transgene-complemented knockout mice developed occasional axonal 
swellings similar to those found in knockout mice. These swellings were 
indistinguishable from swellings found as part of a wider neurodegenerative process 
in aged hemizygous mice from the #72 transgenic line (Anderson et al., 1998). The 
swellings in #72 transgene-complemented knockout mice may reflect an incomplete 
rescue of the knockout phenotype or the partial development of the aged #72 
hemizygote phenotype. Alterations of Pip gene dosage appear to lead to the 
development of axonal changes in these lines of mice with both reduced and 
increased gene dosages causing clinical disease. The severe myelin deficits caused 
by dysmyelination and demyelination, reported in missense Pip gene mutations and 
over-expressing transgenics, probably result from some mechanism other than gene 
dosage as they do not develop in the knockout mouse.
Not all myelin sheaths in the CNS of #72 transgene-complemented knockout mice 
immunostained for Pip gene products using a conformation-independent 
immunohistochemical marker (anti PLP C-terminal antibody). The variable staining 
of myelin sheaths probably reflects a mosaic pattern of transgene expression within 
the oligodendrocyte population. Many factors may cause variegated transgenic 
expression within a population of cells. These include repeat induced gene 
silencing associated with large transgenic arrays and integration-site dependent 
influences on the transgenic promoter (reviewed by Sutherland et al., 1997; Garrick 
et al., 1998; Graubert et al., 1998). Similar stochastic influences on the transgenic 
promoter probably account for variegated transgenic expression in the #72 
transgene-complemented knockout mouse but it is difficult to exclude the possibility 
that only a proportion of myelin sheaths elaborated by a single oligodendrocyte will 
incorporate the transgene products. The development of swollen axons in aged #72
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transgene-complemented knockout mice may reflect the local influence of 
PLP/DM20-deficient oligodendrocyte processes on axonal function although a 
direct association between PLP/DM20-negative myelin sheaths and swollen axons 
could not be shown.
5.5.2 Pip-cDNA and Dm20-cDNA transgenic complementation of 
knockout mice
PlpTgl transgenic complementation of knockout mice resulted in the incorporation 
of the PLP protein isoform into central compact myelin. This demonstrates that the 
PLP protein is capable of appropriate intracellular trafficking, with targeting to and 
incorporation into the myelin sheath, in the absence of the DM20 protein. Although 
PLP and DM20 proteins may interact during intracellular processing, as suggested 
by in vitro studies (Gow et a l, 1994b; Gow and Lazzarini, 1996), this relationship is 
not necessary for trafficking of the PLP protein. However, the sparse nature of 
transgene expression in myelin sheaths of these mice raises the possibility that the 
DM20 protein isoform may facilitate the intracellular trafficking of PLP protein. A 
reciprocal role for the PLP isoform in facilitating intracellular trafficking of the 
DM20 protein is unlikely; rumpshaker mice maintain normal DM20 protein 
trafficking to the cell surface in the presence of low levels of PLP protein 
(Fanarraga et al., 1992) and the ND3a transgene-complemented knockout mice 
incorporate DM20 protein into myelin in the absence of the PLP protein isoform.
Expression of the ND3A transgene in knockout mice did not prevent the 
development of axonal changes or the poor compaction of myelin. As expression of 
this transgene produced high levels of DM20 protein which incorporated into a wide 
range of myelin sheaths within the CNS, it is possible to conclude that the DM20 
protein isoform cannot rescue the knockout phenotype when expressed in isolation. 
Similarly, expression of the PlpTgl transgene in knockout mice did not prevent the 
development of axonal changes. This may reflect a requirement for other Pip gene 
isoforms to be expressed in combination with the PLP protein, before 
neurodegeneration is prevented. However, expression of the PlpTgl transgene in 
knockout mice was poor; low levels of protein were detected by western analysis 
and only a small proportion of myelin sheaths immunostained for transgene 
products. Either of these factors may explain the inability of the PLP protein to 
prevent neurodegeneration in this model which may not reflect the true aetiology of 
the neurodegenerative changes seen. Similarly, although myelin periodicity was 
abnormal in PlpTgl transgene-complemented knockout mice, poor incorporation of 
transgene products into individual myelin sheaths makes definitive comments on the 
ability of the PLP protein to support the structure of the intraperiod line impossible.
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Attempts to supplement the knockout phenotype with the Dm20Tg2 transgene 
proved to be unsuccessful as no protein could be detected by any method. The 
expression of DM20 proteins in the absence of PLP protein in embryonic neural 
tissue (Dickinson et al., 1996), in the PNS (Griffiths et al., 1995) and in ND3A 
transgene-complemented knockout mice demonstrate that the PLP protein isoform 
is not required for the appropriate expression of the DM20 protein. The limited 
expression of the PlpTgl transgene in the knockout line demonstrates that the non­
coding regions contained within the Dm20Tg2 transgene can confer a degree of 
appropriate transgenic regulation. As discussed above (see 5.5.1 #66 and #72 
transgenic complementation o f  knockout mice, page 168), several stochastic 
mechanisms affecting the transgenic promoter may explain the poor levels of 
expression of both of the PlpTgl and Dm20Tgl transgenes. Genomic imprinting in 
transgenic lines has also been widely reported causing variable transgenic repression 
(reviewed by Chaillet, 1994; Tycko, 1997). This can be dependent on the parental 
origin of transgenes, their integration sites or the effect of modifying loci from 
mixed genetic backgrounds. However, the expression of Dm20Tgl transgene 
products in Schwann cells from jimpy mice (Anderson et al., 1997) and detection of 
transcripts in Dm20Tg2 transgene-complemented knockout mice in this study show 
that the transgene is transcriptionally competent. Another explanation may be that 
the transgenic promoter in these two lines of mice promotes expression in the 
Schwann cell but does not have suitable elements to promote expression in the 
oligodendrocyte. Alternatively, the promoter may promote expression of the 
transgenes in a subset of oligodendrocytes or only later during myelination 
explaining the sparse expression of the PlpTgl transgene in small myelin sheaths. 
A combination of these factors may explain the absence of Dm20Tg2 transgene 
products and the low levels of PlpTgl transgene products in transgene- 
complemented knockout mouse.
Although the RT-PCR results support low levels of transgene transcription in both 
the PlpTgl and Dm20Tg2 transgene complemented knockout mice, this data is 
semi-quantitative and may not truly reflect the levels of transgene expression. To 
clarify the level of transgene expression in knockout mice, transcript levels from the 
various transgenic crosses were compared by northern blot analysis (see 7.12 
Northern blotting, page 192). However, difficulties in achieving high levels of 
probe hybridisation prevented accurate assessment of transcript levels even in wild 
type animals. As the clarification of levels of transgene expression was not a 
primary goal of the study and due to time and resource constraints, this avenue of 
research was not pursued.
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5.5.3 PLP-LacZ fusion transgene expression in knockout mice
Plp-LacZ transgenic complementation of the knockout mice demonstrated that the 
PLP-LacZ fusion protein was capable of incorporating into central myelin 
confirming the original findings of Wight et al. (1993). This study adds to these 
original observations as it shows that the fusion protein incorporates into myelin in 
the absence of endogenous Pip gene products. This excludes the possibility that the 
fusion protein incorporated into myelin because of interactions between it and the 
endogenous Pip gene products that may have facilitated its intracellular trafficking 
to and incorporation into central myelin. However, other work in this study does 
not support the additional conclusions that intron 1 is necessary to ensure the correct 
spatial expression of the Pip gene through repressor activity in non-glial cells 
(Wight and Dobretsova, 1997). The appropriate expression of DM20 protein in 
ND3A transgene-complemented knockout mice clearly refute this suggestion as this 
transgene is appropriately expressed in the absence of intron 1. In fact, this study 
provides further evidence that the 5' flanking region of the Pip gene contains the 
necessary regulatory elements to direct tissue specific expression of Pip gene 
products. More recent reports from Dobretsova & Wight (1999) suggest that 
intron 1 contains repressor elements that are regulated through cA-acting elements 
also contained within intron 1. This may explain the contradictory findings between 
their study and this work as it suggests that, although the Pip gene does not require 
the presence of intron 1 for correct spatial expression, intron 1 may form a complete 
regulatory subunit that subtly modulates Pip gene expression.
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6. Final discussion and further work
Data presented in this study has provided valuable insights into the functions of the 
Pip gene. The study aimed to establish if the Pip gene had positive roles in 
myelination and to dissect functional differences between the major isoforms of the 
Pip gene. In addition to clarifying some of these points, the study demonstrated that 
the Pip gene influences normal axonal function and highlighted the complexities of 
the use of transgenic systems in studying gene function. Differences between the 
phenotypes of missense Pip gene mutants and the knockout mouse suggested that 
mechanisms other than the loss of functional Pip gene products might be involved 
in the pathogenesis of the severe dysmyelinating disorders. The study also provided 
strong evidence for genetic redundancy of the murine Pip gene in myelin formation 
and drew comparison with PLP gene function in man. The aim of this section is to 
bring together the phenotypic studies from the transgenic crosses and to suggest 
future areas of work that may clarify some of the points raised by this thesis.
In summary, expression of the Pip gene does not appear to influence 
oligodendrocyte maturation or survival but does increase the ability of 
oligodendrocytes to elaborate myelin sheaths. The absence of PLP and DM20 
proteins does not prevent the formation of large volumes of central myelin. 
However, these proteins increase the stability of the intraperiod line although neither 
is necessary for its formation. Mice deficient in Pip gene products develop 
progressive axonal dysfunction that eventually leads to clinical disease. The axonal 
pathology is similar to changes seen in other Pip gene mutants suggesting that 
alterations in Pip gene dosage affect long-term axonal function and can lead to 
pathology. Although much of the evidence points towards a focal effect of 
oligodendrocytes altering local axonal function in the knockout mouse, the 
possibility that a primary neuronal defect exists cannot be excluded. In particular, 
the recent identification of minor isoforms of the Pip gene (srPlp and srDm20 
transcripts) in subsets of neuronal perikaryia (Bongarzone et al., 1999) highlights 
the potential for the Pip gene to have a direct role in neuronal function.
Developmental delays (Nadon and Duncan, 1996) and high apoptosis rates 
(Grinspan et al., 1998) in maturing oligodendrocytes from missense Pip gene 
mutants coupled with early DM20 protein expression in oligodendrocyte 
progenitors (Lees, 1998) suggest that the Pip gene is involved in oligodendrocyte 
maturation and survival. Although mature oligodendrocyte numbers are maintained 
in the knockout mouse, a subtle reduction in oligodendrocyte viability could be 
compensated for by the excess of glial progenitors that are normally seen in the
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developing CNS (Barres et al., 1992). In order to fully establish that knockout 
oligodendrocytes have normal viability, further work looking at survival of 
immature oligodendrocytes and their progenitors would be necessary. The 
assessment of apoptosis rates in earlier stages during neural development and 
myelination of the knockout mouse may clarify these points. An alternative 
approach could utilise expression of the Plp-LacZ transgene in the knockout mouse. 
A similar transgene construct has been used to study development of early Dm20 
transcript-expressing oligodendrocyte progenitors in the developing murine CNS 
(Spassky et al., 1998) as the transgene product provides a valuable marker for this 
cell type. This could be utilised to compare the early development of this subset of 
oligodendrocytes in the developing CNS of knockout mice, in which these cells 
cannot be identified conventionally as they do not express Dm20 transcripts, with 
control animals.
Mounting evidence supports the ability of oligodendrocytes to influence axonal 
function in the mature CNS and the knockout mouse may provide an example of 
disruption of these mechanisms. However, the development of axonal changes 
cannot be ascribed with confidence to the failure of Pip gene expression in the 
mature oligodendrocytes of these mice until two points have been clarified. Firstly, 
the possibility that a primary neuronal defect results from the loss of an, as-yet 
unidentified, role for the Pip gene in the neurone must be excluded. Secondly, 
although knockout oligodendrocytes appear to have comparatively normal 
phenotypes, the CNS environment in which axonal swellings develop has always 
been devoid of Pip gene products. The possibility that loss of Pip gene expression 
affects neuronal function during development resulting in axonal changes later in 
life cannot be excluded. The clarification of these points hinges on the ability to 
induce axonal changes by introducing PLP/DM20-deficient oligodendrocytes to 
axons that have developed in a normal neural environment. The production of an 
inducible Pip gene knockout allele through, for example, a CVe-LoxP recombinase 
system would provide a model for examining these points in vivo. However, this 
would require a large time and resource commitment, would necessitate a second 
phenotypic characterisation and would not address the issue of the neuronal or 
oligodendroglial origin of axonal swellings. More readily accessible in vivo 
approaches exist that can build on the work from the knockout mouse. Intraocular 
injection of oligodendrocytes is an established technique that has been shown to 
induce myelination of the retinal neuro-epithelium of the rat (Laeng et al., 1996). 
This technique would provide a useful starting point from which to study the ability 
of PLP/DM20-deficient oligodendrocytes to induce axonal changes in wild type 
animals over a protracted period. Other transplantation techniques in immature 
animals and dysmyelinated mutants could also be used to induce myelination in
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other neural areas such as the spinal cord.
In vitro approaches may provide sophisticated models for establishing the nature of 
oligodendroglial-axonal interactions that lead to the development of axonal 
swellings. Initial studies would establish if co-culturing PIJP/DM20-deficient 
neurones and glia induced axonal changes. If an axonal phenotype develops, the 
effects of altering expression of the Pip gene and its isoforms in the neuronal and 
oligodendroglial populations can be assessed. In addition, the use of conditioned 
medium may clarify whether a focal oligodendrocyte effect or a secreted product 
influences axonal function. Although this may provide a valuable model, the major 
limitations may prove to be the difficulty in inducing in vitro myelination and of 
maintaining cultures for long enough for axonal pathology to develop. Slice 
cultures may offer a similar in vitro approach overcoming some of these problems.
The mechanisms leading to axonal dysfunction must be ascertained in order to 
establish how the Pip gene influences neuronal function. A more detailed 
morphometric analysis of the cytoskeletal elements may prove beneficial in 
confirming that knockout axons develop normally. However, pilot 
immunocytochemical (Griffiths et al., 1998) and electron microscopic investigations 
show no obvious abnormalities in the majority of axons from knockout mice before 
axonal swellings and degeneration develop. Similarly, although semi-quantitative 
western blotting may highlight abnormalities of cytoskeletal metabolism, isolated 
axonal changes are likely to be masked by the predominance of apparently normal 
cytoskeletal elements. A more productive approach may be to study axonal 
function directly. Primary investigations would aim to establish if axonal transport 
is disrupted and, if so, what mechanisms may be involved. The optic nerve offers 
an ideal area to examine as it is easily accessible and all axons are orientated in one 
direction. The introduction of tracer molecules into the retinal ganglion cell layer to 
study anterograde axonal transport and into the superior colliculus to study 
retrograde axonal transport are well established techniques (for example Caleo, 
1996). In vitro approaches may also prove useful for studying individual axoglial 
interactions but hinge on the ability to identify a neuronal phenotype.
Transgenic complementation demonstrated that the PLP protein can incorporate into 
myelin in the absence of DM20 protein. In addition, transgenic complementation 
showed that the DM20 protein expressed in isolation could not prevent the 
development of neurodegenerative changes or maintain myelin compaction in the 
knockout mouse. However, the separation of potential roles of PLP and DM20 
proteins was hampered by the poor expression of the PlpTgl transgene. The failure 
to prevent myelin ultrastructural abnormalities and neurodegeneration in PlpTgl
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transgene-complemented knockout mice may have resulted because both PLP and 
DM20 protein isoforms are necessary to achieve these goals. Alternatively, these 
findings may reflect the low levels of PLP protein isoform expression in the 
PlpTgl transgene complemented-knockout mouse. Immunohistochemical and 
morphometric analyses of knockout mice complemented with both the PlpTgl and 
ND3A transgenes would address these issues. Such a study may clarify the 
influence of the DM20 protein on the trafficking of the PLP protein and may 
establish how the loss of these two proteins contributes to the development of the 
knockout phenotype. An alternative hypothesis is that the inability to rescue the 
knockout phenotype with PlpTgl transgenic complementation may relate to the 
absence of srPLP and srDM20 protein isoforms in the neurones of these mice. The 
generation of transgene constructs expressing these minor isoforms would be a 
useful addition to the array of transgenic lines available for modifying the knockout 
phenotype.
The balance of data from this study suggests that although the expression of the Pip 
gene does not appear to be important in oligodendrocyte maturation and survival, it 
does improve the ability of oligodendrocytes to elaborate myelin sheaths. This is 
demonstrated by the selective dysmyelination of small diameter fibres in knockout 
mice and trend towards the predominance of PLP/DM20-positive myelin sheaths in 
the heterozygous knockout mouse (I.R. Griffiths, personal communication). The 
Pip gene may have an early role in axo-oligodendroglial interaction, possibly in the 
initiation of axoglial contact or myelin compaction. The instability of the 
intraperiod line in knockout mice provides evidence that Pip gene products interact 
at the cell surface and may have adhesive properties. These properties might 
indicate a role in stabilising initial axoglial contact or in signal transduction 
pathways. Further morphometric analysis to establish the effect of transgenic 
complementation on the ability of knockout oligodendrocytes to initiate myelin 
sheath formation would begin to dissect the roles of the Pip gene in this process. 
The efficacy of the initial stages of axoglial interaction in the knockout mouse might 
best be addressed using in vitro culture systems. If a phenotype can be established, 
transfection studies could address the role of each isoform in these processes and 
blocking epitopes using monoclonal antisera may dissect the link between 
PLP/DM20 structure and function.
Data from this study show that the Pip gene has a degree of genetic redundancy in 
the murine CNS, a phenomenon that is increasingly being recognised in gene 
knockout studies (reviewed by Nowak et al., 1997; Brookfield, 1997; Gibson and 
Spring, 1998). Although genetic redundancy may provide some insights into the 
pathogenesis of Pip gene-related disease, it complicates the search for roles that the
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Pip gene fulfils in neural development. It is possible, for example, that the Pip gene 
is not vital for myelination but that the role that the Pip gene or a closely related 
member of the same gene family can fulfil in myelination is important. An example 
of genetic redundancy masking the importance of roles that genes fulfil in 
myelination is seen with Mbp and PO gene expression in the PNS. Although MBP 
protein can be shown to contribute to major dense line formation in the CNS, both 
PO and MBP proteins can fulfil this role in the PNS and both must be lost in order to 
cause PNS major dense line decompaction (Martini et al., 1995). In order to 
establish if the Pip gene has important roles, genes that have the potential to replace 
those roles must be identified and examined. In the knockout mouse, initial 
investigations to find candidates for replacing Pip gene function, aimed at 
identifying significant upregulation of members of the DM  gene family, proved 
unsuccessful (Klugmann et al., 1997). An alternative approach is to create double 
gene knockout mice deficient in both Pip and M6a or Pip and M6b genes. These 
mice have been generated but have similar phenotypes to the Pip gene knockout 
mouse suggesting that M6a and M6b genes do not replace the functions of the Pip 
gene in the murine CNS (I.R. Griffiths, personal communication). Further attempts 
to identify genes that may replace the roles of the Pip gene must be aimed at 
identifying upregulated genes within the CNS of knockout mice or identifying and 
screening additional members of the DM  gene family.
The Pip gene knockout mouse has provided a useful model for a subset of PMD 
disorders and a valuable tool for future investigations into the functions of the 
isoforms of the Pip gene. It has raised relevant questions about the pathogenesis of 
Pip gene-related disease and has highlighted the contribution that axonal changes 
make in myelin disorders. The differences in onset of disease and PNS changes 
between knockout mice and humans with functional PLP gene null-alleles raises the 
possibility that the gene may fulfil different roles in the two species. Importantly, 
the knockout mouse has shown the possibility that the mature oligodendrocyte 
influences the axon through a Pip gene-mediated mechanism. This highlights 
potential new roles for the Pip gene in axoglial interaction.
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7. Appendix
7.1 APES-coated slides
APES-coated slides were used for mounting sections for in situ hybridisation and 
immunocytochemistry. Slides were soaked overnight in 5% Decon 90 (Decon Lab 
Ltd), a detergent, to remove grease, washed in distilled water and oven dried. Once 
dry, the slides were soaked in 0.25% APES (Sigma) in methylated spirit in a fume 
hood for 2 minutes. They were rinsed in DEPC-treated water for 2 minutes and 
oven-dried wrapped in foil. Treated slides were stored at room temperature.
7.2 DEPC-treated water
A 0.1% solution of DEPC was made in distilled water and left for at least 12 hours 
to inactivate and contaminating RNases. To destroy the DEPC before use, the water 
was autoclaved at 151b.in"2 for 20 minutes and stored sealed at room temperature 
until use.
7.3 Fixatives
7.3.1 Buffered neutral formaldehyde, 4% (BNF)
For 1 litre of fixative:
100 ml 40% formaldehyde (Merck)
900 ml tap water
4 g sodium dihydrogen phosphate
8 g di-potassium hydrogen phosphate
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7.3.2 Karnovsky's modified fixative (parafoimaldehyde/ 
glutaraldehyde 4%/5%)
For 500 ml of fixative:
250 ml 8% paraformaldehyde 1
100 ml 25% glutaraldehyde
150 ml 0.08M cacodylate buffer^
250 mg Calcium chloride
Filter, adjust to pH 7.2 and store at 4°C
18% Paraformaldehyde: 20 g paraformaldehyde made up to 250 ml with DW
heat to 65°C
add a few drops of 1M NaOH until solution clears 
allow to cool
20.08M Cacodylate buffer: 17.1224g sodium cacodylate dissolved in 1 litre of DW
adjust pH to 7.2
7.3.3 Periodate-lysine-paraformaldehyde
For 1 litre of fixative:
Buffered lysine solution: 13.7g lysine monohydrate in 375ml DW
1.8g sodium hydrogen phosphate in 100ml DW 
mix the two solutions to give 475ml buffer, pH7.4
10% Paraformaldehyde: 20g paraformaldehyde made up to 250 ml with DW
heat to 65 °C
add a few drops of 1M NaOH until solution clears 
allow to cool
The two solutions were stored at 4°C until required (overnight if necessary). 
Immediately before use the two solutions were mixed and made up to a final volume 
of 1 litre using 0.1M phosphate buffer. 2.14g sodium periodate was added and 
allowed to dissolve.
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7.3.4 4% Paraformaldehyde in PBS
For 500 ml of fixative:
500ml of PBS were added to 20g paraformaldehyde, heated to 65°C and cleared by 
the addition of a few drops of 1M NaOH. The solution was filtered, allowed to cool 
and the pH was adjusted to 7.2.
7.4 Tissue processing protocols
7.4.1 Paraffin wax processing
Tissues were passed through the following solutions before being blocked in 
paraffin:
1) 70% methylated spirit/5 % phenol 2 hr room temperature
2) 90% methylated spirit/5 % phenol 2 hr room temperature
3) methylated spirit 2 hr room temperature
4) ethanol/5% phenol 2 hr room temperature
5) ethanol/5% phenol 1 hr room temperature
6) ethanol/5% phenol 1 hr room temperature
V) 1% celloidin in methyl benzoate 1 4 hr room temperature
S) xylene 1 hr room temperature
9) xylene 1 hr room temperature
10) xylene 1 hr room temperature
11) paraffin wax 6 hr 60°C
12) paraffin wax 6 hr 60°C
iNecoloidine (Merck) solution for microscopy was considered to be 100% celloidin 
(lm l added per 100ml methyl benzoate).
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7.4.2 Resin processing
Tissues were passed through the following solutions before being embedded in 
resin:
1) isotonic cacodylate buffer 50 min 4°C
2) 1% OSO4 in cacodylate buffer 2 hr room temperature
3) isotonic cacodylate buffer 1 30 min room temperature
4) 50% ethanol 5 min 4°C
5) 50% ethanol 10 min 4°C
6) 70% ethanol 5 min 4°C
7) 70% ethanol 10 min 4°C
8) 80% ethanol 5 min 4°C
9) 80% ethanol 10 min 4°C
10) 90% ethanol 5 min 4°C
11) 90% ethanol 10 min 4°C
12) ethanol 20 min 4°C
130 ethanol 20 min 4°C
14) propylene oxide 15 min room temperature
15) propylene oxide 15 min room temperature
16) 1:3 resin2;propylene oxide 13 hr room temperature
17) 1:2 resin:propylene oxide 6 hr room temperature
18) 1:2 res in: propylene oxide 18 hr room temperature
19) resin 4 hr 30°C
Processed samples were positioned in resin filled silicon moulds and left to 
polymerise overnight at 60°C.
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isotonic cacodylate buffer:
16.05g sodium cacodylate
3.8g sodium chloride
0.055g calcium chloride
0.102g magnesium chloride
Made up to 1 litre with DW and pH adjusted to 7.2
2Araldite resin:
30g araldite CY212 (resin)
25.2g dodecanyl succinic anhydride (hardener)
1.2ml 2,4,6-tri-dimethylaminomethyl-phenol (accelerator)
1.0ml di-butyl phthalate (plasticiser)
7.5 In situ hybridisation solutions and protocols
7.5.1 20x SSC (Sodium chloride/sodium citrate)
This wash contained 3M sodium chloride, 0.3M sodium citrate:
1753g sodium chloride
882g sodium citrate
Made up to 10 litres with DW
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7.5.2 Prehybridisation washes
Cryosections were kept at 4°C before fixation to prevent activity of endogenous 
RNases. They were slowly thawed by incubating them in ice-chilled 4% 
paraformaldehyde that was allowed to heat slowly to room temperature during the 
first 20 minutes incubation step. The remaining steps and all the steps for paraffin 
sections were performed at room temperature.
1) 4% paraformaldehyde/ PBS 20 min
2) PBS 5 min
3) PBS 5 min
4) 40|ug.ml"l proteinase K
(in 50mM Tris, 5mM EDTA, pH 7.6)
7.5 min
5) PBS 5 min
6) 4% paraformaldehyde/ PBS 5 min
7 a) 
b)
0.1M triethanolamine/ 0.25% acetic anhydride
refresh by adding more acetic anhydride to a 
total concentration of 0.5%
5 min 
5 min
8) PBS 5 min
9) 0.85% saline 5 min
10) methylated spirits 5 min
11) 100% ethanol 5 min
12) 100% ethanol 5 min
13) air dry for at least 2 hours
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7.5.3 Post-hybridisation washes
1) 2x SSC 2.5 hr 50°C
2) 2x SSC/ 50% formamide 1.5 hr 50°C
3) O.lxSSC 30 min room temperature
4) TBS (pH7.5) 15 min room temperature
5) 10% foetal calf serum in TBS 
(pH7.5)
45 min room temperature
6) 1:500 Anti-Digoxigenin-AP Fab 
fragment in TBS (pH7.5)
1 hr room temperature
7) TBS (pH7.5) 5 min room temperature
8) TBS (pH7.5) 30 min room temperature
9) O.lM Tris/O.lM NaCl/ 
0.05M MgCl2/pH9.5
5 min room temperature
10) substrate buffer* 5 min -12 hr room temperature
11) running water 30 min room temperature
*see 7.5.4 Alkaline phosphate substrate buffer, page 183
7.5.4 Alkaline phosphate substrate buffer
3.375mg nitroblue tetrazolium salt in 70% dimethylformamide
1.75mg 5-bromo-4-chloro-3-indolyphosphate, toluidinium salt solution in 
100% dimethylformamide
10ml 0.1M Tris, 0.1M NaCl, 0.05M MgCl2, pH 9.5
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7.6 Staining protocols
Sections were passed through the following solutions
7.6.1 Dewaxing and hydration of paraffin sections
1) xylene 2 mins
2) absolute alcohol 2 mins
3) methylated spirit 2 mins
4) water 2 mins
5) Lugols iodine 1 min
6) water 1 min
7) 5% sodium thiosulphate 1 min
8) water 2 mins
7.6.2 Dehydration and clearing of sections
i) methylated spirits 2 mins
2) absolute alcohol 2 mins
3) absolute alcohol 2 mins
4) histoclear 2 mins
5) xylene 2 mins
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7.6.3 H aem atoxylin and eosin
1) xylene 2 mins
2) absolute alcohol 2 mins
3) methylated spirit 2 mins
4) water 2 mins
5) Lugols iodine 1 min
6) water 1 min
7) 5% sodium thiosulphate 1 min
8) water 2 mins
9) Mayers haematoxylin 10 mins
10) 1% acid alcohol 3 dips
11) water 2 mins
12) Scots tap water substitute* 1 min
13) water 2 mins
14) methylated spirit 10 secs
15) saturated alcoholic eosin 2 mins
16) methylated spirit 10 secs
17) absolute alcohol 2 mins
18) histoclear 2 mins
19) xylene 5 mins
* for details see 7.7 Staining solutions
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7.6.4 H aem atoxylin
1) running water 2 mins
2) Mayers haematoxylin 50 secs
3) water wash off excess haematoxylin
4) Scots tap water substitute* 30 secs
* for details see 7.7 Staining solutions 
7.6.5 Staining for electron microscopy
1) saturated uranyl acetate in 50% ethanol 15 mins
2) 50% ethanol rinse
3) 50% ethanol rinse
4) distilled water rinse
5) distilled water rinse
6) air dry
7) Reynold's lead citrate1 (Sodium 
hydroxide moistened chamber)
10 mins
8) 1M sodium hydroxide rinse
9) 1M sodium hydroxide rinse
10) 1M sodium hydroxide rinse
11) distilled water several rinses
1 Reynold's lead citrate (1.2mM lead citrate, 1.8mM sodium citrate, pH 12.0)
1.33g lead nitrate dissolved in 15ml DW for 1 min vigorous shaking
1.76g sodium citrate dissolved in 15ml DW for 1 min vigorous shaking
Combine solutions and equilibrate over 30 minutes with occasional shaking. Clear 
with 1M NaOH and make up to final volume of 50ml with distilled water.
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7.7 Staining solutions
7.7.1 Methylene blue/ azur II
1% methylene blue
1% azur II
1% borax
diluted distilled water and filtered before use
7.7.2 Mayers haematoxylin
lg haematoxylin
10g potassium alum
0.2g sodium iodate
in 1 litre of distilled water
bring to boiling point and allow to cool over night then add:
lg citric acid
50g chloral hydrate
7.7.3 Scots tap water substitute
3-5g sodium bicarbonate
20g magnesium sulphate
in 1 litre of distilled water
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7.8 General Buffers
7.8.1 Tris buffered saline
The buffer contained 25mM Tris pH7.4, 136mM NaCl, 2.6mM KCI2.
3g Tris base pH7.5
8g sodium chloride
0.2g potassium chloride
Dissolved in 800ml of DW, pH adjusted to 7.4 with 1M HC1 and volume made up to 
1 litre with DW
7.8.2 Phosphate buffered saline (PBS)
The buffer contained
8g sodium chloride
1.44g disodium hydrogen phosphate
0.24g potassium dihydrogen phosphate
0-2g potassium chloride
Dissolved in 800ml of DW, pH adjusted to 7.4 with 1M HC1 and volume made up to 
1 litre with DW
7.8.3 0.1M phosphate buffer
The buffer contained
77.4ml 1M disodium hydrogen phosphate
22.6ml 1M potassium dihydrogen 
phosphate
In 1 litre of DW, pH adjusted to 7.4 with 1M HC1.
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7.8.4 Tris-EDTA buffer (TE buffer)
The buffer contained lOmM Tris pH 8.0, ImM EDTA:
500pl 1M Tris pH 8.0
lOOpl 0.5M EDTA
Made up to 50ml with SDW
7.8.5 Tris acetate EDTA buffer xlO (TAE buffer)
The buffer contained 40mM Tris acetate, ImM EDTA:
48.4g Tris base
11.4ml glacial acetic acid
20ml 0.5M EDTA
Made up to 1 litre in DW
7.9 Hybaid Recovery™ buffers
All solutions were commercially prepared and supplied with the Hybaid 
R e c o v e r y T M  Quick Flow Midi Kit (Hybaid)
7.9.1 Resuspension solution (Hybaid) containing RNase
50mM Tris-HCl pH8.0
lOmM EDTA
100pg.pl"! RNase
stored at 4°C
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7.9.2 Cell lysis solution (H ybaid)
200mM NaOH
1.0% SDS
7.9.3 Neutralisation solution (Hybaid)
3.2M potassium acetate/ acetic acid pH5.5
7.9.4 Equilibration solution (Hybaid)
600mM NaCl
lOOmM sodium acetate/ acetic acid pH5.0
0.15% Triton X-100
7.9.5 Wash solution (Hybaid)
800mM NaCl
lOOmM sodium acetate/ acetic acid pH5.0
7.10Gel loading dye x6 (for TAE conditions)
30% glycerol in SDW
0.25% bromophenol blue
0.25% xylene cyanol FF
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7.11 Bacteriological media
7.11.1 Luria-Bertani (LB) medium
10g tryptone (Oxid)
5g yeast extract (Oxid)
10g sodium chloride
Made up to 1 litre with DW, pH adjusted to 7.0 using 5N sodium hydroxide and 
autoclaved for 20 minutes at 15psi and stored at 4°C.
7.11.2 Ampicillin-LB medium
lOOpg.ml"! ampicillin was added to LB medium and stored at 4°C.
7.11.3 Ampicillin-LB agar plates
1.2% ampicillin agar plates were prepared by adding 12g agar (Agar bacteriological, 
Oxid) to the LB medium solution before autoclaving. The mixture was autoclaved, 
allowed to cool to ~50°C and lOOpg.ml"! ampicillin was added. 30ml of the 
solution were poured into each 90mm petri dish and stored at 4°C. Before use, the 
plates were incubated at 37°C for 2 hours to reduce the moisture content of the agar 
and thus maintain well-defined colonies.
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7.12Northern blotting
7.12.1 RNA electrophoresis and transfer to nylon membranes
Denaturing gel electrophoresis was used to separate RNA species for northern 
blotting. 5pg aliquots of total cellular RNA in 0.1% formaldehyde, 0.5% 
formamide were heat denatured at 65°C for 15 minutes to destroy secondary RNA 
structures. This allowed RNA species to be separated on the basis of size on 1.3% 
agarose gels containing 6.4% formaldehyde. Electrophoresis was performed using a 
midi-rig (Model H3-SET, Anachem) gel system. The buffer used for 
electrophoresis and for melting agarose contained 0.02M sodium 3-(N-morpholino) 
propane-sulphonic acid, 5mM sodium acetate, ImM EDTA (pH7.0). After 
electrophoresis, the gels were rinsed several times in DEPC-treated water to remove 
formaldehyde.
RNA samples were transferred to Hybond-N+ nylon membranes (Amersham) using 
a SL-8164 capillary blotting unit (Anachem). The nylon membrane was pretreated 
by saturating in DEPC-treated water and then in 20x SSC. Capillary transfer was 
performed in 20x SSC over 3 hours. Once completed, the membrane was rinsed in 
6x SSC to remove any contaminating agarose and air-dried on 3MM filter paper 
(Whatman). RNA was covalently bound to the membrane by UV illumination using 
a XL-1000 (Spectronics Corporation) UV crosslinker.
The membrane was stained with methylene blue to assess RNA transfer and to 
identify the 28S and 18S ribosomal bands that migrate with 5.1 kb and 1.9kb RNA 
species respectively (Darling and Brickell, 1994). This was achieved by washing at 
room temperature in 5% acetic acid for 15 minutes with gentle agitation followed by 
5% sodium acetate/ 0.04% methylene blue for 10 minutes without agitation. Excess 
stain was removed by rinsing in DEPC-treated water and the 28S and 18S band 
positions were marked on the membrane. The membrane was air-dried on 3MM 
filter paper (Whatman) and stored at 4°C wrapped in polyvinyl chloride film (Saran 
Wrap, Dow) before hybridisation.
7.12.2 Random-primed DNA probe production
The pC4 plasmid (Nave et al., 1986) was used to generate random-primed DNA 
probes to detect Pip gene transcripts by northern blotting. The pC4 plasmid 
contains a full-length murine P/p-cDNA generated from the 2.4kb population of Pip 
gene transcripts that was released by BamHl digestion. Probes were generated from 
50ng of linearised pDNA denatured by heating to 100°C for 10 minutes and 
quenched on ice. Random priming using a commercial reaction mix (High Prime,
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Boehringer Mannheim) and 50pCi 32p_a_dCTp (specific activity 37TBq.mM-l; 
<1000Ci.mM~l) (Amersham) produced radiolabelled oligonucleotides. The 
reaction mix was incubated at 37°C for 10 minutes and was then quenched by the 
addition of ethylene-di-amine-tetra-acetate (EDTA) to 0.02M and heating to 65°C 
for 10 minutes. Labelled probe was separated from unincorporated isotope by 
column chromatography using Nick Columns (Pharamcia Biotech) following 
manufacturers’ recommendations. The column filtrate was collected in ~100pl 
aliquots which were assessed for radioactivity. Aliquots with the highest activity 
contained labelled probe and were pooled giving specific activities of 5x10^- 
5x1 ()9 cpm.qg-!. The probe was stored at -20°C until use.
7.12.3 Prehybridisation, hybridisation and washing
Prehybridisation and hybridisation were performed at 65°C in a Micro-4 
hybridisation oven with rotisserie (Hybaid) using preheated Rapid-hyb buffer 
(Amersham). The nylon membrane was saturated with preheated 2x SSC and 
placed in the hybridisation cylinder. To reduce non-specific binding of probe to the 
membrane, the membrane was prehybridised in 10ml of Rapid-hyb buffer for 3 
hours. Immediately before hybridisation, the probe was denatured by heating to 
100°C for 10 minutes and quenched on ice. The probe was mixed with 5 ml of 
preheated Rapid-hyb buffer and added to the prehybridisation solution to hybridise 
overnight. Unbound probe was removed from the membrane by washing in two low 
stringency washes (2x SSC/ 0.1%SDS) followed by two high stringency washes 
(O.lx SSC/ 0.1%SDS). Each wash was performed on a shaking platform at 65°C 
and lasted 30 minutes. Between washes, the background activity of the membrane 
was estimated using a Geiger counter to prevent excessive washing and removal of 
hybridised probe. After washing, the filter was dried on 3MM filter paper 
(Whatman), sealed in a double polythene bag and used for autoradiography.
7.12.4 Autoradiography
Two Cronex 10S radiographic films (DuPont) were exposed to the filter in a 
lightproof cassette at -70°C and developed using a Cronex-130 (DuPont) automatic 
processor. One film was developed after 24 hours to assess probe strength and the 
second film was developed up to 7 days later.
193
8. Abbreviations
International System of Units (SI) notation and other units accepted for use with SI 
notations have been used thoughout this thesis and are not listed.
APES 3-aminopropyltriethoxy-silane
BNF buffered neutral paraformaldehyde
bp base pair
C2-3 second to third cervical spinal cord segments
CAII carbonic anhydrase II
CD2 CD2 antigen (p50), sheep red blood cell receptor
CD44 CD44 antigen (homing function and Indian blood group system)
cDNA complimentary deoxyribonucleic acid
CMT1A Charcot-Marie-Tooth disease type 1A
CNP 2',3',cyclic nucleotide 3'-phosphodiesterase
CNS central nervous system
cpm counts per minute
DAB 3,4,3',4',-tetraminobiphenyl hydrochloride
DAPI 4',6-diamidino-2-phenylindole
dCTP 2' -deoxy-cytidine-5' -triphosphate
DEPC diethyl pyrocarbonate
DM20 26.5kDa protein isoform encoded by Pip gene
DNA deoxyribonucleic acid
DNase deoxyribonuclease
dNTP deoxynucleoside triphosphate
DTT dithiothreitol
DW distilled, deionised water
EAAT2 excitatory amino acid transporter 2
EDTA ethylene-di-amine-tetra-acetate
EGTA ethyleneglycol-bis ((3-aminoethylether)- N,N'-tetraacetic acid
F 1 first filial generation
FITC fluorescein isothiocyanate
gDNA genomic deoxyribonucleic acid
GFAP glial fibrillary acidic protein
golli-mbp gene gene of oligodendrocyte lineage
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H & E haematoxylin and eosin
HNPP hereditary neuropathy with liability to pressure palsies
HSV herpes simplex virus
11-15 interleukin-15
kb kilobase
kDa kiloDalton
LI CAM LI cell adhesion molecule
LacZ beta-galactosidase
LAMP2 lysosome -associated membrane protein 2
LB Luria-Bertani
MAG myelin-associated glycoprotein
MBP myelin basic protein
MOBP myelin-associated oligodendrocytic basic protein
MOG myelin/oligodendrocyte glycoprotein
MOPS 3-(N-morpholino) propane-sulphonic acid
MOSP myelin oligodendrocyte specific protein
Mr relative molecular weight
mRNA messenger ribonucleic acid
neo neomycin resistance
NGS normal goat serum
NTP nucleoside triphosphate
OMIM Online Mendelian Inheritance in Man entry
OMpg oligodendrocyte-myelin glycoprotein
OSP oligodendrocyte specific protein
PO myelin protein zero
PAP peroxidase-anti-peroxidase
PBS phosphate buffered saline
PCR polymerase chain reaction
PDGFRa platelet derived growth factor a  receptor
pDNA plasmid deoxyribonucleic acid
PLP proteolipid protein (30kDa protein isoform encoded by Pip gene)
P-L-P periodate-lysine-paraformaldehyde
PLP gene proteolipid protein (human gene)
Pip gene proteolipid protein (non-human gene)
Pip!PLP gene proteolipid protein (collectively human and non-human genes)
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PlpJP jimpy
PlpJP-4j jimpy-4j
Plpjp-msd myelin synthesis deficient
Plpmd myelin deficient
PlpP1 paralytic tremor
Plpsh shaking pup
Plptmknl targeted mutation of the Pip gene (Klugmann et al. 1997)
PMD Pelizaeus-Merzbacher disease
PMP22 peripheral myelin protein 22
PNS peripheral nervous system
RNA ribonucleic acid
RNase ribonuclease
rpm revolutions per minute
RT-PCR reverse transcription polymerase chain reaction
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SDW sterile distilled water
sec second
SPG2 Spastic Paraplegia Type 2
srDM20 soma-restricted DM20 protein isoform
srPLP soma-restricted PLP protein isoform
Sry gene sex-determining region o f the Y chromosome gene
SSC sodium chloride/sodium citrate buffer
ssDNA single stranded deoxyribonucleic acid
ssRNA single stranded ribonucleic acid
TAE tris acetate ethylene-di-amine-tetra-acetate buffer
Taq thermophilus aquaticus
TBq terabecquerel
TBS tris buffered saline
TE tris ethylene-di-amine-tetra-acetate buffer
TEMED N,N,N,N ’ ,tetramethy lethy lenediamine
tk thymidine kinase
TLCK Na-p-tosyl-l-lysine chloro-methyl ketone
tRNA transfer ribonucleic acid
TXR Texas red
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U unit
UTP uridine-5'-triphosphate
UTR untranslated region
UV ultraviolet
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